<SEC-DOCUMENT>0001558370-23-000269.txt : 20230113 <SEC-HEADER>0001558370-23-000269.hdr.sgml : 20230113 <ACCEPTANCE-DATETIME>20230113163139 ACCESSION NUMBER: 0001558370-23-000269 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 35 CONFORMED PERIOD OF REPORT: 20221130 FILED AS OF DATE: 20230113 DATE AS OF CHANGE: 20230113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BURZYNSKI RESEARCH INSTITUTE INC CENTRAL INDEX KEY: 0000724445 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 760136810 STATE OF INCORPORATION: DE FISCAL YEAR END: 0228 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 000-23425 FILM NUMBER: 23529125 BUSINESS ADDRESS: STREET 1: 12000 RICHMOND AVE CITY: HOUSTON STATE: TX ZIP: 77082 BUSINESS PHONE: (713) 335-5697 MAIL ADDRESS: STREET 1: 9432 KATY FREEWAY CITY: HOUSTON STATE: TX ZIP: 77055 </SEC-HEADER> <DOCUMENT> <TYPE>10-Q <SEQUENCE>1 <FILENAME>bzyr-20221130x10q.htm <DESCRIPTION>10-Q <TEXT> <XBRL> <?xml version='1.0' encoding='UTF-8'?> <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.1.0.3 --> <!-- Based on: iXBRL 1.1 --> <!-- Created on: 1/12/2023 8:13:38 PM --> <!-- iXBRL Library version: 1.0.8263.24741 --> <!-- iXBRL Service Job ID: e70d1f4a-9494-4883-b674-3143885ea079 --> <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:bzyr="http://www.burzynskiresearch.com/20221130" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title>UNITED STATES</title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" xs:nil="true" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" name="us-gaap:CommitmentsAndContingencies" id="Hidden_28uFptHmGkKkuKxIDL4X0w"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" xs:nil="true" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" name="us-gaap:CommitmentsAndContingencies" id="Hidden_X99cv_5SxUOzg5PiZXO-8A"></ix:nonFraction><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityRegistrantName" id="Hidden_mh0lxxWAAUq8ikHJKgRx-g">BURZYNSKI RESEARCH INSTITUTE INC</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityCentralIndexKey" id="Tc_BGNkIF9jyE-grhLdlAYfeA_2_1">0000724445</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:CurrentFiscalYearEndDate" id="Tc_AU4u1C4bikex6mbe7Kbkjg_3_1">--02-28</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:DocumentFiscalYearFocus" id="Tc_JzGP5EFzDkW-27p6XvKwXg_4_1">2023</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:DocumentFiscalPeriodFocus" id="Tc_0XkvixJs8U2O8l5rQ_CQkQ_5_1">Q3</ix:nonNumeric><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:AmendmentFlag" id="Tc_5wio724CykapT-JhmFSNdw_6_1">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="2" name="us-gaap:EarningsPerShareBasic" id="Hidden_yrggzAn32E6tEvWYLtsblQ">0.00</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="2" name="us-gaap:EarningsPerShareBasic" id="Hidden_MmQqWxGyVU-GwPUhGUCbqg">0.00</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Hidden_4KIxsZbLvk-ZlAzTWBAjqg">131448444</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Hidden_MxP-HoYi0UqleVprulvt6A">131448444</ix:nonFraction><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:SecurityExchangeName" id="Hidden_wMAzKWvegEq7ynJU2CLzHg">NONE</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_evElUb8klE-E4VGQk2oa0w">131448444</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_xglGHUNNJEOQ4svyOQ4x-Q">131448444</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ" sign="-" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="2" name="us-gaap:EarningsPerShareBasic" id="Hidden_xXzODA1LyUWnMoeXt_EYwg">0.01</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ" sign="-" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="2" name="us-gaap:EarningsPerShareBasic" id="Hidden_Cki4nmnCHESwy3FyGnIj0Q">0.01</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Hidden_t_yG-6s0rkeg8ROu6SiZ3A">131448444</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" id="Hidden_6cLko7dpk06ZhrvfUJ9WUA">131448444</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="bzyr-20221130.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_3_1_2022_To_11_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_67nM8Z7lXEy5aoImbV3iJg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_C988H_c5lEirXg2bOfyMYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lKswUaIHiEyn9JevGZ0Gvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yFw4lSokjkO_tlKaEbVbfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hhGupecJrkOV3pUvJetcyA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_aZAr42E-wEG4LLyxptSbCQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eXcu2NBnCkKP8GkoLn9imw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__NiklRz9s0eL5ss5vnewgw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2022_aH1WuS8v1UW8yzeokt0qeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NTT6rcWjSkS1DUuU566q9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JvhCi6_6NEyaCy4wUrsXFg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3HnDsSVLSEaSsHcQ_eD5WQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gtjfx8jA70qc4SM14Yj3jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_t40J9Yyvp0eMzCsyd170Lw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QfVTYoRMfUOqPfb1PY4Qtw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_LiQ_dJGijkqI7kTCGFYSOg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lNN1yxnejk2tW8zeN_uI2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OnyyqaGUF0iy63pvlajMzw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2021_qG8hjPs1ckabOxyw-IisaA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0DY2kRmuRkykwMzYCLMEag"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_txIuVwJscEWQsoDWljOsLg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TBAhEDDdsEmkmzUW0oQzAw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ay5nAffd0UKk97xXOpf_iw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UPPp8HvvukaFfAR3iE04GA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6rkROjav_UGQmnIAcgnBEA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XeOxpxRW2k2UySfWnD5UMQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sb_rwZ6nVU-g3e9Wdj7-7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IUIR5alQTkqIkz4yW1duxw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QcYgvQm1sU2dNqhqk7HHhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_1998_To_6_1_1998_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DbEucoULE0aMqQ_3EsFxqA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1998-06-01</xbrli:startDate><xbrli:endDate>1998-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_1997_To_6_1_1997_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_lrGBPtct1kCgRQmYPd7n8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1997-06-01</xbrli:startDate><xbrli:endDate>1997-06-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9J2vQo42mEG22C8KOHHe-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>1996-09-14</xbrli:startDate><xbrli:endDate>1996-09-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nMckWf8ou06gtaq15KVt5A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2022_To_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bYsh9WfHTkq54L3M1Md8eQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8qgAaLYRNECoMmeZnKz0Vw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2021_To_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_k3hpjFE5JU65xKnnzgO2vQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4_eOqZpcUk-67OjGO1pofg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TeJKkXhGtEWygQhcQKp9qw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_k0yzPQpwzUKU2JiaPznW_w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bzyr:WorldwideMedicalConsultantsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bzyr:CarigenLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2012-07-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2021_2QExRwQy1EushHKZUUQPGg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2021_tz3utn4GW0icSAfEmME0tQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Q6hxXm5dK0q5su70AGA9ow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_mGRKAPT_d0i6xvYOzqjuhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bzyr:WarrantsAndStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_q5rwaskLYUu_ZDbHfAs6pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_dopENHjSVkec1zCh35q5Hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bzyr:WarrantsAndStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_kxHbs4IXUEaF_-ZHCfDT7w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_u75x1ek-KkeJ32monPyZiQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bzyr:WarrantsAndStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_CFxwHANUYkWnJB9fZNUxkg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_wVzlOVFTnUa4yodykmvUJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bzyr:WarrantsAndStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_1_2023_NWkE9flst0aP1TfbgyOO3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_us-gaap_TaxPeriodAxis_us-gaap_LatestTaxYearMember_PYUkT8vb4kidxIHJrwE-Mg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_11_30_2022_srt_StatementScenarioAxis_bzyr_HundredPercentFutureTaxableIncomeMember_-mkCDpGPAUaxUXrXRSUTtA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bzyr:HundredPercentFutureTaxableIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_11_30_2022_srt_StatementScenarioAxis_bzyr_EightyPercentFutureTaxableIncomeMember_QhqQJfwexky0p43BckGK3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bzyr:EightyPercentFutureTaxableIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_11_30_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_gY1j0FUXpUGEySuC7dEpCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_ailYsCoPekC30-IUv4AkDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">bzyr:WorldwideMedicalConsultantsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bzyr:CarigenLtdMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2012-07-05</xbrli:startDate><xbrli:endDate>2012-07-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iwKsVl7Vak-URPtHD_l-rw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-09-01</xbrli:startDate><xbrli:endDate>2022-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2022_To_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iTMc4yrn50u2G1IpUUj4rA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2022_To_8_31_2022_fMfAETlwykeXblePySWjcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-06-01</xbrli:startDate><xbrli:endDate>2022-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zp73wx7c8EyZlhK6JxJqcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2022_To_5_31_2022_s5S1WhHB9UqmTCCb06YxWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-03-01</xbrli:startDate><xbrli:endDate>2022-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2021_To_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_I_jFFJLfpEun5ot6_dLYjA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dq8AzYWypkmsekLWBSXMwQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_1_2021_To_8_31_2021_eTo4YOsOQkSH1oSW4mRAFA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-cT_vEjUDUW-S5rQVrW9Gg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_1_2021_To_5_31_2021_UX5UtaTbT0eersU02GWvMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000724445</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_item_REEsf0XHJUOQ1iZoyc7Pvg"><xbrli:measure>bzyr:item</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_patent_dlojMfgdTECMpi5PU4YRsw"><xbrli:measure>bzyr:patent</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:1pt;padding-top:1pt;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><a id="_2fe0c054_6539_4f92_b4db_612e6fe7f657"></a><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">FORM </b><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:DocumentType" id="Narr_AbXyBKBktkmIHP_29qc6SQ"><b style="font-weight:bold;">10-Q</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><a id="_e6824408_20e8_4e08_8a60_866af146e46d"></a><a id="Tc_QoLVwSGB10yfamcgU6X7cg_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:95.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:DocumentQuarterlyReport" id="Tc_10MTbsOyV0C6xqcZ_M59jQ_1_0"><b style="font-family:'Segoe UI Symbol';font-size:11pt;font-weight:bold;">☒</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">For the quarterly period ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:DocumentPeriodEndDate" id="Narr_w4YNRDs_SEmO_42SD_zp5w"><b style="font-size:9pt;font-weight:bold;">November 30, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><a id="_7613fa79_83d4_4456_af09_88ff728cb681"></a><a id="Tc_GwBUAgzKnEmpy-7CUZh9dw_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:95.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:4.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:DocumentTransitionReport" id="Tc_g1g-vKRAzk69WgkXjUdghw_1_0"><b style="font-family:'Segoe UI Symbol';font-size:11pt;font-weight:bold;">☐</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:95.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><b style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">For the transition period from                  to                  </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">Commission file number </b><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityFileNumber" id="Narr_CaEDoqPzq0CIz-oPHBklaw"><b style="font-size:9pt;font-weight:bold;">000-23425</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_mh0lxxWAAUq8ikHJKgRx-g;"><b style="font-family:'Times New Roman','Times','serif';font-size:17pt;font-style:normal;font-weight:bold;">Burzynski Research Institute, Inc.</b></span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Exact name of Registrant as specified in its charter)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><a id="_76152254_2879_43b5_b25e_fd933fba2b49"></a><a id="Tc_Jp4PLfe8Ckuo8O-CIDvgTA_2_0"></a><a id="Tc_QRCeSXfGu068coLQ_xm8xQ_2_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityIncorporationStateCountryCode" id="Tc_heEbLMJyV0OwM5C4oRQUCA_1_0"><b style="font-size:9pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityTaxIdentificationNumber" id="Tc_83iREvvVOEehy286tVGOgQ_1_2"><b style="font-size:9pt;font-weight:bold;">76-0136810</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:48.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(State or other jurisdiction of incorporation or organization)</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(I.R.S. Employer Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityAddressAddressLine1" id="Narr_yaY6weBi2kKzTrBsEInsGg"><b style="font-size:9pt;font-weight:bold;">9432 Katy Freeway</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityAddressAddressLine2" id="Narr_s0PE0MinWUiWG6qOQj4SmQ"><b style="font-size:9pt;font-weight:bold;">Suite 200</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityAddressCityOrTown" id="Narr_T1E8xfa-XUSvbsD5BwIcdA"><b style="font-size:9pt;font-weight:bold;">Houston</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityAddressStateOrProvince" id="Narr_QCUi4ArSnEi5aVZKDVOSrQ"><b style="font-size:9pt;font-weight:bold;">Texas</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;"> </b><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityAddressPostalZipCode" id="Narr_fJt6wEkYekenin-4Tg3YuA"><b style="font-size:9pt;font-weight:bold;">77055</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Address of principal executive offices)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><b style="font-size:9pt;font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:CityAreaCode" id="Narr_ZngzuRcunE2uL6bHFhHqCA"><b style="font-size:9pt;font-weight:bold;">713</b></ix:nonNumeric><b style="font-size:9pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:LocalPhoneNumber" id="Narr_-BJrco17AkSC7OqfdVIFZg"><b style="font-size:9pt;font-weight:bold;">335-5697</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Registrant’s telephone number)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">(Former name, former address, and former fiscal year, if changed since last report)</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><a id="_e3a3194a_3251_4a90_b7a3_6418949fadbd"></a><a id="Tc_54E31dHRa0KolZVZhq0Cjw_1_0"></a><a id="Tc_xVev7rKKxUe_97tPIEzLdg_1_2"></a><a id="Tc_vd8wbHICDESp9ewFkY7uhA_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:28.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:25.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:43.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:28.12%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title of each class</b></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:25.02%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading</b><b style="font-weight:bold;"><br /></b><b style="font-weight:bold;">Symbol(s)</b></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:43.31%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Trading Name of each exchange on which registered</b></p></td></tr><tr><td style="vertical-align:top;width:28.12%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:Security12bTitle" id="Tc_eMnqv1y6qUqc8rbZ9yE4eg_2_0"><span style="font-size:9pt;">None</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:25.02%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:TradingSymbol" id="Tc_B7WU088fQ0upEs49tadljQ_2_2"><span style="font-size:9pt;">BZYR</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:1.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:43.31%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="-sec-ix-hidden:Hidden_wMAzKWvegEq7ynJU2CLzHg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">None</span></span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) </span><span style="font-size:9pt;white-space:pre-wrap;">has been subject to such filing requirements for the past 90 days. </span><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityCurrentReportingStatus" id="Narr_mjp1UTlMBk-N0iRyvpDHIg"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-family:'Times New Roman';font-size:9pt;">⌧</span><span style="font-size:9pt;">  No </span><span style="font-family:'Times New Roman';font-size:9pt;">◻</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule </span><span style="font-size:9pt;white-space:pre-wrap;">405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityInteractiveDataCurrent" id="Narr_Nfe0RSrRckqYkDPtN4mjsw"><span style="font-size:9pt;">Yes</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-family:'Times New Roman';font-size:9pt;">⌧</span><span style="font-size:9pt;">  No </span><span style="font-family:'Times New Roman';font-size:9pt;">◻</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Large accelerated filer <span style="font-family:'Times New Roman';">◻</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 36pt;">Accelerated filer <span style="font-family:'Times New Roman';">◻</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityFilerCategory" id="Narr_l9Dr62_ZjEatGDzVzZJO9Q"><span style="font-size:9pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:9pt;"> </span><span style="font-family:'Times New Roman';font-size:9pt;">⌧</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:9pt;">Smaller reporting company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntitySmallBusiness" id="Narr_syVQooPF1EymhNjVa4uwaA"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">☒</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:9pt;">Emerging growth company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityEmergingGrowthCompany" id="Narr_1BhF5QlU_UikNwXtqB0t3A"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">☐</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family:'Times New Roman';">◻</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 6pt 18pt;"><span style="font-size:9pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule </span><span style="font-size:9pt;white-space:pre-wrap;">12b-2 of the Exchange Act). Yes </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="dei:EntityShellCompany" id="Narr_ROmTDOuexESjq9nlwZ_80g"><span style="font-family:'Segoe UI Symbol';font-size:9pt;">☐</span></ix:nonNumeric><span style="font-size:9pt;">  No </span><span style="font-family:'Times New Roman';font-size:9pt;">⌧</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:center;margin:0pt;">APPLICABLE ONLY TO CORPORATE ISSUERS:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 6pt 18pt;"><span style="white-space:pre-wrap;">Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date: As of January 1, 2023, </span><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_1_1_2023_NWkE9flst0aP1TfbgyOO3A" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_S3oLAVpFCUWnYLnRENwouA">131,448,444</ix:nonFraction> shares of the Registrant’s Common Stock were outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="display:none;font-size:12pt;line-height:0pt;text-align:center;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">​</span></p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_356e4a02_8566_43e7_8a6b_9a219d730c67"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">BURZYNSKI RESEARCH INSTITUTE, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form 10-Q</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Table of Contents</b></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:13.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">PART I — FINANCIAL INFORMATION</p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 9pt;"><a style="font-size:10pt;" href="#Item1FinancialStatements_150768"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item1FinancialStatements_150768"><span style="font-style:normal;font-weight:normal;">Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">3</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 9pt;"><a style="font-size:10pt;" href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Item 2.</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item2ManagementsDiscussionandAnalysisofF"><span style="font-style:normal;font-weight:normal;">Management’s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">11</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 9pt;"><a style="font-size:10pt;" href="#Item4ControlsandProcedures_737311"><span style="font-style:normal;font-weight:normal;">Item 4.</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item4ControlsandProcedures_737311"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">15</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:94.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#PARTIIOTHERINFORMATION_472513"><span style="font-style:normal;font-weight:normal;">PART II — OTHER INFORMATION</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">15</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 9pt;"><a style="font-size:10pt;" href="#Item1LegalProceedings_582067"><span style="font-style:normal;font-weight:normal;">Item 1.</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item1LegalProceedings_582067"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">15</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:13.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 9pt;"><a style="font-size:10pt;" href="#Item6Exhibits_661755"><span style="font-style:normal;font-weight:normal;">Item 6.</span></a></p></td><td style="vertical-align:bottom;width:80.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="font-size:10pt;" href="#Item6Exhibits_661755"><span style="font-style:normal;font-weight:normal;">Exhibits</span></a></p></td><td style="vertical-align:bottom;width:5.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;">16</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_b8bc257a_c9b4_4339_989c_43a544241b5e"></a><a id="Item1FinancialStatements_150768"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="display:inline-block;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">Item 1.</b></span><b style="font-weight:bold;">Financial Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><a id="BURZYNSKIRESEARCHINSTITUTEINC_654791"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BURZYNSKI RESEARCH INSTITUTE, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BALANCE SHEETS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><a id="_89144cea_1074_402c_9149_fd6686366ae7"></a><a id="Tc_3TC8yNZbmECBPWQTWB69rQ_1_2"></a><a id="Tc_Nq3Xy5YhpkG0s4t7GxNYaQ_1_5"></a><a id="Tc_PWfMBjqEp0SUNnAgoHMkDg_2_2"></a><a id="Tc_Zo_JtQ4HU0O_BW7Ob8zo9g_2_5"></a><a id="Tc_0vd2B6ZEDkKf2WHMvvWqsQ_3_0"></a><a id="Tc_CRr4Zv2nFkWe3NvbjBsFoQ_5_0"></a><a id="Tc_-Nd_holRDkyySVV44jL8dw_6_0"></a><a id="Tc_A8Wsgn3aXUeboixLgFR9SA_6_2"></a><a id="Tc_8Hg0sy4yJEe1Y4MmVX4j4Q_6_5"></a><a id="Tc_HgaCokYJBEeFndI4EknpEQ_7_0"></a><a id="Tc_4s727peTuUmjd0UdeQYokg_9_0"></a><a id="Tc_igiFBtBR3Uu6D_h8K3Ow6A_11_0"></a><a id="Tc_pytb_p7FrkSRVgBbcco8Sw_11_2"></a><a id="Tc_U8vVssh0SEG1XpPkkkFwcg_11_5"></a><a id="Tc_0ua0k6u-aECFePHPrWnkgA_13_0"></a><a id="Tc_xOcNbeFjn0GpEtvIpn6eHg_15_0"></a><a id="Tc_H5kReFdVh0KQ0_4ZVm7g3w_16_0"></a><a id="Tc_B2wLJyCBEEarHK48_dIZzg_16_2"></a><a id="Tc_qRECnkxxcEajJFjwEgXGIA_16_5"></a><a id="Tc_Jf0Gu-FBYEmSWaKVt-9-aQ_16_6"></a><a id="Tc_igwjUlCXkE631hQuFXUl8w_17_0"></a><a id="Tc_cBLWqauwEEG2vx227Dt1Sg_19_0"></a><a id="Tc_eaW5iy1Czk-Y-pikqn5_wg_21_0"></a><a id="Tc_nXGq1KppKECAF-JyGbmeYA_23_0"></a><a id="Tc_D8qwGkgO0kGBblAjUO446g_24_0"></a><a id="_3e8f4750_d2bf_4fdd_83d7_7ea524934184"></a><a id="_3e8f4750_d2bf_4fdd_83d7_7ea524934184_2"></a><a id="_3e8f4750_d2bf_4fdd_83d7_7ea524934184_3"></a><a id="Tc_18znyUFkKkumLLZoS1Ydvw_25_0"></a><a id="Tc_MIEnNlGFhUKeXBwbFrmndw_26_0"></a><a id="Tc_1rqBLjwHaEiwrAEzP3-2Nw_28_0"></a><a id="Tc_QrleBkX2iECoMlz8wJa1YQ_30_0"></a><a id="Tc_sk21GGX18km0GeyGconAqw_30_2"></a><a id="Tc_A-neI7l-3Uy5uu3XH0rnbg_30_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">November 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">February 28,</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">ASSETS </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_CYwVw_ls4EGuR2pPVfdIKg_6_3">1,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" id="Tc_GyHjnB7yNkaba9a_-40koA_6_6">3,382</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_dzYem4rH8kSRDkbwJf54qQ_7_3">100</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseCurrent" scale="0" id="Tc_5L72wro49EOWNmVD4X558g_7_6">1,279</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total current assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_IvsQffQC1kqY3YNS7mO_Ag_9_3">1,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="0" id="Tc_oU9lnF6-QkeGfL8cuQUT3g_9_6">4,661</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total assets </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_9_Csp3CylEOTpLi7wc8Lcw_11_3">1,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="0" id="Tc_qmmWyMk3WUG9KthyDAjxOg_11_6">4,661</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Current liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accounts payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="0" id="Tc_f71vJRpQmEWfQAoxitOyjA_16_3">16,650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Accrued liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_ezGOrEpB2kOHgSz7fqrjQA_17_3">11,770</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AccruedLiabilitiesCurrent" scale="0" id="Tc_xqDd3nZMfUayJ8-LMevdMQ_17_6">3,455</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">CURRENT AND TOTAL LIABILITIES</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_h1nNDV4amU2IE7XeXI62Jg_19_3">28,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="0" id="Tc_LGPX6L2hqEa38sFbrkxzaA_19_6">3,455</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Commitments and contingencies </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stockholders’ equity (deficit) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Common stock, $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_U_2k3Cb2Bk2YAUvvCMvXKg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_DiauOSlOwEquWS33tskU0A">.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_2jx6zpT5okeZAFz2rmVIaQ"><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_vWmArepvfU-9GYrIfPOeag">200,000,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_dEZsd3YEbk2YElUSrSfY0Q"><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_K14tv9tXZkuSblpxRhCMMA">131,448,444</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of November 30, 2022 and February 28, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_QAze2GgC0kmyW7M6ok-eYg_24_3">131,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="0" id="Tc_9d11FdMlkEuWk4vzqsXSlA_24_6">131,449</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Additional paid-in capital </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" id="Tc_jXDgLPhoSUOKkIRP18ZNeQ_25_3">126,380,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" id="Tc_oup459wPZEOd3PfpNehvVA_25_6">125,708,240</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Retained deficit </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_8O_FVk2ZHEu_0NpGXqqy-Q_26_3">126,538,777</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="0" id="Tc_1xgWUBZXKkSedsax56jEjg_26_6">125,838,483</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total stockholders’ equity (deficit) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_pXJAoPZKNkuNV0c2zTmgBQ_28_3">26,628</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_SfNYOlTlqkWXOLzdXBBa9w_28_6">1,206</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total liabilities and stockholders’ equity (deficit) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_w1U6FBDS0Uizk1zbu5m5pQ_30_3">1,792</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" id="Tc_AdkzGMtW9EGFM_tfM-0tZA_30_6">4,661</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4a8b631b_979c_4529_af87_8badaa9f43d7"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BURZYNSKI RESEARCH INSTITUTE, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">STATEMENTS OF OPERATIONS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><a id="_35fa4a69_f410_4819_842a_f7bc6b265925"></a><a id="Tc_455DflknKUGHb6pu-fpAag_1_2"></a><a id="Tc_eY8utHE-s0uHYEwFl-nngA_2_2"></a><a id="Tc_UgzrDS9dfUaDaArdwMG9Kg_2_5"></a><a id="Tc_cD75gE12D0mMfPYOIz6ueA_3_0"></a><a id="Tc_6YO9YQT-GUyN_ktmqcyG1Q_4_0"></a><a id="Tc_sVN60u9g30yW7wIgl07_FQ_4_2"></a><a id="Tc_2zmyw6ZlPkOzoUyuZvx_7g_4_5"></a><a id="Tc_jxDmuq74cE-xEXjQ-XzsWA_5_0"></a><a id="Tc_j6cuVoeZyUOwNGoeDt_vVg_7_0"></a><a id="Tc_hgZTA5ORGU6-YV7tK6nCUw_9_0"></a><a id="Tc_myj2bJhGk0qsxv4yGvvALg_11_0"></a><a id="Tc_vomW8GTdjkueH5_JtOx-4w_12_0"></a><a id="Tc_-UXrHtalpUqGGUwQXDc-oQ_12_3"></a><a id="Tc_IcDCRegs3UKy96o34FhmhA_12_6"></a><a id="Tc_sNsa6_btiE2T5MPEuKWmSg_13_0"></a><a id="Tc_NcpRpuJYwUKOMPqGFVpqNw_13_2"></a><a id="Tc_koHsKS0qCkueDovkpnzIOQ_13_5"></a><a id="Tc_ELCk3hKo5UCd32nvOg6N-g_15_0"></a><a id="Tc_bGggco674EahxD0q40UQFw_17_0"></a><a id="Tc_74MwehzN9EO_ZkIyv6nUaA_19_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended November 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_QXX5BTxhIUmltNcE9umI2g_4_3">207,651</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_ihJAurdfkEiPXapJUc2iZg_4_6">214,112</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_tVoYAlsxQ0aCZ1LSkCX-Uw_5_3">44,988</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_j9xDxxlgKU-bqIJYAjw8Qg_5_6">50,664</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total operating expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_0XKwEvbJgEmo4SBLw76_kw_7_3">252,639</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_QSqOlrA28UmxhqwfVTXtjw_7_6">264,776</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_OkByTsJsiE-E8QVVpVpuWg_9_3">252,639</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_liclrK753kGpMCWsuM8Glw_9_6">264,776</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss before provision for income tax </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_DTMArmC7gUC27zXJ_SpxTw_11_3">252,639</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_DOL16PdbN0mBW-HlsrFSjw_11_6">264,776</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Provision for income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_uUywbCC690q8D3V75MQoYA_13_3">252,639</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_kb_oCyTLgEi8iUYlbOY5Cg_13_6">264,776</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Earnings per share information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_yrggzAn32E6tEvWYLtsblQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_cr5NH0ZYgEil-sFRvUbDHQ_17_3">0.00</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_MmQqWxGyVU-GwPUhGUCbqg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" scale="0" id="Tc_o6n0LGnJv0qi9w15NJ_Rvg_17_6">0.00</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average number of common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_EnSHpq7leE-h-OrWASsW5w_19_3">131,448,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_x2wNrdOw40qHJUo4VEzE-A_19_6">131,448,444</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><a id="_a65b0413_4e39_4334_a7e7_487a26892f5b"></a><a id="Tc_G0T8z2ZLh0q2O2pJ9oHWdw_1_2"></a><a id="Tc_kUJboFCw6EGFW3hZdZgn1g_2_2"></a><a id="Tc_HILzVdIEr0OwfNsriH98cA_2_5"></a><a id="Tc_TNteCC9yw0uXNDJlPva4MQ_3_0"></a><a id="Tc_hzG1f1jIN0e1UK34X4125g_4_0"></a><a id="Tc_MnwHTkKTm0iOv3F-VP9ecw_4_2"></a><a id="Tc_jk8pln_eHEy0P729qvoVBg_4_5"></a><a id="Tc_sP4Eew562U6zsi4MuPIwZw_5_0"></a><a id="Tc_KAuZ_IeREEqvoNxfIcpuuA_7_0"></a><a id="Tc_UOPBNNr4cUqliWNWUYXzQQ_9_0"></a><a id="Tc_bbg6Vzb9kEqv_OcIn6rXtA_11_0"></a><a id="Tc_dqNW39T_u0ye_p46I4YTLA_11_3"></a><a id="Tc_a7VhpniMOkOrxydnNIWdvQ_11_6"></a><a id="Tc_sPeRrqxyck-hKvYME4eHUQ_13_0"></a><a id="Tc_eHH0Z2RAxUiaqsvYmb_CFQ_15_0"></a><a id="Tc_QY4pKTzwUU-Ly1kQ6xfVzQ_15_3"></a><a id="Tc_fAhEX6hQd0i_Jwtb0Zxf_w_15_6"></a><a id="Tc_Q4y3Wd0Uik64uFLGjRNSXw_16_0"></a><a id="Tc_uyzA1PE6DEuvshowp116yQ_16_2"></a><a id="Tc_IxTQgtUI_kqmNhLEt-Solw_16_5"></a><a id="Tc_nC4tD8hRJkuNts-AAu3Ggw_18_0"></a><a id="Tc_4Ji0Cib7UUGc8KczYm8DKg_20_0"></a><a id="Tc_GFDKRXFtNEe4zRJwuk3Q_g_22_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended November 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.76%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.74%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Research and development </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_Ke4uPE3ADk-l3YSn-ZMxxw_4_3">545,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" id="Tc_hCzn1WGzFkGX4C6jIcPj8Q_4_6">632,475</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">General and administrative </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_VcBgKSBqU0-SrlYT0TjlVQ_5_3">154,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" id="Tc_Hp3p-jY82UewCGS5n0U4_w_5_6">173,302</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Total operating expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_L5SAQSzSpEWbsVf2I9Rmfw_7_3">700,294</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="0" id="Tc_3n6W5PoLWU-qC0mWt6bzLQ_7_6">805,777</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Operating loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_ityKcVpNG0-hzjGhey5A6g_9_3">700,294</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="0" id="Tc_yursHaOxF0eay7W50pwDmg_9_6">805,777</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Other income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Loss before provision for income tax </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_AgC8KlpV2EWwEwDSGKQ_Uw_13_3">700,294</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" sign="-" scale="0" id="Tc_N07H1LkKUkSzHtotDvl2cA_13_6">805,777</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Provision for income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_xpdgQSIfREurQiiveNd4-w_16_3">700,294</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_vNoDsaId4UGKi7Glwch9-A_16_6">805,777</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Earnings per share information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Basic and diluted loss per common share</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_xXzODA1LyUWnMoeXt_EYwg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_JpCHi69GrUKIKs-RpEZZgw_20_3">0.01</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Cki4nmnCHESwy3FyGnIj0Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareDiluted" sign="-" scale="0" id="Tc_sohTWbrKbEGCpqc2XxhoOg_20_6">0.01</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Weighted average number of common shares outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_OA_I799F6EWKfqwLmmKlFQ_22_3">131,448,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="0" id="Tc_vX2JH6oC80SpeAs6ksndPg_22_6">131,448,444</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">See accompanying notes to financial statements.</p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_09c49be1_3f65_43c1_86e2_b29b3eb5e8e1"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BURZYNSKI RESEARCH INSTITUTE, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">For the Nine Months Ended November 30, 2022 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><a id="_0b6ef3fb_5722_4be1_ba3b_282a7fb74bc0"></a><a id="Tc_94tebWiufkiQIKVEEp81sA_1_7"></a><a id="Tc_6znBxYUPuE28rSK_pBC5jQ_1_13"></a><a id="Tc_D9Vm7dP1hUyhEXb1Vqt3ug_2_2"></a><a id="Tc_RurnuVQLM0aoZdg8yZ-DtA_2_7"></a><a id="Tc_D5IlQ3RjKUaFbFsg4kAivQ_2_10"></a><a id="Tc_NUdSY0VfuUCbjB0Ut6rIBg_2_13"></a><a id="Tc_dOqreLesOkalGEV5eTjwbg_3_2"></a><a id="Tc_P9pW4YaO4UWrC_jjr6kQvQ_3_4"></a><a id="Tc_QVDe7n21fEOF59xrwIAgAA_3_7"></a><a id="Tc_HUovKiFw2UWJ1PYoKhkb2w_3_10"></a><a id="Tc_xK7RHq4k9keQrjxWhQd2Rg_3_13"></a><a id="Tc_Vch1jj2P2ke_vIiA5vVY6A_4_0"></a><a id="Tc_sCMfcTcqdk-rCpzV-P8nLw_4_4"></a><a id="Tc_7IonqKa7yEWORjlalbIUXA_4_7"></a><a id="Tc_TLtk9yxtE0-0MifS4xsfNA_4_10"></a><a id="Tc_pIA7sxnxi0yolxu-kxa3Uw_4_13"></a><a id="Tc_B1jW7lGx20u9FlqdDKo3Tw_6_0"></a><a id="Tc_yjOpMOkpk06hUaxbj8Wulw_6_2"></a><a id="Tc_bpp4JspDmU2qx2z5helo2Q_6_5"></a><a id="Tc_184uK4yPeEG12M4_9hdQEQ_6_11"></a><a id="Tc_Gs9ldBvnIU-IloQONIV3Zg_8_0"></a><a id="Tc_iQ8ie0mncU2iEiM8-XgjVw_8_2"></a><a id="Tc_LCfyCWaw2UCqOtHHtEA7zw_8_5"></a><a id="Tc_CsWSdfnNMUScHUJW7ekegA_8_11"></a><a id="Tc_7-fRkRrlokC2WX1G9VEYSQ_10_0"></a><a id="Tc_f8Ao3Jsbu0GWJBDG69o0mQ_10_2"></a><a id="Tc_dsMokfKjkkOaor0zFL59zw_10_5"></a><a id="Tc_yTNhgxcbfE6Eo5YMSwQUOw_10_8"></a><a id="Tc_IqO9aeOBvUyCrtXNT37tgQ_12_0"></a><a id="Tc_uhFd6nXRik-7QoKEQtb9ng_12_4"></a><a id="Tc_nvexhuscFU--dME9VCm1ZQ_12_7"></a><a id="Tc_BwJPF1pUBkyuAv8aBZDesw_12_10"></a><a id="Tc_dcq7Mmbh00GJ9oQ3n9wlyA_12_13"></a><a id="Tc_Jzvq_ovTC0mCYpJiKcdlOg_14_0"></a><a id="Tc_0t4SG6jTSUScIex9iDofYA_14_2"></a><a id="Tc_2DS8S9t7SUOXtuyZFOdN6A_14_5"></a><a id="Tc_K7Oz-G7C3EWkZROqNX5KpQ_14_11"></a><a id="Tc_PQ_pJYt5J02JS6cf3OIp3w_16_0"></a><a id="Tc_f3cUjWlaNUCUeoQq48G37A_16_2"></a><a id="Tc_so9D56Z4yE28qagyrbPBVQ_16_5"></a><a id="Tc__eck_2hzJUWBdGNRmx8nuA_16_11"></a><a id="Tc_wpXvZk5Z4kOlEk4rQIzIIA_18_0"></a><a id="Tc_IIQqMBL83U6He6mY1gL2sg_18_2"></a><a id="Tc_mDgc3EVCJkSayxjpt5wl3g_18_5"></a><a id="Tc_EZ9k0G5bAkmmTH3PZT21TA_18_8"></a><a id="Tc_oeyYAKiHj0m7O83KnJux9g_20_0"></a><a id="Tc_hjBW1UyxrUeRXab7Gp4dUw_20_4"></a><a id="Tc_SrShnkz9LEOYyjzH3PQUOQ_20_7"></a><a id="Tc_zU4EGx-b406Y2mZvyo0v0g_20_10"></a><a id="Tc_Bt4i_3ygUUesVK3FLVA2pg_20_13"></a><a id="Tc_rL0ksHNiy0STbMHnLtvYmQ_22_0"></a><a id="Tc_Lmp8WzGzpkyxZ5Czdxji7Q_22_2"></a><a id="Tc_-OSJtmL-XUGUQYXAsejdfw_22_5"></a><a id="Tc_mnf_AxmM-EO-ErYyK1Fp2Q_22_11"></a><a id="Tc_ZqVvUN82jESOMuxOAvSloA_24_0"></a><a id="Tc_lgL8e7FZEEat-P9f1U6mGA_24_2"></a><a id="Tc_QjUyQ8r-7kekTGv13_1pNg_24_5"></a><a id="Tc_iq2Ua9J2TUCUB27ujIUWcQ_24_11"></a><a id="Tc_oNylylXhmEaLV_SEUh-gSA_26_0"></a><a id="Tc_WZhV_5pNS0u09b8thGFsig_26_2"></a><a id="Tc_CgcyRvmKXEyoqmhYCWWUDw_26_5"></a><a id="Tc_atFZN3JY50iZIT-4XG9xuw_26_8"></a><a id="Tc_bpRHs1OcSkySIQVXRZ1e4w_28_0"></a><a id="Tc_V5-rK4mKO0y7IozMEImbmw_28_4"></a><a id="Tc_NM8bG6EmpE6gt0tbmr184Q_28_7"></a><a id="Tc_ptJHZMFj50GKlgMHGUcViw_28_10"></a><a id="Tc_8eCr6mRpnUyWruyDGheP5w_28_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Retained</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.8%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders’</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.8%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"> </b><b style="font-weight:bold;">(Deficit)</b></p></td></tr><tr><td style="vertical-align:top;width:41.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at February 28, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6rkROjav_UGQmnIAcgnBEA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_cFgaapqOG0i6-N2h5HPqUQ_4_2">131,448,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6rkROjav_UGQmnIAcgnBEA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_j_aoxcQRiEuLU-WLltkoqA_4_5">131,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JvhCi6_6NEyaCy4wUrsXFg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_rF10uk78vk6A_cuhH4Pz7g_4_8">125,708,240</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NTT6rcWjSkS1DUuU566q9g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_qMpzdorBwEuNtHeAlhzBGg_4_11">125,838,483</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_kjcRnmyoX0un4oLeYDTx3g_4_14">1,206</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash contributed by S.R. Burzynski M.D., Ph.D. </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zp73wx7c8EyZlhK6JxJqcQ" decimals="0" format="ixt:numdotdecimal" name="bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed" scale="0" id="Tc_u1glexgBZkexTCby4vAdlQ_6_8">40,517</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_5_31_2022_s5S1WhHB9UqmTCCb06YxWQ" decimals="0" format="ixt:numdotdecimal" name="bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed" scale="0" id="Tc_eaPqVFCrqEyMjerDObqtSw_6_14">40,517</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D. </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zp73wx7c8EyZlhK6JxJqcQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" id="Tc_6u3lxp-xtkSuzhTU3GtbtQ_8_8">151,334</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_5_31_2022_s5S1WhHB9UqmTCCb06YxWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" id="Tc_pr9xgwEkeUqeL9ETHVPQMw_8_14">151,334</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8qgAaLYRNECoMmeZnKz0Vw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_Wo8QawXeY0qzlFTIPHTNng_10_11">231,737</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_5_31_2022_s5S1WhHB9UqmTCCb06YxWQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_4tie8V90QUyPVFU-Tsfdbw_10_14">231,737</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at May 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UPPp8HvvukaFfAR3iE04GA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_3ww0D2C_UkC1U7_gpjgnRg_12_2">131,448,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UPPp8HvvukaFfAR3iE04GA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_yoGQvjR1ZUS6iC9PraZymg_12_5">131,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__NiklRz9s0eL5ss5vnewgw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_U-o-PcpwIUKPXu2t0qZl9g_12_8">125,900,091</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eXcu2NBnCkKP8GkoLn9imw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_LUMdXKn0VkGwTrKCeFErUA_12_11">126,070,220</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_5_31_2022_aH1WuS8v1UW8yzeokt0qeA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_Mjog1Hwqnkq5UPPSXxBheQ_12_14">38,680</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash contributed by S.R. Burzynski M.D., Ph.D. </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_6_1_2022_To_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iTMc4yrn50u2G1IpUUj4rA" decimals="0" format="ixt:numdotdecimal" name="bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed" scale="0" id="Tc_6wtOOei1PkCjVTQkCM4Czw_14_8">86,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_6_1_2022_To_8_31_2022_fMfAETlwykeXblePySWjcQ" decimals="0" format="ixt:numdotdecimal" name="bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed" scale="0" id="Tc_REwyeXOMokW5pYuN30uiRQ_14_14">86,017</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D. </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_6_1_2022_To_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iTMc4yrn50u2G1IpUUj4rA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" id="Tc_ZLDkDZtFo02jmpA8jD60kw_16_8">154,943</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_6_1_2022_To_8_31_2022_fMfAETlwykeXblePySWjcQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" id="Tc_LpzhSCJv0E2TCubpZsxrEg_16_14">154,943</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_6_1_2022_To_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bYsh9WfHTkq54L3M1Md8eQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_Gu_bH7a5fUWUHhJ45TLqjg_18_11">215,918</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_6_1_2022_To_8_31_2022_fMfAETlwykeXblePySWjcQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_7_olKEAEbkaX5eBd1sQErg_18_14">215,918</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance August 31, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ay5nAffd0UKk97xXOpf_iw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc__77k5-8A40OMvtydbU9jRA_20_2">131,448,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ay5nAffd0UKk97xXOpf_iw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_bCniGGwc9UWH0Xck_NcyOg_20_5">131,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hhGupecJrkOV3pUvJetcyA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_ILW_77Z0U0KorkTeukt7Sg_20_8">126,141,051</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yFw4lSokjkO_tlKaEbVbfg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_PLN7e5Dgykqq0YHQ7dGm6w_20_11">126,286,138</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_8_31_2022_aZAr42E-wEG4LLyxptSbCQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_6HS1UoA470Kd6SXRcf45aA_20_14">13,638</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash contributed by S.R. Burzynski M.D., Ph.D. </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iwKsVl7Vak-URPtHD_l-rw" decimals="0" format="ixt:numdotdecimal" name="bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed" scale="0" id="Tc_9BWen__u606zTj3BB-Ztbg_22_8">48,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" format="ixt:numdotdecimal" name="bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed" scale="0" id="Tc_w26tfTWnpk6RUI4uXyVu3w_22_14">48,017</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D. </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iwKsVl7Vak-URPtHD_l-rw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" id="Tc_lI2QKCWypU-JfkdGK5Va0g_24_8">191,632</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" id="Tc_xygo01tuIEykSWxYLL3sjQ_24_14">191,632</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nMckWf8ou06gtaq15KVt5A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_4r_xbZxlpEGFCTKfyUC9MQ_26_11">252,639</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_LL6uMa4JmUGN-w1t8xZBcQ_26_14">252,639</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:41.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at November 30, 2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TBAhEDDdsEmkmzUW0oQzAw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_FyfoijdQUUm_UBDPKsYxgw_28_2">131,448,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TBAhEDDdsEmkmzUW0oQzAw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_RPS1lBKcDEeW1z4cdzM-cg_28_5">131,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lKswUaIHiEyn9JevGZ0Gvg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_1IXYAIFtK0u533aPy0SKiQ_28_8">126,380,700</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_C988H_c5lEirXg2bOfyMYw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_iC8caDxxX0K1Munxaduimw_28_11">126,538,777</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_wv6V0T1XTUas73odvYBgmA_28_14">26,628</ix:nonFraction>)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BURZYNSKI RESEARCH INSTITUTE, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">STATEMENT OF STOCKHOLDERS’ EQUITY (DEFICIT)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">For the Nine Months Ended November 30, 2021 </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><a id="_c83b2d33_5711_447a_8f8b_045ea4602615"></a><a id="Tc_MgHDwh9_bkmW7K3IFLmSiA_1_7"></a><a id="Tc_jo7_SdeYqEyIGDvGI5HCQg_1_13"></a><a id="Tc_ABQ1ZJzp0UO-YzIwd0_0DA_2_2"></a><a id="Tc_bXP0NqHh0UK74wHo1ql4YQ_2_7"></a><a id="Tc_s5Zya3ldvUWuXMZKGX9tNw_2_10"></a><a id="Tc__mghCYynC0e95OkmcvD4HA_2_13"></a><a id="Tc_xmymCcomz06CTrKoVgMqgA_3_2"></a><a id="Tc_Ah8dJQ--Qk6mCeI4rzz7tQ_3_4"></a><a id="Tc_8iT2FSm9lk6QqUe_SWVbLw_3_7"></a><a id="Tc_CfKnjdWB5EyO5vX8Sjmkgg_3_10"></a><a id="Tc_JDNWMsLFSUqSZ2_0pVlaHg_3_13"></a><a id="Tc_F6VJdh_R00S7PBW0pRLxQQ_4_0"></a><a id="Tc_qx7CrQ4yJUO5uZMFzvRfIw_4_4"></a><a id="Tc_dzF8PMecnEmP3oWMqUlgXw_4_7"></a><a id="Tc_J3zNN8yQaEOZwWWHXAn83w_4_10"></a><a id="Tc_uu7bus1S7Emaa0VEmTyRgw_4_13"></a><a id="Tc_DC8UGXsUp0WSQKdOMQM8Lg_6_0"></a><a id="Tc_0TnDq7mvRUawn_munttBCg_6_2"></a><a id="Tc_PRotj86-PU64ciziMz4jPw_6_5"></a><a id="Tc_wyT0eshU8Ei1zooqGTSx5w_6_11"></a><a id="Tc_bBBi_BftjU66K2d_LPioIg_8_0"></a><a id="Tc_vvHcA3d-KkSb6dTjergZ1Q_8_2"></a><a id="Tc_TizgrQfCAUenvYts82tTYg_8_5"></a><a id="Tc_Oq9ecIA8OECcfdxtuhRVBw_8_11"></a><a id="Tc_UAGDZb747UmsOucA29ieoA_10_0"></a><a id="Tc_njnM-uh4xkC0oM0b0xnMBg_10_2"></a><a id="Tc_vJRNFRdTckKWtp5fSATncg_10_5"></a><a id="Tc_oD7ahR2_X0yGrz6LUz728A_10_8"></a><a id="Tc_q4I13HcfpEG_X6zz-dnIcw_12_0"></a><a id="Tc_W6Zk_d1AwU2dhkYsuQA7pA_12_4"></a><a id="Tc_EwizK5AIBEeuS4SP1CztaQ_12_7"></a><a id="Tc_zoGZTzRBW025jAH9JKDpIg_12_10"></a><a id="Tc_uc2G0Fuq6Ea2z6GL6dQMOw_12_13"></a><a id="Tc_WEHrXiJUQEupsYNStomfow_14_0"></a><a id="Tc_d2zCaXNPIUu_2WxtoGnE9Q_14_2"></a><a id="Tc_JdhFOuL7Ok2Equ-WlquMrw_14_5"></a><a id="Tc_ZdZ2MRFe60mfd9jg73Dcvw_14_11"></a><a id="Tc_7xGtKsqeXkmxQQS_bcnhUQ_16_0"></a><a id="Tc_QTao8TRBGE2Pr8ZXXWMVnQ_16_2"></a><a id="Tc_lhgGv9g0m0m0eD3N5SIIKw_16_5"></a><a id="Tc_3wkBH-x96k-pci24hSHLfA_16_11"></a><a id="Tc_zBqnRdEoU0GHY0czlePBFA_18_0"></a><a id="Tc_U9ABTyvPREGPjrQLtMXsfA_18_2"></a><a id="Tc_20x-vvm9m0uv0BLKGHkN_w_18_5"></a><a id="Tc_LuUmDHhssk659dXQKsGP6g_18_8"></a><a id="Tc_wD4IjRSjWkuY5fIFXn9zow_20_0"></a><a id="Tc_BxIDBq7IQ0K0vCPQyMBGSA_20_4"></a><a id="Tc_9emS0Iq8MUCO4T4WYZOEjw_20_7"></a><a id="Tc_WldnKyo4FUORNVRlAzehBA_20_10"></a><a id="Tc_Jo9wK-P3rkOsQfzYfRRV3Q_20_13"></a><a id="Tc_ci5_jPEYf0Oswheh7SHIrg_22_0"></a><a id="Tc_HzwxzLEddEWl5lek9gphYA_22_2"></a><a id="Tc_uJqwqJGzFkK6YDGscWlrlA_22_5"></a><a id="Tc_pZUKYSfte0GQrwgVepeUCw_22_11"></a><a id="Tc_gPNn4F2fTUuJKdCyuaHTgA_24_0"></a><a id="Tc_tNouh7LiI0yQk1IiEAYqgw_24_2"></a><a id="Tc_Aj_5dQqu3EuhONtleaYnsw_24_5"></a><a id="Tc_XecfTSr-_kyFRaZShD5l6w_24_11"></a><a id="Tc_oLz-RdKSgU-AOz_QcVRDIA_26_0"></a><a id="Tc_UtsY4OjprEyHBxKXh3PHQg_26_2"></a><a id="Tc_D26MKdKahEWH4teFMdFQrw_26_5"></a><a id="Tc_DedJ7htfyk-kbpr_TmhEUQ_26_8"></a><a id="Tc_fEAT63e_4E2ZS4AgjMMkTQ_28_0"></a><a id="Tc_IQeKmQR110-21ASTWj9bVA_28_4"></a><a id="Tc__BovrMN1CUSHAf2um_zfcw_28_7"></a><a id="Tc_-ikCoLO6GEqLa9ODmJjZiQ_28_10"></a><a id="Tc_8MXz95XZ8EK_5cxvyZwPbw_28_13"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:19.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Retained</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders’</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:7.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity (Deficit)</b></p></td></tr><tr><td style="vertical-align:top;width:41.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at February 28, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QcYgvQm1sU2dNqhqk7HHhQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_VGaGgp6i2Ey0ZgIDREoikg_4_2">131,448,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QcYgvQm1sU2dNqhqk7HHhQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc__icU0a3Yu0mNMonZ55U6sA_4_5">131,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_txIuVwJscEWQsoDWljOsLg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_junwrPKJIEmkVHIaNLNv3Q_4_8">124,684,535</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0DY2kRmuRkykwMzYCLMEag" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_DJg880nLckeBdwIG5ZLuOw_4_11">124,861,827</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2021_tz3utn4GW0icSAfEmME0tQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_HIwVQV1kzkeHQ6S5eAHmlQ_4_14">45,843</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash contributed by S.R. Burzynski M.D., Ph.D. </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-cT_vEjUDUW-S5rQVrW9Gg" decimals="0" format="ixt:numdotdecimal" name="bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed" scale="0" id="Tc_jhgJAXpOlU6YJn4APebaug_6_8">84,967</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_5_31_2021_UX5UtaTbT0eersU02GWvMg" decimals="0" format="ixt:numdotdecimal" name="bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed" scale="0" id="Tc_6Hs2hpbqPEuYXNQf9cmdbg_6_14">84,967</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D. </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-cT_vEjUDUW-S5rQVrW9Gg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" id="Tc_OOVnJD1P5kKQjK63guAtyQ_8_8">215,926</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_5_31_2021_UX5UtaTbT0eersU02GWvMg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" id="Tc_tDGrLJuX4E-TWCd3fxCHrA_8_14">215,926</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TeJKkXhGtEWygQhcQKp9qw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_8PzGLXh8AEq34v8mnsUTQw_10_11">316,283</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_5_31_2021_UX5UtaTbT0eersU02GWvMg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_9BuKPUFn1EOinNJB7WAEcQ_10_14">316,283</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at May 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IUIR5alQTkqIkz4yW1duxw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_FGVFJWs--EKbwTnxBN2dQA_12_2">131,448,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IUIR5alQTkqIkz4yW1duxw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_GnFUYCDKx0e0VpTdPzctuw_12_5">131,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OnyyqaGUF0iy63pvlajMzw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_mh3mPRXLqkCiweS8oVXSaA_12_8">124,985,428</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lNN1yxnejk2tW8zeN_uI2A" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_6_1GuNJcwE6JnEUsHmbHmQ_12_11">125,178,110</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_5_31_2021_qG8hjPs1ckabOxyw-IisaA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_dCGs3Xe3L06Yc0Mzet2Ttw_12_14">61,233</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash contributed by S.R. Burzynski M.D., Ph.D. </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_6_1_2021_To_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dq8AzYWypkmsekLWBSXMwQ" decimals="0" format="ixt:numdotdecimal" name="bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed" scale="0" id="Tc_qm98gL0EeEW_C6SuBTL4lA_14_8">87,717</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_6_1_2021_To_8_31_2021_eTo4YOsOQkSH1oSW4mRAFA" decimals="0" format="ixt:numdotdecimal" name="bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed" scale="0" id="Tc_1MkehFilGUeFLGZPsFV8lQ_14_14">87,717</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D. </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_6_1_2021_To_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dq8AzYWypkmsekLWBSXMwQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" id="Tc_TQv0IjUjzU2iV3z2yyrWjQ_16_8">170,403</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_6_1_2021_To_8_31_2021_eTo4YOsOQkSH1oSW4mRAFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" id="Tc_4Q3AFkl5OEin9M7yQc8GwQ_16_14">170,403</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_6_1_2021_To_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4_eOqZpcUk-67OjGO1pofg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_JmxpKH5EVUOCNjpr5d86Vg_18_11">224,718</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_6_1_2021_To_8_31_2021_eTo4YOsOQkSH1oSW4mRAFA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_NudSdsCcLE2BVSlfdpL2Tw_18_14">224,718</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance August 31, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sb_rwZ6nVU-g3e9Wdj7-7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_98c_qj2J2EeFw5xEM6T2Dw_20_2">131,448,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sb_rwZ6nVU-g3e9Wdj7-7w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_wYSEO93yEkalLQoAxb1vCQ_20_5">131,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QfVTYoRMfUOqPfb1PY4Qtw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_Yr2p8z3sMEWDBTxr3bCMww_20_8">125,243,548</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_t40J9Yyvp0eMzCsyd170Lw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_LvE8GRdUlkWj229iPJ9-jQ_20_11">125,402,828</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_8_31_2021_LiQ_dJGijkqI7kTCGFYSOg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_JcIpectafECXb6lcEnOI6g_20_14">27,831</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash contributed by S.R. Burzynski M.D., Ph.D. </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_I_jFFJLfpEun5ot6_dLYjA" decimals="0" format="ixt:numdotdecimal" name="bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed" scale="0" id="Tc_T19POTbaxkK8lBqL4GowSw_22_8">100,017</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" format="ixt:numdotdecimal" name="bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed" scale="0" id="Tc_CbBbHHiO00iaHObBe7IQ5g_22_14">100,017</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D. </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_I_jFFJLfpEun5ot6_dLYjA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" id="Tc_FrxTzcguUEujhnbz0THsZQ_24_8">197,940</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalOther" scale="0" id="Tc_arhDhopNZ0uq1UY7obbsIg_24_14">197,940</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">—</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_k3hpjFE5JU65xKnnzgO2vQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_Jjkga7TqAU2peGjP1Xmg2Q_26_11">264,776</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_M67eP-h8z0uL6rOG6bLazw_26_14">264,776</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:41.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:41.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Balance at November 30, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XeOxpxRW2k2UySfWnD5UMQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharesOutstanding" scale="0" id="Tc_QEnrr3utdUmBultVb0Ub2A_28_2">131,448,444</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.03%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XeOxpxRW2k2UySfWnD5UMQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_1ibGcZiDW0qLmxPFnr-QQQ_28_5">131,449</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.27%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gtjfx8jA70qc4SM14Yj3jw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_6oELFffTfEmQVyn2wxbB1w_28_8">125,541,505</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.96%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3HnDsSVLSEaSsHcQ_eD5WQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="0" id="Tc_RQ-TgjGp10CQNSs-Gx5THg_28_11">125,667,604</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2021_2QExRwQy1EushHKZUUQPGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="0" id="Tc_GJrbqP6uY0KAioe1GX_OfA_28_14">5,350</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">See accompanying notes to financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_d226e28d_0a8d_4da0_a88e_6daa10dbf38f"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BURZYNSKI RESEARCH INSTITUTE, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">STATEMENTS OF CASH FLOWS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">(UNAUDITED)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><a id="_be1ebf7e_57e6_45c0_a69b_92c20c10620f"></a><a id="Tc_uNk6KhqGOkmVTsktcrartA_1_2"></a><a id="Tc_GMXfpxVZUUeuY6WPJFe_7Q_2_2"></a><a id="Tc_d0QN74FMlEqyHoYfrEYfHg_2_5"></a><a id="Tc_djVpacZg30-eOIC4f3nzAg_3_0"></a><a id="Tc_nxInkhh5T0-sc4F7IuXP-A_4_0"></a><a id="Tc_jq9iDG5BeUyCDsNXWYIT-g_4_2"></a><a id="Tc_ipjKs_2NpEOtvMjRDtgrMQ_4_5"></a><a id="Tc_RP7yelwY6kKr56TUjFmfUg_5_0"></a><a id="Tc_aAaGhai2dkCBKKFg_1pY7g_6_0"></a><a id="Tc_tS-6z6eDVUCBVA_-40qSDA_8_0"></a><a id="Tc_I6499F_tL0eKtdSZD5UkpA_9_0"></a><a id="Tc_q49djN4y9kqgObGysUDJwg_10_0"></a><a id="Tc_QKWTOswq4EyiKP2eJg9ilQ_11_0"></a><a id="Tc_eWl_qLgcOUCV1rqGeJ_vsg_13_0"></a><a id="Tc_yS1U4Ilq2ES5NJ2obv_7Wg_15_0"></a><a id="Tc_07vAjozBVUSuSFrZfqw7SQ_16_0"></a><a id="Tc_Fv2a5rUWGEuJTpJ6w55V2Q_18_0"></a><a id="Tc_vwM1BeUxi0ykBn4BaKF4_Q_20_0"></a><a id="Tc__rAYYd2wQkWTND06a29Hqg_22_0"></a><a id="Tc_DgHXPB09TkKdPYRbFDp12g_24_0"></a><a id="Tc_dL9O4QlsJ0eRI1P98uPgmg_24_2"></a><a id="Tc_JHUvhK-CakGrZZF_cbBsQA_24_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended November 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CASH FLOWS FROM OPERATING ACTIVITIES </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Net loss </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_NWD-nVhv30WyYdw32gTcNw_4_3">700,294</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" sign="-" scale="0" id="Tc_h0zW0KpgOEyMH3zToRt61g_4_6">805,777</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Adjustments to reconcile net loss to net cash used by operating activities: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D. </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="bzyr:ClinicalTrialExpensesPaid" scale="0" id="Tc_fxYj8iD2SkSqMTCLJ0W7mQ_6_3">497,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="bzyr:ClinicalTrialExpensesPaid" scale="0" id="Tc_yq8XR2H9-UyneWJm3RL1Sw_6_6">584,270</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 24pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 18pt;">Changes in operating assets and liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Prepaids</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" sign="-" scale="0" id="Tc_7yyqT8cIsEudxzWrHCN_Dg_9_3">1,179</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidExpense" scale="0" id="Tc_WMHYFIs8EUafJIJyJNAvrQ_9_6">80</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accounts payable </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="0" id="Tc_OZ5ETSdC806mcRVlRF_naw_10_3">16,650</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="0" id="Tc_N3EUjtExNUyFd4vxIx24dA_10_6">31,123</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 24pt;">Accrued liabilities </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="0" id="Tc_u-9SkkDKhEuTIfJXmcFFiQ_11_3">8,315</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" sign="-" scale="0" id="Tc_Yje6F6_U9EuGb2UEqGr1xg_11_6">14,287</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">NET CASH USED BY OPERATING ACTIVITIES </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_IxeuQKTKZ0Kisso5_g_MPA_13_3">176,241</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="0" id="Tc_CYj2datPsUOkvqteCALVZw_13_6">266,997</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CASH FLOWS FROM FINANCING ACTIVITIES </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Contribution of capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromContributedCapital" scale="0" id="Tc_RG1TiH94wkObxcjvZD0_Tg_16_3">174,551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromContributedCapital" scale="0" id="Tc_NFY8OV0ddE22iZPBs_wsaw_16_6">272,701</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">NET CASH PROVIDED BY FINANCING ACTIVITIES </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_EMRjifAZ2EeQPfkSvSJlyQ_18_3">174,551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" id="Tc_YcP5mgjKBk-Ga84OLh0Gyw_18_6">272,701</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">NET INCREASE (DECREASE) IN CASH </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" sign="-" scale="0" id="Tc_XPOW-3wzlEynjbhxglBR4Q_20_3">1,690</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" scale="0" id="Tc_Y2qVE9DKP0eecAVvIPzxJQ_20_6">5,704</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CASH AT BEGINNING OF PERIOD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_jxj7zqmzcUK2xsYIZ79pMA_22_3">3,382</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_2_28_2021_tz3utn4GW0icSAfEmME0tQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_a2ygXW1MpkeEdAZk_Tx1Pg_22_6">62</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:right;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:74.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">CASH AT END OF PERIOD</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc_n2htFpO--kaLI2jxu4cRqg_24_3">1,692</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.25%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2021_2QExRwQy1EushHKZUUQPGg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" id="Tc__Tu3-Vs-OE6rU2vdScVtGQ_24_6">5,766</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">See accompanying notes to financial statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_42c3817c_ca53_4fe5_8785_197b664fe33d"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BURZYNSKI RESEARCH INSTITUTE, INC.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NOTES TO FINANCIAL STATEMENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_gRpGNCq08ECxBwUuJqY_PQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE A.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">BASIS OF PRESENTATION</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The financial statements of Burzynski Research Institute, <span style="white-space:pre-wrap;">Inc. (the “Company”), a Delaware corporation, include expenses incurred related to clinical trials, which were sanctioned by the U.S. Food and Drug Administration (FDA) in 1993, for Antineoplaston drugs used in the treatment of cancer. These expenses are incurred directly by S.R. Burzynski, M.D., Ph.D. (Dr. </span><span style="white-space:pre-wrap;">Burzynski or “SRB”) on behalf of the Company and have been reported as research and development costs and as additional paid-in capital. Other funds received from Dr. </span><span style="white-space:pre-wrap;">Burzynski have also been reported as additional paid-in capital. Expenses related to Dr. </span><span style="white-space:pre-wrap;">Burzynski’s medical practice (unrelated to the clinical trials) have not been included in these financial statements. Dr. Burzynski is the President, Chairman of the Board and owner of approximately </span><ix:nonFraction unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="3" format="ixt:numdotdecimal" name="bzyr:OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard" scale="-2" id="Narr__nNxLZizvUSYOsrGV1Vy-w">81.0</ix:nonFraction>% of the outstanding common stock of the Company, and also is the inventor and original patent holder of certain drug products known as “Antineoplastons.” </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company and Dr. <span style="white-space:pre-wrap;">Burzynski have entered into various agreements as further described in Note B. The License Agreement between the Company and Dr. Burzynski provided the Company the exclusive right in the United States, Canada and Mexico to use, manufacture, develop, sell, distribute, sublicense and otherwise exploit all the rights, titles and interest in Antineoplaston drugs used in the treatment of cancer, once the drug is approved for sale by the FDA. On July 2, 2019, the License Agreement terminated upon the expiration of the last patent licensed to the Company under such agreement. As such, the Company does not currently have licenses to any patents with respect to Antineoplastons. The Company does own </span><ix:nonFraction unitRef="Unit_Standard_patent_dlojMfgdTECMpi5PU4YRsw" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="INF" format="ixt-sec:numwordsen" name="bzyr:NumberOfPatentsOwned" scale="0" id="Narr_y9iDBZF7NkSREWtt825jEg">one</ix:nonFraction> US patent which was recently issued on May 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company is primarily engaged as a research and development facility for Antineoplaston drugs being tested for the use in the treatment of cancer. The Company’s investigational new drug application (“IND”) 43742 is currently under full clinical hold and the Company cannot enroll new patients into any clinical trials until the full clinical hold is removed by the FDA. At this time, however, <ix:nonFraction unitRef="Unit_Standard_item_REEsf0XHJUOQ1iZoyc7Pvg" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="INF" format="ixt-sec:numwordsen" name="bzyr:NumberOfAntineoplastonDrugsThatReceivedFDAApproval" scale="0" id="Narr_STI7GYlH_0WvWSb4bIeFQg">none</ix:nonFraction> of the Antineoplaston drugs have received FDA approval; further, there can be no assurance that FDA approval will be granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Certain disclosures and information normally included in financial statements have been condensed or omitted. In the opinion of management of the Company, these financial statements contain all adjustments necessary for a fair presentation of financial position as of November 30, 2022 and February 28, 2022, results of operations for the three and nine months ended November 30, 2022 and 2021, and cash flows for the nine months ended November 30, 2022 and 2021. All adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results to be expected for a full year. These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;background:#00ff00;">​</span></p><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="Tb_5A6EestbFEeLpu8wK9a8jg" continuedAt="Tb_5A6EestbFEeLpu8wK9a8jg_cont1" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE B.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">ECONOMIC DEPENDENCY</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The Company has not generated significant revenues since its inception and has suffered losses from operations, has a working capital deficit and has an accumulated deficit. Dr. Burzynski has funded the capital and operational needs of the Company through his medical practice since inception, and has entered into various agreements to continue such funding.</span> Because the Company is entirely dependent upon the contributions for research provided by Dr. Burzynski under a research funding agreement, the Company would not be able to continue conducting its clinical trials if Dr. Burzynski ceased funding the Company’s research. In such event, the Company would be required to find immediate funding which may not be available on acceptable terms or at all. If this were to occur and the Company were not able to find adequate sources of funding, the Company would be required to cease operations. Even with Dr. Burzynski’s continued contributions under a research funding agreement, the Company may be required to seek additional capital through equity or debt financing or the sale of assets until the Company’s operating revenues are sufficient to cover operating costs and provide positive cash flow; however, there can be no assurance that the Company will be able to raise such additional capital on acceptable terms to the Company. In addition, there can be no assurance that the Company will ever achieve positive operating cash flow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></ix:nonNumeric></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_5A6EestbFEeLpu8wK9a8jg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The Company is economically dependent on its funding through Dr. Burzynski’s medical practice. In the past, a portion of Dr. Burzynski’s patients have been admitted and treated as part of the clinical trial programs. The Company’s IND 43742 is currently under full clinical hold and the Company cannot enroll new patients into any clinical trials until the full clinical hold is removed by the FDA. The FDA imposes numerous regulations and requirements regarding these patients, and the Company is subject to inspection at any time by the FDA. These regulations are complex and subject to interpretation and though it is management’s intention to comply fully with all such regulations, there is the risk that the Company is not in compliance and is thus subject to sanctions imposed by the FDA. In addition, as with any medical practice, Dr. Burzynski is subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice. The risks associated with Dr. Burzynski’s medical practice directly affect his ability to fund the operations of the Company.</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><a id="Tc_vJJ-NsBoUkW7ML7Yhvkb7w_1_3"></a><a id="Tc_Lpvl6qJSdEyRghn5gQ7zjQ_2_1"></a><a id="Tc_D5bJ9JWVCUOsPuAU1Nhlbw_2_3"></a><a id="Tc_9naJ8JDSBkafGarix1PrSw_3_1"></a><a id="Tc_u8xxH5DGVEOtNYogvria-Q_3_3"></a><a id="Tc_C1BPsSqJ5Uu8bBSOldjCfQ_4_1"></a><a id="Tc_PK-oCpmQM0Oy-WXIC3hIVQ_4_3"></a><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_Hc6XexBTQ0qsAa-vi0qYAQ" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE C.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">STOCK OPTIONS AND WARRANTS</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">At November 30, 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_item_REEsf0XHJUOQ1iZoyc7Pvg" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="INF" format="ixt-sec:numwordsen" name="bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" scale="0" id="Narr_uzLrQ6WZckSx5Fp16v_2Dw">one</ix:nonFraction> stock-based employee compensation plan, which is described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">On September 14, 1996, the Company granted <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9J2vQo42mEG22C8KOHHe-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Narr_0X1iuf1uaUGbIpzPBMbfaw">600,000</ix:nonFraction> stock options, with an exercise price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ" contextRef="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9J2vQo42mEG22C8KOHHe-A" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Narr_4hPVTaghtEiWejSSVJzl3Q">0.35</ix:nonFraction><span style="white-space:pre-wrap;"> per share, to an officer who is no longer with the Company. </span>The options vested as follows:</p><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" id="Tb_a5whp90HAkmXdQNl1NKO2Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vesting Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9J2vQo42mEG22C8KOHHe-A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Tc_9azp6HeFWUi9AxjaUtdLlg_2_0">400,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">September 14, 1996</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_6_1_1997_To_6_1_1997_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_lrGBPtct1kCgRQmYPd7n8Q" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Tc_DOu75leMrkSjliSIjtcD0Q_3_0">100,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">June 1, 1997</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_6_1_1998_To_6_1_1998_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DbEucoULE0aMqQ_3EsFxqA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" id="Tc_Df8H72L-pkaBZranw_TzYQ_4_0">100,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">June 1, 1998</p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The options are valid in perpetuity. </span><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_3_1_2022_To_11_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_67nM8Z7lXEy5aoImbV3iJg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Narr_9chjAb2Xb0Srt3TxDCqdlA">None</ix:nonFraction> of the options have been exercised as of November 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company accounts for share-based payments to non-employees in accordance with the guidance provided by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718, <i style="font-style:italic;">Compensation – Stock Compensation</i> to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity’s own operations and supersedes the guidance in ASC 505-50.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;">Effective July 5, 2012, the Company entered into a Marketing and Consulting Agreement (the “Marketing Agreement”) with Worldwide Medical Consultants, Inc. (“WMC”) and CARIGEN, LTD (“SRB”), an entity wholly-owned and controlled by Dr. Burzynski, pursuant to which WMC will (i) provide SRB with various marketing and consulting services to assist SRB in locating and developing cancer or health related centers in certain foreign markets and (ii) make payments to the Company equal to </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ" contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_ailYsCoPekC30-IUv4AkDw" decimals="2" format="ixt:numdotdecimal" name="bzyr:PercentageOfConsultingFeeToBeReceivedAsPerAgreement" scale="-2" id="Narr_Vt3MQ4jbREOtdEM11hbQNw">10</ix:nonFraction>%</span><span style="font-size:10pt;"> of each consulting fee received by WMC for the aforementioned services provided to SRB, net of certain expenses incurred by WMC (“WMC Payment”). In consideration of the WMC Payment, the Company agreed to grant to WMC warrants to acquire an aggregate of </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_k0yzPQpwzUKU2JiaPznW_w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" id="Narr_Az5QnKpx10CWXT8YlV7R2Q">2,000,000</ix:nonFraction></span><span style="font-size:10pt;"> shares of the Company’s Common Stock, exercisable at </span><span style="font-size:10pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ" contextRef="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_k0yzPQpwzUKU2JiaPznW_w" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="Narr_qn-B4YB1DkKqXLsTNViw7g">0.10</ix:nonFraction></span><span style="font-size:10pt;"> per share with a </span><ix:nonNumeric contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_ailYsCoPekC30-IUv4AkDw" format="ixt-sec:durwordsen" name="bzyr:ClassOfWarrantOrRightsExercisePeriod" id="Narr_m5aBmSx-YUedPOu8khhqrg"><span style="font-size:10pt;">ten year</span></ix:nonNumeric><span style="font-size:10pt;"> exercise period, with </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_ailYsCoPekC30-IUv4AkDw" decimals="INF" format="ixt:numdotdecimal" name="bzyr:SharesVestingUponExecutionOfAgreement" scale="0" id="Narr_HR8Iv4ry70mhiiJagrrlbw">1,000,000</ix:nonFraction></span><span style="font-size:10pt;"> shares vesting upon execution of the agreement (the "Initial Warrants") and the remaining </span><span style="font-size:10pt;"><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_ailYsCoPekC30-IUv4AkDw" decimals="INF" format="ixt:numdotdecimal" name="bzyr:RemainingSharesToVestUponFirstClosingOfAgreement" scale="0" id="Narr_wiw8wRLqI0aKMRAvsKF6vw">1,000,000</ix:nonFraction></span><span style="font-size:10pt;"> shares to vest upon the first closing of a transaction by SRB as a result of the services provided by WMC under the Marketing Agreement. The Marketing Agreement was terminated effective as of July 5, 2019 pursuant to its terms. The Initial Warrants expired on July 5, 2022 and were never exercised.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_qmuC7AxMq0Oi3twODYDdeA" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE D.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">LOSS PER COMMON SHARE</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company accounts for loss per share in accordance with FASB ASC 260, <i style="font-style:italic;">Earnings per Share</i>. Basic loss per share amounts are calculated by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the periods, including the dilutive effect of all common stock equivalents. Dilutive options and warrants that are issued during a period or that expire or are canceled during a period are reflected in the computations for the time they were outstanding during the periods being reported. During the three and nine months ended November 30, 2022 and 2021, <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_3_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_CFxwHANUYkWnJB9fZNUxkg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_inT3yJ4V3Eqh66fJpup0Sg"><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_9_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_kxHbs4IXUEaF_-ZHCfDT7w" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_E4EbosmIxUikQ01pygmNyw"><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_3_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_q5rwaskLYUu_ZDbHfAs6pw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_a91NNemd3EO6wY5jb2wgHA"><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_9_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Q6hxXm5dK0q5su70AGA9ow" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_WFHgtaIcAE28pOEQBK8HRA">600,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> stock options and <ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_3_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_wVzlOVFTnUa4yodykmvUJw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_az9o4f8ah0iQQrzIRmFdNw"><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_9_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_u75x1ek-KkeJ32monPyZiQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_Zq4iX6WrI0K0D_sN_PHtaQ"><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_3_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_dopENHjSVkec1zCh35q5Hg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_MzFTeplZU0qjQ4PC73MVgw"><ix:nonFraction unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA" contextRef="Duration_9_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_mGRKAPT_d0i6xvYOzqjuhw" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Narr_hSwgaVHNS0OmF_Y2UsYBQA">1,600,000</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> warrants and stock options, respectively, were excluded from the calculation of diluted loss per share because their effect would be anti-dilutive.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_949aa15e_9eee_4758_a03b_232dadbfd0ad"></a><a id="Tc_gMlm4Uwm406z2oC6EaXyvQ_1_2"></a><a id="Tc_fsHj-4HGvUmSzryj9C-xow_2_2"></a><a id="Tc_o9d-sO9jR0KCgYKQFvieuA_2_5"></a><a id="Tc_LqjGJn7aTUCcvPnh4A22lA_3_0"></a><a id="Tc_-XL-XjN0SUWAuPt7RE7vyA_3_2"></a><a id="Tc_i84ouW8fN0uDnb9RBl77PQ_3_5"></a><a id="Tc_8rK_gcqWiUmOG03DcFQt4g_4_0"></a><a id="Tc_lQO-ykb5qECt24xKyMA7zA_5_0"></a><a id="Tc_JTpBSDVlj0WH_oDLGPI4Mw_6_0"></a><a id="Tc_MVOJJFiLiUei0uxOEhlPyg_7_0"></a><a id="Tc_DbEbRlymYUmkBaj2DyLexQ_7_3"></a><a id="Tc_Ihx5Iu2iyU6o5PEobMpnsA_7_6"></a><a id="Tc_LIqNjt3s9k6Xyw2ZL5INLg_8_0"></a><a id="Tc_uvFbki5-4ESL9OriXh8chw_8_2"></a><a id="Tc_4lSdoezIGEKrnwSVj_8dhQ_8_3"></a><a id="Tc_AE7IP5Lq9kaHUYviCStBVw_8_5"></a><a id="Tc_Xj1rCT-xREiVK7vn4_JZtA_8_6"></a><a id="_c0c6af4e_e12e_4383_941f_1566db55c1df"></a><a id="Tc_1iT38vCAOka-3Y5koucFkA_1_2"></a><a id="Tc_GsMSXdLJc0G6dC0dqNImmQ_2_2"></a><a id="Tc_uCtC0z-TPkWtYOMW6n1rQA_2_5"></a><a id="Tc_vDXuE1jy5kOrbELGZkvQQg_3_0"></a><a id="Tc_oWDPzJ58QEKpHxvIPz0crg_3_2"></a><a id="Tc_zq3-Q9ahG0-ZAX2h26zokQ_3_5"></a><a id="Tc_AdvhCGWSYUu_7tSvXy1Auw_4_0"></a><a id="Tc_WINzDhvim02yIIMkP_hySg_5_0"></a><a id="Tc_7ZACwCHe0keIK9sYsQA9gQ_6_0"></a><a id="Tc_ArlvHQ6MmkOS2IYvVtCV5w_7_0"></a><a id="Tc_9NNVATYM5k6yz6CnpjqOmA_7_3"></a><a id="Tc__GdT04EmIUadwB8W2W5oBA_7_6"></a><a id="Tc_KyWV2SgGaUKSe82yr7r99w_8_0"></a><a id="Tc_h0_cLfeQ3UKWfGRRll2nqw_8_2"></a><a id="Tc_IHgz73qTlUOw933E0eNPnw_8_3"></a><a id="Tc_Z80QCf-F4E27MhU_uQcW3g_8_5"></a><a id="Tc_I0xCt5cD7k60UqFku1HoTA_8_6"></a><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_Zz-p5pLRokepfwo1wxMUag" escape="true"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE E.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">INCOME TAXES</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company follows the provisions of FASB ASC 740, <i style="font-style:italic;">Income Taxes</i><span style="white-space:pre-wrap;">. The Company is not aware of any material unrecognized tax uncertainties as a result of tax positions previously taken.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company recognizes interest and penalties as interest expense when they are accrued or assessed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;white-space:pre-wrap;">The federal income tax returns of the Company for 2021, 2020, and 2019 are subject to examination by the IRS, generally for </span><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_gY1j0FUXpUGEySuC7dEpCA" format="ixt-sec:durwordsen" name="bzyr:IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination" id="Narr_--4VoN1LOECPcYyP_-LggQ"><span style="font-size:10pt;">three years</span></ix:nonNumeric><span style="font-size:10pt;"> after they are filed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The actual provision for income tax for the three and nine months ended November 30, 2022 and 2021 differ from the amounts computed by applying the U.S. federal income tax rate of <ix:nonFraction unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_A7Ckl44IskqDxisVVhx_YQ"><ix:nonFraction unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_1sJSO1J5c0yb4kAsD6mlPQ"><ix:nonFraction unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_WRT1dwr0bEug-Nqs5tyRoQ"><ix:nonFraction unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Narr_HuVKQsEOcUqs9n0MlrLrcw">21</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction>% to the pretax loss as a result of the following:</p><ix:nonNumeric contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="Tb_eRxdekB7cU2sQnDjAHqo2Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended November 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_mfbv36wIkkW1xVXiCxxUrw_3_3">53,054</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_ff_jzN7Gw0O0wYdRrqWeiA_3_6">55,603</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxed directly to Dr. Burzynski </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationDeductions" scale="0" id="Tc_MRT6-jHENkmEqUqkcHqZ3g_4_3">53,054</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationDeductions" scale="0" id="Tc_80J0mInHqkG8MoraZkvqrA_4_6">55,603</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible expenses and other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" id="Tc_TUYPMvzfbE6UCamKXMcdRw_5_3">2,728</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" sign="-" scale="0" id="Tc_HpdvQm6wHEuMN-HT5jnpFA_5_6">6,968</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="0" id="Tc_6e2Fwo8LiECwaOKiYJsRdg_6_3">2,728</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_x7AZuq3RMEuVz7xtxm0U6w_6_6">6,968</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.29%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended November 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_xXvLf4rmhk2FimikZiChzg_3_3">147,062</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" sign="-" scale="0" id="Tc_Kg89E9QgVUqSTUt4N6HUeQ_3_6">169,213</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxed directly to Dr. Burzynski </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationDeductions" scale="0" id="Tc_XFhOPdaEBUK16ln0RV4UJg_4_3">147,062</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationDeductions" scale="0" id="Tc_JVUHCb41qUiJZLNOt622vw_4_6">169,213</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible expenses and other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" scale="0" id="Tc_qlVskqwvNkegEKTWTloX5A_5_3">5,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationNondeductibleExpense" sign="-" scale="0" id="Tc_Vz-0Gg_hmUOibxPQJOptjA_5_6">10,751</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="0" id="Tc_rKeMYrv-_0SdTfYN7puC1w_6_3">5,845</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="0" id="Tc_3BVe5aJALUSQ7gGejnvnHA_6_6">10,751</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">At November 30, 2022, the Company had a net deferred tax asset of $<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="0" id="Narr_Q4_b6GsTeUKIw-HAoV9OJg">0</ix:nonFraction>, which includes a valuation allowance of $<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" id="Narr_qGJuVTUc9EenyeccQgZFuw">164,547</ix:nonFraction><span style="white-space:pre-wrap;">. The Company’s ability to utilize net operating loss ("NOL") carryforwards and alternative minimum tax credit carryforwards will depend on its ability to generate adequate future taxable income. The Company has </span><ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:Revenues" scale="0" id="Narr_OskAeRNHEEui9moWr9E4vQ">no</ix:nonFraction><span style="white-space:pre-wrap;"> historical earnings on which to base an expectation of future taxable income. Accordingly, a full valuation allowance for deferred tax assets has been provided.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">As a result of the Tax Cuts and Jobs Act of 2017 (the "Act"), NOL carryforwards generated in years beginning after December 31, 2017, would carryforward indefinitely, and would apply to <ix:nonFraction unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="2" format="ixt:numdotdecimal" name="bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards" scale="-2" id="Narr_ZCHKFmC2aU2VijGRRlpJcg">80</ix:nonFraction>% of future taxable income. Under the Act, carrybacks of NOLs were disallowed. In March 2020, the Coronavirus Aid, Relief, and Economic Security ("CARES") Act was enacted providing a five-year carryback for losses incurred in 2018, 2019, or 2020, which allows companies to modify tax returns up to five years prior to offset taxable income from those tax years. The CARES Act also temporarily suspended the NOL limit of <ix:nonFraction unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="2" format="ixt:numdotdecimal" name="bzyr:PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct" scale="-2" id="Narr_vr0RiisQ9kOb_B80Z9-fHw">80</ix:nonFraction>%<span style="white-space:pre-wrap;"> of taxable income through December 31, 2020, but the NOLs generated in 2018 and forward would still carryforward indefinitely. Effective January 1, 2021, NOL carryforwards generated will only apply to </span><ix:nonFraction unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="2" format="ixt:numdotdecimal" name="bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards" scale="-2" id="Narr_NoWIdTxCKEOpeS2bi6nP0g">80</ix:nonFraction>% of future taxable income according to the Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">As of November 30, 2022, the Company has net operating loss carryforwards in the amount of $<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="As_Of_11_30_2022_us-gaap_TaxPeriodAxis_us-gaap_LatestTaxYearMember_PYUkT8vb4kidxIHJrwE-Mg" decimals="0" format="ixt:numdotdecimal" name="bzyr:TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards" scale="0" id="Narr_i5R4raHR9Um4dgaoDjq5tw">473,902</ix:nonFraction> that will expire between 2026 and 2038, and $<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" format="ixt:numdotdecimal" name="bzyr:NetOperatingLossCarryForwardIndefinitely" scale="0" id="Narr_wVNlC9dS_0mbrRyA0rGvyA">106,782</ix:nonFraction> that will carryforward indefinitely, of which $<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_srt_StatementScenarioAxis_bzyr_HundredPercentFutureTaxableIncomeMember_-mkCDpGPAUaxUXrXRSUTtA" decimals="0" format="ixt:numdotdecimal" name="bzyr:NetOperatingLossCarryForwardIndefinitely" scale="0" id="Narr_8zuIJR3O1EGvpA-Op9F7ZA">78,948</ix:nonFraction> applies to <ix:nonFraction unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ" contextRef="Duration_3_1_2022_To_11_30_2022_srt_StatementScenarioAxis_bzyr_HundredPercentFutureTaxableIncomeMember_-mkCDpGPAUaxUXrXRSUTtA" decimals="2" format="ixt:numdotdecimal" name="bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards" scale="-2" id="Narr_Lvd5iki5H02fKqYq4VRQ4Q">100</ix:nonFraction>% of future taxable income and $<ix:nonFraction unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" contextRef="Duration_3_1_2022_To_11_30_2022_srt_StatementScenarioAxis_bzyr_EightyPercentFutureTaxableIncomeMember_QhqQJfwexky0p43BckGK3w" decimals="0" format="ixt:numdotdecimal" name="bzyr:NetOperatingLossCarryForwardIndefinitely" scale="0" id="Narr_thtQRJ-d00yuFX0ln24How">27,834</ix:nonFraction> applies to <ix:nonFraction unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ" contextRef="Duration_3_1_2022_To_11_30_2022_srt_StatementScenarioAxis_bzyr_EightyPercentFutureTaxableIncomeMember_QhqQJfwexky0p43BckGK3w" decimals="2" format="ixt:numdotdecimal" name="bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards" scale="-2" id="Narr_Kic-n82i-kmSeq-VYb-efQ">80</ix:nonFraction>% of future taxable income.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_f286bee5_fba7_4c43_a809_7b4628e051da"></a><a id="Item2ManagementsDiscussionandAnalysisofF"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following is a discussion of the financial condition of the Company as of November 30, 2022, and the results of operations comparing the three and nine months ended November 30, 2022 and 2021. It should be read in conjunction with the financial statements and the notes thereto included elsewhere in this report and in conjunction with the Annual Report on Form 10-K for the year ended February 28, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Forward-Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Certain matters discussed in this quarterly report, except for historical information contained herein, may constitute “forward-looking statements” that are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Forward-looking statements provide current expectations of future events based on certain assumptions. These statements encompass information that does not directly relate to any historical or current fact and often may be identified with words such as “anticipates,” “believes,” “expects,” “estimates,” “intends,” “plans,” “projects” and other similar expressions. Management’s expectations and assumptions regarding Company operations and other future results are subject to risks, uncertainties and other factors that could cause actual results to differ materially from the anticipated results or other expectations expressed in the forward-looking statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Introduction</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company is primarily engaged as a research and development facility of drugs currently being tested for the use in the treatment of cancer, and provides consulting services. The Company’s clinical trial initiated in April 2016 for children and adults with Diffuse Intrinsic Pontine Glioma (DIPG) (protocol “BT-55”) is currently under full clinical hold.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On September 3, 2004, the FDA granted the Company’s request for “orphan drug designation” (“ODD”) for the Company’s Antineoplastons (A10 & AS2-1 Antineoplaston) for treatment of patients with brain stem glioma and, on October 30, 2008, the FDA granted the Company’s request for ODD for Antineoplastons (A10 and AS2-1 Antineoplaston) for the treatment of gliomas.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On January 13, 2009, the Company announced that the Company had reached an agreement with the FDA for the Company to move forward with a pivotal Phase III clinical trial of combination Antineoplaston therapy plus radiation therapy in patients with newly diagnosed diffuse, intrinsic brainstem gliomas (“DBSG”). The agreement was made under the FDA’s Special Protocol Assessment procedure, meaning that the design and planned analysis of the Phase III study of combination Antineoplastons A10 and AS2-1 plus radiation therapy (“RT”) in patients with newly-diagnosed, diffuse, intrinsic brainstem glioma (protocol “BT-52”), are acceptable to support a regulatory submission seeking new drug approval. However, the FDA placed a full clinical hold on IND 43742 regarding such Phase III clinical trial. Please see the section below entitled “Clinical Hold on Phase II and Phase III Clinical Trials.”</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Clinical Hold on Phase II and Phase III Clinical Trials</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In a letter dated June 25, 2012, the Company informed the FDA of a serious adverse event in which a patient who was receiving Antineoplastons developed grade 4 hypernatremia and subsequently died. The Antineoplaston-related hypernatremia was categorized by the investigator as possibly related to the study drug. Of the 2,297 patients who have received at least one dose of Antineoplastons, the serious adverse events (SAEs) which have been experienced are as follows:  hemoglobin (grade 3: 0.13%; grade 4: 0.04%), extravasation (grade 3: 0.04%), pain (grade 3: 0.04%), fatigue (grade 3: 0.09%; grade 4: 0.04%), fever (grade 3: 0.09%), injection site reaction (grade 3: 0.04%), vomiting (grade 3: 0.09%), hypernatremia (grade 3: 0.09%; grade 4: 1.12%; grade 5: 0.26%), confusion (grade 3: 0.04%), seizure (grade 3: 0.04%), somnolence (grade 3: 0.35%; grade 4: 0.04%), pain: head/headache (grade 3: 0.09%) and pain: joint (grade 3: 0.04%).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On July 30, 2012, the FDA placed a partial clinical hold for enrollment of new pediatric patients under single patient protocols or in any of the active Phase II or Phase III studies under IND 43742. The FDA imposed this partial clinical hold because, according to the FDA, insufficient information had been submitted by the Company to allow the FDA to determine whether the potential patient benefit justifies the potential risks of treatment use, and that the potential risks are not unreasonable in the context of the disease or condition to be treated. The FDA cited 21 C.F.R. § 312.42(b)(2)(i), 21 C.F.R. § 312.42(b)(1)(iv), and 21 C.F.R. § 312.42(b)(3)(i), as grounds for imposition of a clinical hold; and 21 C.F.R. § 312.305(a)(2), a criteria for expanded access use. The FDA advised the Company that until it resolved the matter to the FDA’s satisfaction, the Company could not enroll new pediatric patients in any protocol under such IND. The Company later notified the FDA in a September 24, 2012 letter that it was closing pediatric protocol BT-10 (under IND 43742) for enrollment effective September 25, 2012, and that it would also terminate the protocol once all active patients had completed the study. As of February 17, 2015, all patients discontinued treatment under protocol BT-10 and such protocol was closed as of March 10, 2015.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In a teleconference on January 9, 2013 between the FDA and the Company, followed by a letter of the same date, the FDA notified the Company that the agency was placing IND 43742 on partial clinical hold, due to a lack of a complete response to the issues raised by the FDA and what the FDA deemed a misleading, erroneous, and incomplete investigator brochure. The FDA cited 21 C.F.R. § 312.42(b)(2)(i) and 21 C.F.R. § 312.42(b)(1)(iii), as grounds for imposition of a clinical hold. The FDA further advised the Company that until it resolved the matter to the FDA’s satisfaction, that the Company could not enroll new adult or pediatric patients in any protocol under such IND. The FDA also placed protocol BT-52 on clinical hold due to what the FDA deemed to be an unreasonable and significant risk of illness or injury to human subjects. The FDA cited 21 C.F.R. § 312.42(b)(2)(i) and 21 C.F.R.§ 312.42(B)(1)(i), as grounds for imposition of a clinical hold. The FDA advised the Company that until it resolved the matter to the FDA’s satisfaction, the Company could not legally conduct the identified clinical study under such IND. In a teleconference with the FDA on September 16, 2013 and pursuant to the Company’s notification letter dated September 17, 2013, the Company notified the FDA that the proposed Phase III protocol BT-54 had been withdrawn from further consideration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">After several amendments to the IND which were reviewed by the FDA, the FDA concluded that BT-52 can be initiated and the partial clinical hold was removed by the FDA on June 20, 2014.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Additionally, the Company received IRB approval on February 4, 2015 for FDA reviewed protocol BT-55 open label, Phase II study of Antineoplaston A10 and AS2-1 in patients with a Diffuse Intrinsic Brainstem Glioma (DIPG) in five treatment groups based on patients age and prior treatment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On April 20, 2016, the Company received a full clinical hold letter from the FDA based on FDA’s inspection of S.R. Burzynski’s manufacturing facility in March 2015. On April 27, 2016, the Company requested to change the full clinical hold to partial clinical hold to allow patient #1 to continue the Antineoplaston treatment according to protocol BT-55, since the patient was enrolled before the full clinical hold was imposed. Based on the FDA’s position regarding the Company’s request on April 27, 2016 and the Company’s teleconference with the FDA on May 3, 2016, the Company removed patient #1 from the study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A temporary restraining order from the US District Court of Rhode Island allowed the resumption of patient #1’s Antineoplaston therapy on May 17, 2016. As a result of such temporary restraining order, a subsequent letter from the FDA dated May 26, 2016 informed the Company that the full clinical hold was replaced and a partial clinical hold was imposed. As a result, patient #1 restarted treatment under IND 43742.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On June 14, 2016, the FDA issued a letter to the Company in connection with the FDA’s inspection of S.R. Burzynski’s manufacturing facility (the “SRB Manufacturing”) in March 2015. The SRB Manufacturing addressed the issues raised in the letter in a response letter submitted to the FDA on July 5, 2016 and in subsequent letters.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On February 20, 2017, BRI informed the FDA of the death of patient #1 on February 19, 2017. No new patients can be enrolled to protocol BT-55 or BT-52 until the partial hold on IND 43742 is lifted. On August 24, 2017, the FDA imposed a full clinical hold on IND 43742 until deficiencies regarding the SRB Manufacturing are resolved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Complaint Filed by the Texas Medical Board Against Dr. Burzynski</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On March 3, 2017, the Texas Medical Board issued their final ruling regarding the complaint filed on December 11, 2013 and subsequently amended in July 2014 and November 2014, against Dr. Stanislaw R. Burzynski, who serves as our President and the Chairman of our Board of Directors. The Texas Medical Board made allegations that Dr. Burzynski had acted unprofessionally and failed to meet standards of care under the state’s Medical Practice Act. In the final ruling, the Texas Medical Board found that Dr. Burzynski was subject to sanction for various failures that included supervision of foreign medical graduates, untimely and insufficient informed consent, medical record support documentation, tumor measurement reporting inaccuracy, and lack of disclosure of ownership interest in a pharmacy. As a result, Dr. Burzynski was reprimanded. His Texas license was suspended for five years but that suspension was stayed and he was placed under probation under terms and conditions that include having billing practice monitored by a billing monitor for 12 consecutive monitoring cycles, enrolling and completing a physicians education program ethics course, following informed consent protocol, passing the Medical Jurisprudence Examination, and compliance with the Medical Practice Act and other statutes regulating Dr. Burzynski’s practice. As requested as part of the terms and conditions of his final order, Dr. Burzynski has completed payment of an administrative penalty and restitution, submission of all informed consent forms for review,  submission of an ownership interest disclosure form for review, and he has completed continuing medical education. On August 31, 2022, Dr. Burzynski was notified by the Texas Medical Board that the final order had been successfully terminated effective as of August 17, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Termination of License Agreement</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Pursuant to the terms of the License Agreement dated June 29, 1983, as superseded by an Amended License Agreement dated April 24, 1989 and a Second Amended License Agreement dated March 1, 1990 between the Company and Dr. Burzynski (collectively, the “License Agreement”), the License Agreement terminated on July 2, 2019 upon the expiration of the last patent licensed to the Company from Dr. Burzynski. As of July <span style="white-space:pre-wrap;">2, 2019, all patents previously licensed by the Company under the License Agreement have expired. </span>The Company does own one US patent which was recently issued on May 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Results of Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Three Months Ended November 30, 2022 Compared to Three Months Ended November 30, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Research and development costs were approximately $208,000 and $214,000 for the three months ended November 30, 2022 and 2021, respectively. The decrease of $6,000 or 3% was due to a decrease in personnel costs of $25,000 and consulting and quality control costs of $5,000, offset by an increase in facility and equipment costs of $21,000 and materials costs of $2,000, as a result of a reduction of requirements imposed by the Food and Drug Administration.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">General and administrative expenses were approximately $45,000 and $51,000 for the three months ended November 30, 2022 and 2021, respectively.  The decrease of $6,000 or 11% was due to an decrease in legal and other professional costs of $6,000 as a result of a decrease in requests from regulatory agencies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">The Company had net losses of approximately $253,000 and $265,000 for the three months ended November 30, 2022 and 2021, respectively.  The decrease in the net loss from 2021 to 2022 is primarily due to an overall decrease in research and development costs and a decrease in general and administrative expenses of the Company as described above.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Nine Months Ended November 30, 2022 Compared to Nine Months Ended November 30, 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">Research and development costs were approximately $546,000 and $632,000 for the nine months ended November 30, 2022 and 2021, respectively. The decrease of $87,000 or 14% was due to a decrease in personnel costs of $90,000 and consulting and quality control costs of $5,000, offset by an increase in materials costs of $2,000 and facility and equipment costs of $6,000, as a result of a reduction of requirements imposed by the Food and Drug Administration.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">General and administrative expenses were approximately $154,000 and $173,000 for the nine months ended November 30, 2022 and 2021, respectively.  The decrease of $19,000 or 11% was due to a decrease in legal and other professional costs of $23,000, offset by an increase in other costs of $4,000 as a result of a decrease in requests from regulatory agencies.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;">The Company had net losses of approximately $700,000 and $806,000 for the nine months ended November 30, 2022 and 2021, respectively.  The decrease in the net loss from 2021 to 2022 is primarily due to an overall decrease in research and development costs and general and administrative expenses of the Company as described above.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:0pt;"><span style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></span><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Liquidity and Capital Resources</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company’s operations have been funded entirely by contributions from Dr. Burzynski and from funds generated from Dr. Burzynski’s medical practice. Effective March 1, 1997, the Company entered into a Research Funding Agreement with Dr. Burzynski (the “Research Funding Agreement”), pursuant to which the Company agreed to undertake all scientific research in connection with the development of new or improved Antineoplastons for the treatment of cancer and Dr. Burzynski agreed to fund the Company’s Antineoplaston research for that purpose. Under the Research Funding Agreement, the Company hires such personnel as is required to conduct Antineoplaston research, and Dr. Burzynski funds the Company’s research expenses, including expenses to conduct the clinical trials. Dr. Burzynski also provides the Company laboratory and research space as needed to conduct the Company’s research activities. The Research Funding Agreement also provides that Dr. Burzynski may fulfill his funding obligations in part by providing the Company such administrative support as is necessary for the Company to manage its business. Dr. Burzynski pays the full amount of the Company’s monthly and annual budget of expenses for the operation of the Company, together with other unanticipated but necessary expenses which the Company incurs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The amounts which Dr. Burzynski is obligated to pay under the agreement shall be reduced dollar for dollar by the following: (1) any income which the Company receives for services provided to other companies for research and/or development of other products, less such identifiable marginal or additional expenses necessary to produce such income, or (2) the net proceeds of any stock offering or private placement which the Company receives during the term of the agreement up to a maximum of $1,000,000 in a given Company fiscal year.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Research Funding Agreement, as amended, contains an annual automatic renewal provision providing for an additional one-year term, unless one party notifies the other party at least thirty days prior to the expiration of the then current term of the agreement of its intention not to renew the agreement. Subject to the foregoing, the term of the Research Funding Agreement was renewed and extended until February 28, 2023. It is expected that the Research Funding Agreement will continue to renew each year prospectively unless terminated under the provisions of the agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Research Funding Agreement automatically terminates in the event that Dr. Burzynski owns less than fifty percent of the outstanding shares of the Company, or is removed as President and/or Chairman of the Board of the Company, unless Dr. Burzynski notifies the Company in writing of his intention to continue the agreement notwithstanding this automatic termination provision.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company estimates that it will spend approximately $250,000 during the remaining quarter of the fiscal year ending February 28, 2023. While the Company anticipates that Dr. Burzynski will continue to fund the Company’s research and FDA- related costs, there is no assurance that Dr. Burzynski will be able to continue to fund the Company’s operations pursuant to the Research Funding Agreement or otherwise. In addition, Dr. Burzynski’s medical practice has successfully funded the Company’s research activities over the last 25 years and, in 1997, his medical practice was expanded to include traditional cancer treatment options such as chemotherapy, gene-targeted therapy, immunotherapy and hormonal therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Because the Company currently is entirely dependent upon the contributions for research provided by Dr. Burzynski under the Research Funding Agreement, the Company would not be able to continue conducting its clinical trials if Dr. Burzynski ceased funding the Company’s research. In such event, the Company would be required to find immediate funding which may not be available on acceptable terms or at all. If this were to occur and the Company were not able to find adequate sources of funding, the Company would be required to cease operations. Even with Dr. Burzynski’s continued contributions under the Research Funding Agreement, the Company may be required to seek additional capital through equity or debt financing or the sale of assets until the Company’s operating revenues are sufficient to cover operating costs and provide positive cash flow; however, there can be no assurance that the Company will be able to raise such additional capital on acceptable terms to the Company. In addition, there can be no assurance that the Company will ever achieve positive operating cash flow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4590ef87_f575_4694_936c_ee0da8665a09"></a><a id="Item4ControlsandProcedures_737311"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 4. Controls and Procedures</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Within the 90 days prior to the date of this report, the Company carried out an evaluation, under the supervision and with the participation of the Company’s management, including the Company’s principal executive and financial officers, of the effectiveness of the Company’s disclosure controls and procedures pursuant to Rule 13a-14 under the Securities Exchange Act of 1934, as amended. Based on that evaluation, the Company’s principal executive and financial officers concluded that the Company’s disclosure controls and procedures are effective in timely alerting them to material information required to be included in periodic filings with the Securities and Exchange Commission. A controls system cannot provide absolute assurance, however, that the objectives of the controls system are met, and no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within a company have been detected. There were no significant changes in the Company’s internal controls or in other factors that could significantly affect internal controls over financial reporting that occurred during the fiscal quarter ended November 30, 2022 that have materially affected or are reasonably likely to materially affect our internal controls subsequent to that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><a id="_c9f05eed_62da_4028_acc1_7f592861d9c5"></a><a id="PARTIIOTHERINFORMATION_472513"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PART II — OTHER INFORMATION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><a id="Item1LegalProceedings_582067"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 1. Legal Proceedings</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company’s activities are subject to regulation by various governmental agencies, including the FDA, which regularly monitor the Company’s operations and often impose requirements on the conduct of its clinical trials and other aspects of the Company’s business operations. The Company’s policy is to comply with all such regulatory requirements. From time to time, the Company is also subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice. The Company seeks to minimize its exposure to claims of this type wherever possible.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Currently, the Company is not a party to any material pending legal proceedings. Moreover, the Company is not aware of any such legal proceedings that are contemplated by governmental authorities with respect to the Company or any of its properties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e02a3742_f29d_41bc_a977_33402c305f2b"></a><a id="Item6Exhibits_661755"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Item 6. Exhibits</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;font-weight:bold;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.1</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;color:auto;font-family:""'Times New Roman','Times','serif'"";font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/724445/0000950110-97-001598-index.html"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-line:none;">Certificate of Incorporation of the Company, as amended (incorporated by reference from Exhibits 3(i)— (iii) to Form 10-SB filed with the Securities and Exchange Commission on November 25, 1997 (File No.000-23425)).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">3.2</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;color:auto;font-family:""'Times New Roman','Times','serif'"";font-size:10pt;" href="https://www.sec.gov/Archives/edgar/data/724445/0000950110-97-001598-index.html"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-line:none;">Amended Bylaws of the Company (incorporated by reference from Exhibit 3 (iv) to Form 10-SB filed with the Securities and Exchange Commission on November 25, 1997 (File No.000-23425)).</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.1</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;color:auto;font-family:""'Times New Roman','Times','serif'"";font-size:10pt;" href="bzyr-20221130xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-line:none;">Certification of Chief Executive Officer pursuant to Rules 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as amended, filed herewith.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31.2</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;color:auto;font-family:""'Times New Roman','Times','serif'"";font-size:10pt;" href="bzyr-20221130xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-line:none;">Certification of Principal Financial Officer pursuant to Rules 13a-14 and 15d-14 of the Securities Exchange Act of 1934, as amended, filed herewith.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.1</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;color:auto;font-family:""'Times New Roman','Times','serif'"";font-size:10pt;" href="bzyr-20221130xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-line:none;">Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">32.2</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><a style="-sec-extract:exhibit;color:auto;font-family:""'Times New Roman','Times','serif'"";font-size:10pt;" href="bzyr-20221130xex32d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;text-decoration-line:none;">Certification of Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, filed herewith.</span></a></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.INS</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.SCH</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.CAL</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.DEF</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.LAB</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">101.PRE</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:center;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:top;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">104</p></td><td style="vertical-align:bottom;width:2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="margin-top:21.6pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_4e9dd751_2658_4246_8f95_536aaf02f33c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-indent:36pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In accordance with the requirements of the Exchange Act, the Company caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td colspan="2" style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BURZYNSKI RESEARCH INSTITUTE, INC.</b></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:top;width:47%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Stanislaw R. Burzynski</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stanislaw R. Burzynski,</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chairman of the Board of Directors</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: January 13, 2023</p></td><td style="vertical-align:top;width:3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div> <div style="background-color:#000000;clear:both;height:2pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border:0;"></div></body></html> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-31.1 <SEQUENCE>2 <FILENAME>bzyr-20221130xex31d1.htm <DESCRIPTION>EX-31.1 <TEXT> <!--Enhanced HTML document created with Toppan Merrill Bridge 9.14.0.96--><!--Created on: 1/12/2023 08:13:35 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF CHIEF EXECUTIVE OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO RULES 13a-14 AND 15d-14</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Section 302 of the Sarbanes-Oxley Act of 2002)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Stanislaw R. Burzynski, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">1.     I have reviewed this quarterly report on Form 10-Q of Burzynski Research Institute, Inc. (“BRI”);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">2.     Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">3.     Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of BRI as of, and for, the periods presented in this quarterly report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">4.     I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for BRI and have:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to BRI is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designated such internal control over financial reporting, or caused such internal control over financial reporting to be designated under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of BRI’s disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this quarterly report any change in BRI’s internal control over financial reporting that occurred during BRI’s most recent fiscal quarter (BRI’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, BRI’s internal control over financial reporting; and</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5.     I have disclosed, based on our most recent evaluation of internal control over financial reporting, to BRI’s auditors and the audit committee of BRI’s board of directors (or persons performing the equivalent functions of an audit committee):</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:50pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect BRI’s ability to record, process, summarize and report financial information; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:50pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Any fraud, whether or not material, that involves management or other employees who have a significant role in BRI’s internal control over financial reporting.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: January 13, 2023</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Stanislaw R. Burzynski</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stanislaw R. Burzynski,</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chairman of the Board of Directors</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-31.2 <SEQUENCE>3 <FILENAME>bzyr-20221130xex31d2.htm <DESCRIPTION>EX-31.2 <TEXT> <!--Enhanced HTML document created with Toppan Merrill Bridge 9.14.0.96--><!--Created on: 1/12/2023 08:13:35 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT 31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">PURSUANT TO RULES 13a-14 AND 15d-14</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">OF THE SECURITIES EXCHANGE ACT OF 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Section 302 of the Sarbanes-Oxley Act of 2002)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">I, Patryk P. Goscianski, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">1.     I have reviewed this quarterly report on Form 10-Q of Burzynski Research Institute, Inc. (“BRI”);</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">​</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">2.     Based on my knowledge, this quarterly report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this quarterly report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">​</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">3.     Based on my knowledge, the financial statements, and other financial information included in this quarterly report, fairly present in all material respects the financial condition, results of operations and cash flows of BRI as of, and for, the periods presented in this quarterly report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">​</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">4.     I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal controls over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for BRI and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;"><font style="margin-left:0pt;visibility:hidden;">​</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to BRI is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">​</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designated such internal control over financial reporting, or caused such internal control over financial reporting to be designated under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><div style="margin-top:2pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">​</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of BRI’s disclosure controls and procedures and presented in this quarterly report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this quarterly report based on such evaluation; and</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this quarterly report any change in BRI’s internal control over financial reporting that occurred during BRI’s most recent fiscal quarter (BRI’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, BRI’s internal control over financial reporting; and</font></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 12pt 18pt;">5.     I have disclosed, based on our most recent evaluation of internal control over financial reporting, to BRI’s auditors and the audit committee of BRI’s board of directors (or persons performing the equivalent functions of an audit committee):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;">(a)   All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect BRI’s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;">(b)   Any fraud, whether or not material, that involves management or other employees who have a significant role in BRI’s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: January 13, 2023</p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Patryk P. Goscianski</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patryk P. Goscianski,</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Secretary and Treasurer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-32.1 <SEQUENCE>4 <FILENAME>bzyr-20221130xex32d1.htm <DESCRIPTION>EX-32.1 <TEXT> <!--Enhanced HTML document created with Toppan Merrill Bridge 9.14.0.96--><!--Created on: 1/12/2023 08:13:35 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification of Chief Executive Officer Pursuant to 18 U.S.C. § 1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Section 906 of the Sarbanes-Oxley Act of 2002)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Quarterly Report of Burzynski Research Institute, Inc. (the “Company”) on Form 10-Q for the period ended November 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A signed original of this written statement required by Section 906 has been provided to Burzynski Research Institute, Inc. and will be retained by Burzynski Research Institute, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: January 13, 2023</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Stanislaw R. Burzynski</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stanislaw R. Burzynski</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chairman of the Board of Directors</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Executive Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-32.2 <SEQUENCE>5 <FILENAME>bzyr-20221130xex32d2.htm <DESCRIPTION>EX-32.2 <TEXT> <!--Enhanced HTML document created with Toppan Merrill Bridge 9.14.0.96--><!--Created on: 1/12/2023 08:13:35 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">EXHIBIT 32.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification of Principal Financial Officer Pursuant to 18 U.S.C. § 1350</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">(Section 906 of the Sarbanes-Oxley Act of 2002)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Quarterly Report of Burzynski Research Institute, Inc. (the “Company”) on Form 10-Q for the period ended November 30, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:</p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">A signed original of this written statement required by Section 906 has been provided to Burzynski Research Institute, Inc. and will be retained by Burzynski Research Institute, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p><div align="left"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"></div></div></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: January 13, 2023</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:50%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Patryk P. Goscianski</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Patryk P. Goscianski</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Secretary and Treasurer</p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">(Principal Financial Officer)</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">​</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.SCH <SEQUENCE>6 <FILENAME>bzyr-20221130.xsd <DESCRIPTION>EX-101.SCH <TEXT> <XBRL> <?xml version="1.0" encoding="us-ascii"?> <!--XBRL document created with Toppan Merrill Bridge 10.1.0.3 --> <!--Based on XBRL 2.1--> <!--Created on: 1/12/2023 8:13:44 PM--> <!--Modified on: 1/12/2023 8:13:44 PM--> <xsd:schema targetNamespace="http://www.burzynskiresearch.com/20221130" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:bzyr="http://www.burzynskiresearch.com/20221130" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"> <xsd:annotation> <xsd:appinfo> <link:roleType roleURI="http://www.burzynskiresearch.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults"> <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/StatementBalanceSheets" id="StatementBalanceSheets"> <link:definition>00100 - Statement - BALANCE SHEETS</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" id="StatementStatementsOfOperations"> <link:definition>00200 - Statement - STATEMENTS OF OPERATIONS</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows"> <link:definition>00400 - Statement - STATEMENTS OF CASH FLOWS</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" id="DisclosureIncomeTaxesDetails"> <link:definition>40501 - Disclosure - INCOME TAXES (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation"> <link:definition>00090 - Document - Document and Entity Information</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical"> <link:definition>00105 - Statement - BALANCE SHEETS (Parenthetical)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" id="StatementStatementOfStockholdersEquityDeficit"> <link:definition>00300 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentation" id="DisclosureBasisOfPresentation"> <link:definition>10101 - Disclosure - BASIS OF PRESENTATION</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/DisclosureEconomicDependency" id="DisclosureEconomicDependency"> <link:definition>10201 - Disclosure - ECONOMIC DEPENDENCY</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrants" id="DisclosureStockOptionsAndWarrants"> <link:definition>10301 - Disclosure - STOCK OPTIONS AND WARRANTS</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShare" id="DisclosureLossPerCommonShare"> <link:definition>10401 - Disclosure - LOSS PER COMMON SHARE</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes"> <link:definition>10501 - Disclosure - INCOME TAXES</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsTables" id="DisclosureStockOptionsAndWarrantsTables"> <link:definition>30303 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables"> <link:definition>30503 - Disclosure - INCOME TAXES (Tables)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentationDetails" id="DisclosureBasisOfPresentationDetails"> <link:definition>40101 - Disclosure - BASIS OF PRESENTATION (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" id="DisclosureStockOptionsAndWarrantsDetails"> <link:definition>40301 - Disclosure - STOCK OPTIONS AND WARRANTS (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails" id="DisclosureLossPerCommonShareDetails"> <link:definition>40401 - Disclosure - LOSS PER COMMON SHARE (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:roleType roleURI="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" id="DisclosureIncomeTaxesOperatingLossCarryforwardsDetails"> <link:definition>40502 - Disclosure - INCOME TAXES - Operating Loss Carryforwards (Details)</link:definition> <link:usedOn>link:presentationLink</link:usedOn> <link:usedOn>link:calculationLink</link:usedOn> <link:usedOn>link:definitionLink</link:usedOn> </link:roleType> <link:linkbaseRef xlink:type="simple" xlink:href="bzyr-20221130_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" /> <link:linkbaseRef xlink:type="simple" xlink:href="bzyr-20221130_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" /> <link:linkbaseRef xlink:type="simple" xlink:href="bzyr-20221130_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" /> <link:linkbaseRef xlink:type="simple" xlink:href="bzyr-20221130_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" /> </xsd:appinfo> </xsd:annotation> <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" /> <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" /> <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" /> <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" /> <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" /> <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" /> <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" /> <xsd:import namespace="http://xbrl.sec.gov/country/2022" schemaLocation="https://xbrl.sec.gov/country/2022/country-2022.xsd" /> <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" /> <xsd:element name="IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination" id="bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" /> <xsd:element name="AdjustmentsToAdditionalPaidInCapitalCashContributed" id="bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" /> <xsd:element name="ClinicalTrialExpensesPaid" id="bzyr_ClinicalTrialExpensesPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" /> <xsd:element name="OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard" id="bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="instant" /> <xsd:element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" id="bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" /> <xsd:element name="WorldwideMedicalConsultantsIncMember" id="bzyr_WorldwideMedicalConsultantsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" /> <xsd:element name="CarigenLtdMember" id="bzyr_CarigenLtdMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" /> <xsd:element name="PercentageOfConsultingFeeToBeReceivedAsPerAgreement" id="bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" /> <xsd:element name="ClassOfWarrantOrRightsExercisePeriod" id="bzyr_ClassOfWarrantOrRightsExercisePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" /> <xsd:element name="SharesVestingUponExecutionOfAgreement" id="bzyr_SharesVestingUponExecutionOfAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" /> <xsd:element name="RemainingSharesToVestUponFirstClosingOfAgreement" id="bzyr_RemainingSharesToVestUponFirstClosingOfAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" /> <xsd:element name="MarketingAgreementAbstract" id="bzyr_MarketingAgreementAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" /> <xsd:element name="OperatingLossCarryforwardsExpirationPeriodAxis" id="bzyr_OperatingLossCarryforwardsExpirationPeriodAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" /> <xsd:element name="OperatingLossCarryforwardsExpirationPeriodDomain" id="bzyr_OperatingLossCarryforwardsExpirationPeriodDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" /> <xsd:element name="CountryAxis" id="bzyr_CountryAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" /> <xsd:element name="MajorSupplierAxis" id="bzyr_MajorSupplierAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" /> <xsd:element name="NameOfMajorSupplierDomain" id="bzyr_NameOfMajorSupplierDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" /> <xsd:element name="NumberOfAntineoplastonDrugsThatReceivedFDAApproval" id="bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval" type="xbrli:integerItemType" substitutionGroup="xbrli:item" abstract="false" nillable="true" xbrli:periodType="duration" /> <xsd:element name="DefinedBenefitPlanHealthCareAxis" id="bzyr_DefinedBenefitPlanHealthCareAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" /> <xsd:element name="DefinedBenefitPlanHealthCareDomain" id="bzyr_DefinedBenefitPlanHealthCareDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" /> <xsd:element name="PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards" id="bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" /> <xsd:element name="TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards" id="bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="instant" /> <xsd:element name="PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct" id="bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" /> <xsd:element name="NetOperatingLossCarryForwardIndefinitely" id="bzyr_NetOperatingLossCarryForwardIndefinitely" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" /> <xsd:element name="HundredPercentFutureTaxableIncomeMember" id="bzyr_HundredPercentFutureTaxableIncomeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" /> <xsd:element name="EightyPercentFutureTaxableIncomeMember" id="bzyr_EightyPercentFutureTaxableIncomeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" /> <xsd:element name="NumberOfPatentsOwned" id="bzyr_NumberOfPatentsOwned" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" /> <xsd:element name="WarrantsAndStockOptionsMember" id="bzyr_WarrantsAndStockOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" /> </xsd:schema> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.CAL <SEQUENCE>7 <FILENAME>bzyr-20221130_cal.xml <DESCRIPTION>EX-101.CAL <TEXT> <XBRL> <?xml version="1.0" encoding="us-ascii"?> <!--XBRL document created with Toppan Merrill Bridge 10.1.0.3 --> <!--Based on XBRL 2.1--> <!--Created on: 1/12/2023 8:13:44 PM--> <!--Modified on: 1/12/2023 8:13:44 PM--> <link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance"> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#StatementBalanceSheets" roleURI="http://www.burzynskiresearch.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#StatementStatementsOfOperations" roleURI="http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#StatementStatementsOfCashFlows" roleURI="http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" /> <calculationLink xlink:role="http://www.burzynskiresearch.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="Assets" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638091512246065359" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="us-gaap_AssetsCurrent_638091512246065359" order="1" use="optional" weight="1" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638091512246065359" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638091512246065359" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638091512246065359" order="1" use="optional" weight="1" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638091512246065359" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638091512246065359" xlink:to="us-gaap_PrepaidExpenseCurrent_638091512246065359" order="2" use="optional" weight="1" priority="2" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="LiabilitiesAndStockholdersEquity" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638091512246065359" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638091512246065359" order="1" use="optional" weight="1" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638091512246065359" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638091512246065359" xlink:to="us-gaap_AccountsPayableCurrent_638091512246065359" order="1" use="optional" weight="1" priority="8" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638091512246075362" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638091512246065359" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638091512246075362" order="2" use="optional" weight="1" priority="9" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638091512246075362" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638091512246075362" order="2" use="optional" weight="1" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638091512246075362" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638091512246075362" xlink:to="us-gaap_CommonStockValue_638091512246075362" order="1" use="optional" weight="1" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638091512246075362" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638091512246075362" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638091512246075362" order="2" use="optional" weight="1" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638091512246075362" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638091512246075362" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638091512246075362" order="3" use="optional" weight="1" /> </calculationLink> <calculationLink xlink:role="http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="NetIncomeLossAvailableToCommonStockholdersBasic" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638091512246075362" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638091512246075362" order="1" use="optional" weight="1" priority="2" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638091512246075362" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638091512246075362" xlink:to="us-gaap_OperatingIncomeLoss_638091512246075362" order="1" use="optional" weight="1" priority="2" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638091512246085359" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638091512246075362" xlink:to="us-gaap_OperatingExpenses_638091512246085359" order="1" use="optional" weight="-1" priority="2" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638091512246085359" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638091512246085359" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638091512246085359" order="1" use="optional" weight="1" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638091512246085359" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638091512246085359" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638091512246085359" order="2" use="optional" weight="1" /> </calculationLink> <calculationLink xlink:role="http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638091512246085359" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638091512246085359" order="1" use="optional" weight="1" priority="2" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital_638091512246085359" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638091512246085359" xlink:to="us-gaap_ProceedsFromContributedCapital_638091512246085359" order="1" use="optional" weight="1" priority="1" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638091512246085359" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638091512246085359" order="2" use="optional" weight="1" priority="2" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638091512246085359" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638091512246085359" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638091512246085359" order="1" use="optional" weight="1" priority="1" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_ClinicalTrialExpensesPaid" xlink:label="bzyr_ClinicalTrialExpensesPaid_638091512246085359" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638091512246085359" xlink:to="bzyr_ClinicalTrialExpensesPaid_638091512246085359" order="2" use="optional" weight="1" priority="1" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638091512246085359" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638091512246085359" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638091512246085359" order="3" use="optional" weight="-1" priority="3" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638091512246095362" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638091512246085359" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638091512246095362" order="4" use="optional" weight="1" priority="1" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638091512246095362" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638091512246085359" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638091512246095362" order="5" use="optional" weight="1" priority="1" /> </calculationLink> <calculationLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - INCOME TAXES (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="IncomeTaxExpenseBenefit" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638091512246095362" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638091512246095362" order="1" use="optional" weight="1" priority="2" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationDeductions" xlink:label="us-gaap_IncomeTaxReconciliationDeductions_638091512246095362" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationDeductions_638091512246095362" order="2" use="optional" weight="-1" priority="2" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638091512246095362" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638091512246095362" order="3" use="optional" weight="1" priority="2" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638091512246095362" /> <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638091512246095362" order="4" use="optional" weight="1" priority="2" /> </calculationLink> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.DEF <SEQUENCE>8 <FILENAME>bzyr-20221130_def.xml <DESCRIPTION>EX-101.DEF <TEXT> <XBRL> <?xml version="1.0" encoding="us-ascii"?> <!--XBRL document created with Toppan Merrill Bridge 10.1.0.3 --> <!--Based on XBRL 2.1--> <!--Created on: 1/12/2023 8:13:44 PM--> <!--Modified on: 1/12/2023 8:13:44 PM--> <link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt"> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#StatementStatementOfStockholdersEquityDeficit" roleURI="http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureStockOptionsAndWarrantsDetails" roleURI="http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureLossPerCommonShareDetails" roleURI="http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" roleURI="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" /> <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" /> <link:roleRef roleURI="http://www.burzynskiresearch.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="bzyr-20221130.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" /> <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" /> <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" /> <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" /> <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" /> <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" /> <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" /> <link:definitionLink xlink:type="extended" xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:title="Extensible Enumeration Domain Members" /> <link:definitionLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults"> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_1" xlink:title="us-gaap_IncomeTaxAuthorityAxis_1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_1" xlink:title="us-gaap_IncomeTaxAuthorityDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeTaxAuthorityAxis_1" xlink:to="us-gaap_IncomeTaxAuthorityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeTaxAuthorityAxis_1 To us-gaap_IncomeTaxAuthorityDomain_1" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_1" xlink:title="us-gaap_TaxPeriodAxis_1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_1" xlink:title="us-gaap_TaxPeriodDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TaxPeriodAxis_1" xlink:to="us-gaap_TaxPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TaxPeriodAxis_1 To us-gaap_TaxPeriodDomain_1" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" /> <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" /> <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" /> <link:loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_CountryAxis" xlink:label="bzyr_CountryAxis_1" xlink:title="bzyr_CountryAxis_1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2022/country-2022.xsd#country_AllCountriesDomain" xlink:label="country_AllCountriesDomain_1" xlink:title="country_AllCountriesDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="bzyr_CountryAxis_1" xlink:to="country_AllCountriesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:bzyr_CountryAxis_1 To country_AllCountriesDomain_1" order="1" /> <link:loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_DefinedBenefitPlanHealthCareAxis" xlink:label="bzyr_DefinedBenefitPlanHealthCareAxis_1" xlink:title="bzyr_DefinedBenefitPlanHealthCareAxis_1" /> <link:loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_DefinedBenefitPlanHealthCareDomain" xlink:label="bzyr_DefinedBenefitPlanHealthCareDomain_1" xlink:title="bzyr_DefinedBenefitPlanHealthCareDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="bzyr_DefinedBenefitPlanHealthCareAxis_1" xlink:to="bzyr_DefinedBenefitPlanHealthCareDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:bzyr_DefinedBenefitPlanHealthCareAxis_1 To bzyr_DefinedBenefitPlanHealthCareDomain_1" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" /> <link:loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_OperatingLossCarryforwardsExpirationPeriodAxis" xlink:label="bzyr_OperatingLossCarryforwardsExpirationPeriodAxis_1" xlink:title="bzyr_OperatingLossCarryforwardsExpirationPeriodAxis_1" /> <link:loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_OperatingLossCarryforwardsExpirationPeriodDomain" xlink:label="bzyr_OperatingLossCarryforwardsExpirationPeriodDomain_1" xlink:title="bzyr_OperatingLossCarryforwardsExpirationPeriodDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="bzyr_OperatingLossCarryforwardsExpirationPeriodAxis_1" xlink:to="bzyr_OperatingLossCarryforwardsExpirationPeriodDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:bzyr_OperatingLossCarryforwardsExpirationPeriodAxis_1 To bzyr_OperatingLossCarryforwardsExpirationPeriodDomain_1" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:title="us-gaap_ConcentrationRiskByBenchmarkAxis_1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_1" xlink:title="us-gaap_ConcentrationRiskBenchmarkDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis_1" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByBenchmarkAxis_1 To us-gaap_ConcentrationRiskBenchmarkDomain_1" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:title="us-gaap_ConcentrationRiskByTypeAxis_1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain_1" xlink:title="us-gaap_ConcentrationRiskTypeDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="us-gaap_ConcentrationRiskByTypeAxis_1" xlink:to="us-gaap_ConcentrationRiskTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_ConcentrationRiskByTypeAxis_1 To us-gaap_ConcentrationRiskTypeDomain_1" order="1" /> <link:loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_MajorSupplierAxis" xlink:label="bzyr_MajorSupplierAxis_1" xlink:title="bzyr_MajorSupplierAxis_1" /> <link:loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_NameOfMajorSupplierDomain" xlink:label="bzyr_NameOfMajorSupplierDomain_1" xlink:title="bzyr_NameOfMajorSupplierDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="bzyr_MajorSupplierAxis_1" xlink:to="bzyr_NameOfMajorSupplierDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:bzyr_MajorSupplierAxis_1 To bzyr_NameOfMajorSupplierDomain_1" order="1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" /> <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" /> <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" /> </link:definitionLink> <definitionLink xlink:role="http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_SharesOutstanding" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed" xlink:label="bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" priority="1" use="optional" /> </definitionLink> <definitionLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - STOCK OPTIONS AND WARRANTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="dei_LegalEntityAxis" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_WorldwideMedicalConsultantsIncMember" xlink:label="bzyr_WorldwideMedicalConsultantsIncMember" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="dei_EntityDomain" xlink:to="bzyr_WorldwideMedicalConsultantsIncMember" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_CarigenLtdMember" xlink:label="bzyr_CarigenLtdMember" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="bzyr_CarigenLtdMember" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:label="bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_MarketingAgreementAbstract" xlink:label="bzyr_MarketingAgreementAbstract" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="bzyr_MarketingAgreementAbstract" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement" xlink:label="bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="bzyr_MarketingAgreementAbstract" xlink:to="bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="bzyr_MarketingAgreementAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="bzyr_MarketingAgreementAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_ClassOfWarrantOrRightsExercisePeriod" xlink:label="bzyr_ClassOfWarrantOrRightsExercisePeriod" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="bzyr_MarketingAgreementAbstract" xlink:to="bzyr_ClassOfWarrantOrRightsExercisePeriod" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_SharesVestingUponExecutionOfAgreement" xlink:label="bzyr_SharesVestingUponExecutionOfAgreement" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="bzyr_MarketingAgreementAbstract" xlink:to="bzyr_SharesVestingUponExecutionOfAgreement" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_RemainingSharesToVestUponFirstClosingOfAgreement" xlink:label="bzyr_RemainingSharesToVestUponFirstClosingOfAgreement" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="bzyr_MarketingAgreementAbstract" xlink:to="bzyr_RemainingSharesToVestUponFirstClosingOfAgreement" priority="1" use="optional" /> </definitionLink> <definitionLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails" xlink:type="extended" xlink:title="40401 - Disclosure - LOSS PER COMMON SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_WarrantsAndStockOptionsMember" xlink:label="bzyr_WarrantsAndStockOptionsMember" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="bzyr_WarrantsAndStockOptionsMember" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" /> </definitionLink> <definitionLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - INCOME TAXES (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="us-gaap_IncomeTaxExaminationTable" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_InternalRevenueServiceIRSMember" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="us-gaap_IncomeTaxExaminationLineItems" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_IncomeTaxExaminationTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination" xlink:label="bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationDeductions" xlink:label="us-gaap_IncomeTaxReconciliationDeductions" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationDeductions" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_Revenues" priority="1" use="optional" /> </definitionLink> <definitionLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - INCOME TAXES - Operating Loss Carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_TaxPeriodAxis" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_LatestTaxYearMember" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="srt_StatementScenarioAxis" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_HundredPercentFutureTaxableIncomeMember" xlink:label="bzyr_HundredPercentFutureTaxableIncomeMember" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bzyr_HundredPercentFutureTaxableIncomeMember" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_EightyPercentFutureTaxableIncomeMember" xlink:label="bzyr_EightyPercentFutureTaxableIncomeMember" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="bzyr_EightyPercentFutureTaxableIncomeMember" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards" xlink:label="bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct" xlink:label="bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards" xlink:label="bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards" priority="1" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_NetOperatingLossCarryForwardIndefinitely" xlink:label="bzyr_NetOperatingLossCarryForwardIndefinitely" /> <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="bzyr_NetOperatingLossCarryForwardIndefinitely" priority="1" use="optional" /> </definitionLink> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.LAB <SEQUENCE>9 <FILENAME>bzyr-20221130_lab.xml <DESCRIPTION>EX-101.LAB <TEXT> <XBRL> <?xml version="1.0" encoding="us-ascii"?> <!--XBRL document created with Toppan Merrill Bridge 10.1.0.3 --> <!--Based on XBRL 2.1--> <!--Created on: 1/12/2023 8:13:44 PM--> <!--Modified on: 1/12/2023 8:13:44 PM--> <link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt"> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" /> <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link"> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document and Entity Information</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Quarterly Report</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line Two</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BALANCE SHEETS</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ASSETS</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaids</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES AND STOCKHOLDERS' DEFICIT</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities, Current</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CURRENT AND TOTAL LIABILITIES</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and contingencies</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity (deficit)</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, $.001 par value; 200,000,000 shares authorized; 131,448,444 shares issued and outstanding as of November 30, 2022 and February 28, 2022</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital, Common Stock</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained deficit</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity (deficit)</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity (deficit)</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value (in dollars per share)</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares authorized</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF OPERATIONS</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating loss</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss before provision for income tax</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Available to Common Stockholders, Basic</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LOSS PER COMMON SHARE</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings per share information:</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per common share Basic</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss per common share Diluted</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of common shares outstanding Basic</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of common shares outstanding Diluted</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Deficit</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares, Outstanding</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance (in shares)</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed" xlink:label="bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed" xlink:to="bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the cash contributed by the individual that is reported as additional paid-in capital, which is used to fund general operating expenses during the reporting year.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Cash Contributed</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash contributed by S.R. Burzynski, M.D., Ph.D.</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Clinical Trial Expenses</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF CASH FLOWS</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH FLOWS FROM OPERATING ACTIVITIES</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used by operating activities:</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_ClinicalTrialExpensesPaid" xlink:label="bzyr_ClinicalTrialExpensesPaid" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_ClinicalTrialExpensesPaid" xlink:to="bzyr_ClinicalTrialExpensesPaid_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_ClinicalTrialExpensesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the clinical trial expenses that are incurred by the entity which are used in the treatment of cancer during the reporting period.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_ClinicalTrialExpensesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical Trial Expenses Paid</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_ClinicalTrialExpensesPaid_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaids</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accrued Liabilities</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET CASH USED BY OPERATING ACTIVITIES</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH FLOWS FROM FINANCING ACTIVITIES</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromContributedCapital" xlink:to="us-gaap_ProceedsFromContributedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Contributed Capital</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromContributedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contribution of capital</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET CASH PROVIDED BY FINANCING ACTIVITIES</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET INCREASE (DECREASE) IN CASH</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH AT END OF PERIOD</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CASH AT BEGINNING OF PERIOD</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PRESENTATION</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PRESENTATION</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ECONOMIC DEPENDENCY</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note Disclosure [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ECONOMIC DEPENDENCY</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK OPTIONS AND WARRANTS</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK OPTIONS AND WARRANTS</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LOSS PER COMMON SHARE</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME TAXES</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share Based Compensation Arrangement by Share Based Payment Award Options Vested [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of options vested</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of actual provision for income tax that differs from the amounts computed by applying the U.S. federal income tax rate to the pretax loss</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard" xlink:label="bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard" xlink:to="bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage interest of ownership held by the President of the Company, whom is also the Chairman of the Board.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ownership Interest Percentage Held by Company President and Chairman of Board</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of outstanding stock owned by the President and Chairman of the Board</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_NumberOfPatentsOwned" xlink:label="bzyr_NumberOfPatentsOwned" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_NumberOfPatentsOwned" xlink:to="bzyr_NumberOfPatentsOwned_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_NumberOfPatentsOwned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patents owned.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_NumberOfPatentsOwned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Patents Owned</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_NumberOfPatentsOwned_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of patents owned</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval" xlink:label="bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval" xlink:to="bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of antineoplaston drugs that have received FDA approval.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Antineoplaston Drugs that Received FDA Approval</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of antineoplaston drugs that have received FDA approval</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Axis]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Award Type [Domain]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock options</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Legal Entity [Axis]</label> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity [Domain]</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_WorldwideMedicalConsultantsIncMember" xlink:label="bzyr_WorldwideMedicalConsultantsIncMember" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_WorldwideMedicalConsultantsIncMember" xlink:to="bzyr_WorldwideMedicalConsultantsIncMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_WorldwideMedicalConsultantsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Worldwide Medical Consultants Inc.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_WorldwideMedicalConsultantsIncMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Worldwide Medical Consultants, Inc. ("WMC")</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Axis]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Related Party [Domain]</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_CarigenLtdMember" xlink:label="bzyr_CarigenLtdMember" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_CarigenLtdMember" xlink:to="bzyr_CarigenLtdMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_CarigenLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Carigen Ltd., an entity wholly owned and controlled by Dr. Burzynski.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_CarigenLtdMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CARIGEN, LTD ("SRB")</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STOCK OPTIONS AND WARRANTS</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:label="bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:to="bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The number of share-based compensation plans approved by the entity's shareholders.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement, by Share Based Payment Award, Number of Plans</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of stock-based employee compensation plan</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price (in dollars per share)</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested in Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vested (in shares)</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_MarketingAgreementAbstract" xlink:label="bzyr_MarketingAgreementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_MarketingAgreementAbstract" xlink:to="bzyr_MarketingAgreementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_MarketingAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketing Agreement [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_MarketingAgreementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketing Agreement</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement" xlink:label="bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement" xlink:to="bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of consulting fee to be received by the Company per the marketing agreement.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Consulting Fee to be Received as Per Agreement</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consulting fee (as a percent)</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right Number of Securities to be Called by Warrants or Rights WMC Payment Consideration</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants to be granted to acquire shares of common stock (in shares)</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Right, Exercise Price of Warrants or Rights</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable price (in dollars per share)</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_ClassOfWarrantOrRightsExercisePeriod" xlink:label="bzyr_ClassOfWarrantOrRightsExercisePeriod" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_ClassOfWarrantOrRightsExercisePeriod" xlink:to="bzyr_ClassOfWarrantOrRightsExercisePeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_ClassOfWarrantOrRightsExercisePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the exercise period for warrants exercisable.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_ClassOfWarrantOrRightsExercisePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Warrant or Rights Exercise Period</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_ClassOfWarrantOrRightsExercisePeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercise period</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_SharesVestingUponExecutionOfAgreement" xlink:label="bzyr_SharesVestingUponExecutionOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_SharesVestingUponExecutionOfAgreement" xlink:to="bzyr_SharesVestingUponExecutionOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_SharesVestingUponExecutionOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the shares vesting upon execution of the agreement.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_SharesVestingUponExecutionOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares Vesting upon Execution of Agreement</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_SharesVestingUponExecutionOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares vesting upon execution of the agreement</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_RemainingSharesToVestUponFirstClosingOfAgreement" xlink:label="bzyr_RemainingSharesToVestUponFirstClosingOfAgreement" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_RemainingSharesToVestUponFirstClosingOfAgreement" xlink:to="bzyr_RemainingSharesToVestUponFirstClosingOfAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_RemainingSharesToVestUponFirstClosingOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the remaining shares to vest upon the first closing of a transaction by SRB as a result of the services provided by WMC under the marketing agreement.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_RemainingSharesToVestUponFirstClosingOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining Shares to Vest upon First Closing of Agreement</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_RemainingSharesToVestUponFirstClosingOfAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Remaining shares to vest upon the first closing of a transaction by SRB under the marketing agreement</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_WarrantsAndStockOptionsMember" xlink:label="bzyr_WarrantsAndStockOptionsMember" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_WarrantsAndStockOptionsMember" xlink:to="bzyr_WarrantsAndStockOptionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_WarrantsAndStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to warrants and stock options.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_WarrantsAndStockOptionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants and stock options</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares excluded from calculation of diluted loss per share (in shares)</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="us-gaap_IncomeTaxExaminationTable" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationTable" xlink:to="us-gaap_IncomeTaxExaminationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination [Table]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Axis]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Authority [Domain]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InternalRevenueServiceIRSMember" xlink:to="us-gaap_InternalRevenueServiceIRSMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InternalRevenueServiceIRSMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IRS</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="us-gaap_IncomeTaxExaminationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationLineItems" xlink:to="us-gaap_IncomeTaxExaminationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExaminationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination" xlink:label="bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination" xlink:to="bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the period after filing income tax returns subject to examination by the taxing authority.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Examination, Period after Filing Income Tax Returns Subject to Examination</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period after filing income tax returns subject to examination</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. federal income tax rate (as a percent)</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Actual income tax benefit</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected expense (benefit)</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationDeductions" xlink:label="us-gaap_IncomeTaxReconciliationDeductions" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationDeductions" xlink:to="us-gaap_IncomeTaxReconciliationDeductions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Reconciliation, Deductions</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationDeductions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Taxed directly to Dr. Burzynski</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Reconciliation, Nondeductible Expense</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nondeductible expenses and other adjustments</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Reconciliation, Change in Deferred Tax Assets Valuation Allowance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Expense (Benefit)</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision for income tax</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net [Abstract]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax asset</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation allowance</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Historical earnings</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsTable" xlink:to="us-gaap_OperatingLossCarryforwardsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Table]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Period [Axis]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxPeriodDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Period [Domain]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LatestTaxYearMember" xlink:to="us-gaap_LatestTaxYearMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LatestTaxYearMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026 to 2038</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementScenarioAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario [Axis]</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Scenario, Unspecified [Domain]</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_HundredPercentFutureTaxableIncomeMember" xlink:label="bzyr_HundredPercentFutureTaxableIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_HundredPercentFutureTaxableIncomeMember" xlink:to="bzyr_HundredPercentFutureTaxableIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_HundredPercentFutureTaxableIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to 100% future taxable income.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_HundredPercentFutureTaxableIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">100% of future taxable income</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_EightyPercentFutureTaxableIncomeMember" xlink:label="bzyr_EightyPercentFutureTaxableIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_EightyPercentFutureTaxableIncomeMember" xlink:to="bzyr_EightyPercentFutureTaxableIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_EightyPercentFutureTaxableIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information relating to 80% future taxable income.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_EightyPercentFutureTaxableIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">80% of future taxable income</label> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Loss Carryforwards [Line Items]</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforwards</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards" xlink:label="bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards" xlink:to="bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The percentage of future taxable income for which net operating loss carryforward indefinitely.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of Future Taxable Income, Net Operating Loss Carryforwards</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future taxable income (in Percent)</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct" xlink:label="bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct" xlink:to="bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the percentage of NOL limit on taxable income under the CARES act.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage on Net Operating loss Carryforwards Limit of Taxable Income Under Coronavirus Aid, Relief, and Economic Security Act</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Percentage of NOL limit on taxable income under the CARES act</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards" xlink:label="bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards" xlink:to="bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of net operating loss carryforwards that will carryforward in accordance with Tax Cuts and Jobs Act of 2017.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tax Cuts and Jobs Act of 2017, Net Operating Loss Carryforwards</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforward in accordance with the Act</label> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_NetOperatingLossCarryForwardIndefinitely" xlink:label="bzyr_NetOperatingLossCarryForwardIndefinitely" xmlns="http://www.xbrl.org/2003/linkbase" /> <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="bzyr_NetOperatingLossCarryForwardIndefinitely" xlink:to="bzyr_NetOperatingLossCarryForwardIndefinitely_lbl" xmlns="http://www.xbrl.org/2003/linkbase" /> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="bzyr_NetOperatingLossCarryForwardIndefinitely_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">It represents net operating loss carryforward indefinite period.</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="bzyr_NetOperatingLossCarryForwardIndefinitely_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Operating Loss Carry Forward Indefinitely</label> <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="bzyr_NetOperatingLossCarryForwardIndefinitely_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net operating loss carryforward indefinite period</label> </link:labelLink> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EX-101.PRE <SEQUENCE>10 <FILENAME>bzyr-20221130_pre.xml <DESCRIPTION>EX-101.PRE <TEXT> <XBRL> <?xml version="1.0" encoding="us-ascii"?> <!--XBRL document created with Toppan Merrill Bridge 10.1.0.3 --> <!--Based on XBRL 2.1--> <!--Created on: 1/12/2023 8:13:44 PM--> <!--Modified on: 1/12/2023 8:13:44 PM--> <link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance"> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#StatementBalanceSheets" roleURI="http://www.burzynskiresearch.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#StatementStatementsOfOperations" roleURI="http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#StatementStatementOfStockholdersEquityDeficit" roleURI="http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#StatementStatementsOfCashFlows" roleURI="http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureBasisOfPresentation" roleURI="http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureEconomicDependency" roleURI="http://www.burzynskiresearch.com/role/DisclosureEconomicDependency" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureStockOptionsAndWarrants" roleURI="http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrants" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureLossPerCommonShare" roleURI="http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShare" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureIncomeTaxes" roleURI="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureStockOptionsAndWarrantsTables" roleURI="http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsTables" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureBasisOfPresentationDetails" roleURI="http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentationDetails" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureStockOptionsAndWarrantsDetails" roleURI="http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureLossPerCommonShareDetails" roleURI="http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureIncomeTaxesDetails" roleURI="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" xmlns="http://www.xbrl.org/2003/linkbase" /> <roleRef xlink:type="simple" xlink:href="bzyr-20221130.xsd#DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" roleURI="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xmlns="http://www.xbrl.org/2003/linkbase" /> <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" /> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="CoverAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638091512246205369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentType_638091512246205369" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport_638091512246205369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentQuarterlyReport_638091512246205369" order="2" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638091512246205369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentTransitionReport_638091512246205369" order="3" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638091512246205369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638091512246205369" order="4" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638091512246205369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFileNumber_638091512246205369" order="5" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638091512246205369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityRegistrantName_638091512246205369" order="6" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638091512246205369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638091512246205369" order="7" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638091512246205369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638091512246205369" order="8" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638091512246205369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638091512246205369" order="9" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2_638091512246215368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressAddressLine2_638091512246215368" order="10" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638091512246215368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638091512246215368" order="11" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638091512246215368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638091512246215368" order="12" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638091512246215368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638091512246215368" order="13" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638091512246215368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CityAreaCode_638091512246215368" order="14" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638091512246215368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_LocalPhoneNumber_638091512246215368" order="15" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638091512246215368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_Security12bTitle_638091512246215368" order="16" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638091512246215368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_TradingSymbol_638091512246215368" order="17" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638091512246215368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_AmendmentFlag_638091512246215368" order="18" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638091512246215368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_SecurityExchangeName_638091512246215368" order="19" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638091512246215368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638091512246215368" order="20" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638091512246225366" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638091512246225366" order="21" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638091512246225366" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityFilerCategory_638091512246225366" order="22" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638091512246225366" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntitySmallBusiness_638091512246225366" order="23" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638091512246225366" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638091512246225366" order="24" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638091512246225366" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityShellCompany_638091512246225366" order="25" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638091512246225366" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638091512246225366" order="26" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638091512246225366" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638091512246225366" order="27" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638091512246235367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638091512246235367" order="28" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638091512246235367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638091512246235367" order="29" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638091512246235367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638091512246235367" order="30" use="optional" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638091512246235367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638091512246235367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638091512246235367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638091512246235367" xlink:to="us-gaap_AssetsCurrentAbstract_638091512246235367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638091512246235367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638091512246235367" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638091512246235367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent_638091512246235367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638091512246235367" xlink:to="us-gaap_PrepaidExpenseCurrent_638091512246235367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638091512246235367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638091512246235367" xlink:to="us-gaap_AssetsCurrent_638091512246235367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638091512246245367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638091512246235367" xlink:to="us-gaap_Assets_638091512246245367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638091512246245367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638091512246245367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638091512246245367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638091512246245367" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638091512246245367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638091512246245367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638091512246245367" xlink:to="us-gaap_AccountsPayableCurrent_638091512246245367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent_638091512246245367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638091512246245367" xlink:to="us-gaap_AccruedLiabilitiesCurrent_638091512246245367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638091512246245367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638091512246245367" xlink:to="us-gaap_Liabilities_638091512246245367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies_638091512246245367" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638091512246245367" xlink:to="us-gaap_CommitmentsAndContingencies_638091512246245367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638091512246355368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638091512246245367" xlink:to="us-gaap_StockholdersEquityAbstract_638091512246355368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638091512246355368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638091512246355368" xlink:to="us-gaap_CommonStockValue_638091512246355368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_638091512246355368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638091512246355368" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_638091512246355368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638091512246355368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638091512246355368" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638091512246355368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638091512246355368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638091512246355368" xlink:to="us-gaap_StockholdersEquity_638091512246355368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638091512246355368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638091512246245367" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638091512246355368" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - BALANCE SHEETS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638091512246365373" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638091512246365373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638091512246365373" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638091512246365373" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638091512246365373" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638091512246365373" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638091512246365373" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638091512246365373" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="IncomeStatementAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638091512246365373" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638091512246365373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638091512246365373" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638091512246365373" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638091512246365373" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638091512246365373" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638091512246365373" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638091512246365373" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638091512246365373" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638091512246365373" xlink:to="us-gaap_OperatingExpenses_638091512246365373" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638091512246365373" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638091512246365373" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638091512246365373" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_638091512246365373" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638091512246375370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638091512246375370" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract_638091512246375370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_638091512246375370" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638091512246375370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638091512246375370" xlink:to="us-gaap_EarningsPerShareBasic_638091512246375370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638091512246375370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638091512246375370" xlink:to="us-gaap_EarningsPerShareDiluted_638091512246375370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638091512246375370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638091512246375370" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638091512246375370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638091512246375370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract_638091512246375370" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638091512246375370" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" xlink:type="extended" xlink:title="00300 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="StatementOfStockholdersEquityAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638091512246375370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638091512246375370" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638091512246375370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638091512246375370" xlink:to="us-gaap_StatementEquityComponentsAxis_638091512246375370" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638091512246375370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638091512246375370" xlink:to="us-gaap_CommonStockMember_638091512246375370" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638091512246375370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638091512246375370" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638091512246375370" order="2" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638091512246375370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638091512246375370" xlink:to="us-gaap_RetainedEarningsMember_638091512246375370" order="3" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638091512246385368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638091512246375370" xlink:to="us-gaap_EquityComponentDomain_638091512246385368" order="4" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638091512246385368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638091512246375370" xlink:to="us-gaap_StatementLineItems_638091512246385368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638091512246385368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638091512246385368" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638091512246385368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638091512246385368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638091512246385368" xlink:to="us-gaap_StockholdersEquity_638091512246385368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_638091512246385368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638091512246385368" xlink:to="us-gaap_SharesOutstanding_638091512246385368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed" xlink:label="bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed_638091512246385368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638091512246385368" xlink:to="bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed_638091512246385368" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalOther" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_638091512246385368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638091512246385368" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalOther_638091512246385368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638091512246385368" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638091512246385368" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638091512246385368" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_6380915122463853681" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638091512246385368" xlink:to="us-gaap_StockholdersEquity_6380915122463853681" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_6380915122463853681" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638091512246385368" xlink:to="us-gaap_SharesOutstanding_6380915122463853681" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638091512246395369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638091512246395369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638091512246395369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638091512246395369" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_638091512246395369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638091512246395369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638091512246395369" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638091512246395369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_ClinicalTrialExpensesPaid" xlink:label="bzyr_ClinicalTrialExpensesPaid_638091512246395369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638091512246395369" xlink:to="bzyr_ClinicalTrialExpensesPaid_638091512246395369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638091512246395369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638091512246395369" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638091512246395369" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_638091512246395369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638091512246395369" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_638091512246395369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638091512246395369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638091512246395369" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638091512246395369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_638091512246395369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638091512246395369" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_638091512246395369" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638091512246395369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_638091512246395369" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638091512246395369" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638091512246395369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638091512246395369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital_638091512246395369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638091512246395369" xlink:to="us-gaap_ProceedsFromContributedCapital_638091512246395369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638091512246395369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_638091512246395369" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638091512246395369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638091512246395369" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_638091512246395369" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638091512246405371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638091512246405371" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6380915122464053711" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6380915122464053711" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - BASIS OF PRESENTATION" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638091512246405371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638091512246405371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureEconomicDependency" xlink:type="extended" xlink:title="10201 - Disclosure - ECONOMIC DEPENDENCY" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="StockholdersEquityNoteAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638091512246405371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_638091512246405371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrants" xlink:type="extended" xlink:title="10301 - Disclosure - STOCK OPTIONS AND WARRANTS" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638091512246405371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638091512246405371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShare" xlink:type="extended" xlink:title="10401 - Disclosure - LOSS PER COMMON SHARE" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638091512246405371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638091512246405371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="10501 - Disclosure - INCOME TAXES" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638091512246415374" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638091512246415374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsTables" xlink:type="extended" xlink:title="30303 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_638091512246415374" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock_638091512246415374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="30503 - Disclosure - INCOME TAXES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638091512246415374" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_638091512246415374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentationDetails" xlink:type="extended" xlink:title="40101 - Disclosure - BASIS OF PRESENTATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard" xlink:label="bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard_638091512246415374" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard_638091512246415374" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_NumberOfPatentsOwned" xlink:label="bzyr_NumberOfPatentsOwned_638091512246415374" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="bzyr_NumberOfPatentsOwned_638091512246415374" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval" xlink:label="bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval_638091512246415374" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval_638091512246415374" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - STOCK OPTIONS AND WARRANTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638091512246415374" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638091512246415374" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_638091512246415374" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638091512246415374" xlink:to="us-gaap_AwardTypeAxis_638091512246415374" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638091512246415374" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis_638091512246415374" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638091512246415374" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638091512246425370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_638091512246415374" xlink:to="us-gaap_EmployeeStockOptionMember_638091512246425370" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_638091512246425370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638091512246415374" xlink:to="dei_LegalEntityAxis_638091512246425370" order="2" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_638091512246425370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis_638091512246425370" xlink:to="dei_EntityDomain_638091512246425370" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_WorldwideMedicalConsultantsIncMember" xlink:label="bzyr_WorldwideMedicalConsultantsIncMember_638091512246425370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_EntityDomain_638091512246425370" xlink:to="bzyr_WorldwideMedicalConsultantsIncMember_638091512246425370" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638091512246425370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638091512246415374" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638091512246425370" order="3" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_638091512246425370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_638091512246425370" xlink:to="us-gaap_RelatedPartyDomain_638091512246425370" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_CarigenLtdMember" xlink:label="bzyr_CarigenLtdMember_638091512246425370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain_638091512246425370" xlink:to="bzyr_CarigenLtdMember_638091512246425370" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638091512246425370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638091512246415374" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638091512246425370" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans" xlink:label="bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_638091512246425370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638091512246425370" xlink:to="bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans_638091512246425370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638091512246425370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638091512246425370" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638091512246425370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638091512246425370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638091512246425370" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638091512246425370" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_638091512246425370" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638091512246425370" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_638091512246425370" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638091512246435371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638091512246425370" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638091512246435371" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_MarketingAgreementAbstract" xlink:label="bzyr_MarketingAgreementAbstract_638091512246435371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638091512246425370" xlink:to="bzyr_MarketingAgreementAbstract_638091512246435371" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement" xlink:label="bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement_638091512246435371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bzyr_MarketingAgreementAbstract_638091512246435371" xlink:to="bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement_638091512246435371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638091512246435371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bzyr_MarketingAgreementAbstract_638091512246435371" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_638091512246435371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638091512246435371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bzyr_MarketingAgreementAbstract_638091512246435371" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_638091512246435371" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_ClassOfWarrantOrRightsExercisePeriod" xlink:label="bzyr_ClassOfWarrantOrRightsExercisePeriod_638091512246435371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bzyr_MarketingAgreementAbstract_638091512246435371" xlink:to="bzyr_ClassOfWarrantOrRightsExercisePeriod_638091512246435371" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_SharesVestingUponExecutionOfAgreement" xlink:label="bzyr_SharesVestingUponExecutionOfAgreement_638091512246435371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bzyr_MarketingAgreementAbstract_638091512246435371" xlink:to="bzyr_SharesVestingUponExecutionOfAgreement_638091512246435371" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_RemainingSharesToVestUponFirstClosingOfAgreement" xlink:label="bzyr_RemainingSharesToVestUponFirstClosingOfAgreement_638091512246435371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="bzyr_MarketingAgreementAbstract_638091512246435371" xlink:to="bzyr_RemainingSharesToVestUponFirstClosingOfAgreement_638091512246435371" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails" xlink:type="extended" xlink:title="40401 - Disclosure - LOSS PER COMMON SHARE (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638091512246435371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="us-gaap_StatementTable_638091512246435371" order="1" use="optional" priority="2" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638091512246445371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638091512246435371" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638091512246445371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638091512246445371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638091512246445371" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638091512246445371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638091512246445371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638091512246445371" xlink:to="us-gaap_EmployeeStockOptionMember_638091512246445371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_WarrantsAndStockOptionsMember" xlink:label="bzyr_WarrantsAndStockOptionsMember_638091512246445371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638091512246445371" xlink:to="bzyr_WarrantsAndStockOptionsMember_638091512246445371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638091512246445371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638091512246435371" xlink:to="us-gaap_StatementLineItems_638091512246445371" order="2" use="optional" priority="2" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638091512246445371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638091512246445371" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638091512246445371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" xlink:type="extended" xlink:title="40501 - Disclosure - INCOME TAXES (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="us-gaap_IncomeTaxExaminationTable_638091512246445371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExaminationTable_638091512246445371" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis_638091512246455371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationTable_638091512246445371" xlink:to="us-gaap_IncomeTaxAuthorityAxis_638091512246455371" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_638091512246455371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis_638091512246455371" xlink:to="us-gaap_IncomeTaxAuthorityDomain_638091512246455371" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="us-gaap_InternalRevenueServiceIRSMember_638091512246455371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain_638091512246455371" xlink:to="us-gaap_InternalRevenueServiceIRSMember_638091512246455371" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="us-gaap_IncomeTaxExaminationLineItems_638091512246455371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationTable_638091512246445371" xlink:to="us-gaap_IncomeTaxExaminationLineItems_638091512246455371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination" xlink:label="bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination_638091512246455371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems_638091512246455371" xlink:to="bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination_638091512246455371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638091512246455371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems_638091512246455371" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638091512246455371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638091512246455371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems_638091512246455371" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638091512246455371" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638091512246455371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638091512246455371" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_638091512246455371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationDeductions" xlink:label="us-gaap_IncomeTaxReconciliationDeductions_638091512246455371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638091512246455371" xlink:to="us-gaap_IncomeTaxReconciliationDeductions_638091512246455371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpense" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638091512246455371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638091512246455371" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpense_638091512246455371" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638091512246455371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638091512246455371" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_638091512246455371" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit_638091512246455371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_638091512246455371" xlink:to="us-gaap_IncomeTaxExpenseBenefit_638091512246455371" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_638091512246455371" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExaminationLineItems_638091512246455371" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_638091512246455371" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638091512246465383" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638091512246455371" xlink:to="us-gaap_DeferredTaxAssetsNet_638091512246465383" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638091512246465383" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638091512246455371" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638091512246465383" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues_638091512246465383" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638091512246455371" xlink:to="us-gaap_Revenues_638091512246465383" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" /> </presentationLink> <presentationLink xlink:role="http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" xlink:type="extended" xlink:title="40502 - Disclosure - INCOME TAXES - Operating Loss Carryforwards (Details)" xmlns="http://www.xbrl.org/2003/linkbase"> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="IncomeTaxDisclosureAbstract" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsTable" xlink:label="us-gaap_OperatingLossCarryforwardsTable_638091512246465383" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="IncomeTaxDisclosureAbstract" xlink:to="us-gaap_OperatingLossCarryforwardsTable_638091512246465383" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis_638091512246465383" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638091512246465383" xlink:to="us-gaap_TaxPeriodAxis_638091512246465383" order="1" use="optional" priority="2" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain_638091512246465383" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis_638091512246465383" xlink:to="us-gaap_TaxPeriodDomain_638091512246465383" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LatestTaxYearMember" xlink:label="us-gaap_LatestTaxYearMember_638091512246465383" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodDomain_638091512246465383" xlink:to="us-gaap_LatestTaxYearMember_638091512246465383" order="1" use="optional" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_638091512246465383" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638091512246465383" xlink:to="srt_StatementScenarioAxis_638091512246465383" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_638091512246465383" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis_638091512246465383" xlink:to="srt_ScenarioUnspecifiedDomain_638091512246465383" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_HundredPercentFutureTaxableIncomeMember" xlink:label="bzyr_HundredPercentFutureTaxableIncomeMember_638091512246465383" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638091512246465383" xlink:to="bzyr_HundredPercentFutureTaxableIncomeMember_638091512246465383" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_EightyPercentFutureTaxableIncomeMember" xlink:label="bzyr_EightyPercentFutureTaxableIncomeMember_638091512246465383" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain_638091512246465383" xlink:to="bzyr_EightyPercentFutureTaxableIncomeMember_638091512246465383" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" /> <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLossCarryforwardsLineItems" xlink:label="us-gaap_OperatingLossCarryforwardsLineItems_638091512246475372" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsTable_638091512246465383" xlink:to="us-gaap_OperatingLossCarryforwardsLineItems_638091512246475372" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards" xlink:label="bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards_638091512246475372" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638091512246475372" xlink:to="bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards_638091512246475372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct" xlink:label="bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct_638091512246475372" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638091512246475372" xlink:to="bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct_638091512246475372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards" xlink:label="bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards_638091512246475372" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638091512246475372" xlink:to="bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards_638091512246475372" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" /> <loc xlink:type="locator" xlink:href="bzyr-20221130.xsd#bzyr_NetOperatingLossCarryForwardIndefinitely" xlink:label="bzyr_NetOperatingLossCarryForwardIndefinitely_638091512246475372" /> <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLossCarryforwardsLineItems_638091512246475372" xlink:to="bzyr_NetOperatingLossCarryForwardIndefinitely_638091512246475372" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" /> </presentationLink> </link:linkbase> </XBRL> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>11 <FILENAME>R1.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668976257040"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th> <th class="th" colspan="1">9 Months Ended</th> <th class="th" colspan="1"></th> </tr> <tr> <th class="th"><div>Nov. 30, 2022</div></th> <th class="th"><div>Jan. 01, 2023</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Document and Entity Information</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td> <td class="text">10-Q<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td> <td class="text">true<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td> <td class="text">Nov. 30, 2022<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td> <td class="text">000-23425<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td> <td class="text">BURZYNSKI RESEARCH INSTITUTE INC<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td> <td class="text">DE<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td> <td class="text">76-0136810<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td> <td class="text">9432 Katy Freeway<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td> <td class="text">Suite 200<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td> <td class="text">Houston<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td> <td class="text">TX<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td> <td class="text">77055<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td> <td class="text">713<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td> <td class="text">335-5697<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td> <td class="text">None<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td> <td class="text">BZYR<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td> <td class="text">NONE<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td> <td class="text">Yes<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td> <td class="text">Yes<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td> <td class="text">Non-accelerated Filer<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td> <td class="text">true<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td> <td class="text">false<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td> <td class="text"> <span></span> </td> <td class="nump">131,448,444<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td> <td class="text">0000724445<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td> <td class="text">--02-28<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td> <td class="text">2023<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td> <td class="text">Q3<span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_AmendmentFlag</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CityAreaCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CoverAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:gMonthDayItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:fiscalPeriodItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:gYearItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:dateItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentTransitionReport</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_DocumentType</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:submissionTypeItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:stateOrProvinceItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:centralIndexKeyItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityFileNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:fileNumberItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityFilerCategory</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:filerCategoryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:edgarStateCountryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:yesNoItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityRegistrantName</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityShellCompany</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntitySmallBusiness</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:booleanItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:employerIdItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_LocalPhoneNumber</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:normalizedStringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_Security12bTitle</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:securityTitleItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_SecurityExchangeName</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:edgarExchangeCodeItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_TradingSymbol</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>dei_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dei:tradingSymbolItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>12 <FILENAME>R2.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668976266448"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br></strong></div></th> <th class="th"><div>Nov. 30, 2022</div></th> <th class="th"><div>Feb. 28, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td> <td class="nump">$ 1,692<span></span> </td> <td class="nump">$ 3,382<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaids</a></td> <td class="nump">100<span></span> </td> <td class="nump">1,279<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td> <td class="nump">1,792<span></span> </td> <td class="nump">4,661<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td> <td class="nump">1,792<span></span> </td> <td class="nump">4,661<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td> <td class="nump">16,650<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td> <td class="nump">11,770<span></span> </td> <td class="nump">3,455<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">CURRENT AND TOTAL LIABILITIES</a></td> <td class="nump">28,420<span></span> </td> <td class="nump">3,455<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity (deficit)</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $.001 par value; 200,000,000 shares authorized; 131,448,444 shares issued and outstanding as of November 30, 2022 and February 28, 2022</a></td> <td class="nump">131,449<span></span> </td> <td class="nump">131,449<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td> <td class="nump">126,380,700<span></span> </td> <td class="nump">125,708,240<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained deficit</a></td> <td class="num">(126,538,777)<span></span> </td> <td class="num">(125,838,483)<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity (deficit)</a></td> <td class="num">(26,628)<span></span> </td> <td class="nump">1,206<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity (deficit)</a></td> <td class="nump">$ 1,792<span></span> </td> <td class="nump">$ 4,661<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Assets</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockValue</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Liabilities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>13 <FILENAME>R3.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668975338240"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS (Parenthetical) - $ / shares<br></strong></div></th> <th class="th"><div>Nov. 30, 2022</div></th> <th class="th"><div>Feb. 28, 2022</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>BALANCE SHEETS</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td> <td class="nump">$ 0.001<span></span> </td> <td class="nump">$ 0.001<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td> <td class="nump">200,000,000<span></span> </td> <td class="nump">200,000,000<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td> <td class="nump">131,448,444<span></span> </td> <td class="nump">131,448,444<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td> <td class="nump">131,448,444<span></span> </td> <td class="nump">131,448,444<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>14 <FILENAME>R4.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668976307584"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS - USD ($)<br></strong></div></th> <th class="th" colspan="2">3 Months Ended</th> <th class="th" colspan="2">9 Months Ended</th> </tr> <tr> <th class="th"><div>Nov. 30, 2022</div></th> <th class="th"><div>Nov. 30, 2021</div></th> <th class="th"><div>Nov. 30, 2022</div></th> <th class="th"><div>Nov. 30, 2021</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td> <td class="nump">$ 207,651<span></span> </td> <td class="nump">$ 214,112<span></span> </td> <td class="nump">$ 545,960<span></span> </td> <td class="nump">$ 632,475<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td> <td class="nump">44,988<span></span> </td> <td class="nump">50,664<span></span> </td> <td class="nump">154,334<span></span> </td> <td class="nump">173,302<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td> <td class="nump">252,639<span></span> </td> <td class="nump">264,776<span></span> </td> <td class="nump">700,294<span></span> </td> <td class="nump">805,777<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td> <td class="num">(252,639)<span></span> </td> <td class="num">(264,776)<span></span> </td> <td class="num">(700,294)<span></span> </td> <td class="num">(805,777)<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before provision for income tax</a></td> <td class="num">(252,639)<span></span> </td> <td class="num">(264,776)<span></span> </td> <td class="num">(700,294)<span></span> </td> <td class="num">(805,777)<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td> <td class="num">$ (252,639)<span></span> </td> <td class="num">$ (264,776)<span></span> </td> <td class="num">$ (700,294)<span></span> </td> <td class="num">$ (805,777)<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings per share information:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Loss per common share Basic</a></td> <td class="nump">$ 0.00<span></span> </td> <td class="nump">$ 0.00<span></span> </td> <td class="num">$ (0.01)<span></span> </td> <td class="num">$ (0.01)<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Loss per common share Diluted</a></td> <td class="nump">$ 0.00<span></span> </td> <td class="nump">$ 0.00<span></span> </td> <td class="num">$ (0.01)<span></span> </td> <td class="num">$ (0.01)<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of common shares outstanding Basic</a></td> <td class="nump">131,448,444<span></span> </td> <td class="nump">131,448,444<span></span> </td> <td class="nump">131,448,444<span></span> </td> <td class="nump">131,448,444<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of common shares outstanding Diluted</a></td> <td class="nump">131,448,444<span></span> </td> <td class="nump">131,448,444<span></span> </td> <td class="nump">131,448,444<span></span> </td> <td class="nump">131,448,444<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>15 <FILENAME>R5.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668969633408"> <tr> <th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)<br></strong></div></th> <th class="th"><div>Common Stock</div></th> <th class="th"><div>Additional Paid-in Capital</div></th> <th class="th"><div>Retained Deficit</div></th> <th class="th"><div>Total</div></th> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Feb. 28, 2021</a></td> <td class="nump">$ 131,449<span></span> </td> <td class="nump">$ 124,684,535<span></span> </td> <td class="num">$ (124,861,827)<span></span> </td> <td class="num">$ (45,843)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Feb. 28, 2021</a></td> <td class="nump">131,448,444<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed', window );">Cash contributed by S.R. Burzynski, M.D., Ph.D.</a></td> <td class="text"> <span></span> </td> <td class="nump">84,967<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">84,967<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D</a></td> <td class="text"> <span></span> </td> <td class="nump">215,926<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">215,926<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(316,283)<span></span> </td> <td class="num">(316,283)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at May. 31, 2021</a></td> <td class="nump">$ 131,449<span></span> </td> <td class="nump">124,985,428<span></span> </td> <td class="num">(125,178,110)<span></span> </td> <td class="num">(61,233)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at May. 31, 2021</a></td> <td class="nump">131,448,444<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Feb. 28, 2021</a></td> <td class="nump">$ 131,449<span></span> </td> <td class="nump">124,684,535<span></span> </td> <td class="num">(124,861,827)<span></span> </td> <td class="num">(45,843)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Feb. 28, 2021</a></td> <td class="nump">131,448,444<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(805,777)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Nov. 30, 2021</a></td> <td class="nump">$ 131,449<span></span> </td> <td class="nump">125,541,505<span></span> </td> <td class="num">(125,667,604)<span></span> </td> <td class="nump">5,350<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Nov. 30, 2021</a></td> <td class="nump">131,448,444<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at May. 31, 2021</a></td> <td class="nump">$ 131,449<span></span> </td> <td class="nump">124,985,428<span></span> </td> <td class="num">(125,178,110)<span></span> </td> <td class="num">(61,233)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at May. 31, 2021</a></td> <td class="nump">131,448,444<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed', window );">Cash contributed by S.R. Burzynski, M.D., Ph.D.</a></td> <td class="text"> <span></span> </td> <td class="nump">87,717<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">87,717<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D</a></td> <td class="text"> <span></span> </td> <td class="nump">170,403<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">170,403<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(224,718)<span></span> </td> <td class="num">(224,718)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Aug. 31, 2021</a></td> <td class="nump">$ 131,449<span></span> </td> <td class="nump">125,243,548<span></span> </td> <td class="num">(125,402,828)<span></span> </td> <td class="num">(27,831)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Aug. 31, 2021</a></td> <td class="nump">131,448,444<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed', window );">Cash contributed by S.R. Burzynski, M.D., Ph.D.</a></td> <td class="text"> <span></span> </td> <td class="nump">100,017<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">100,017<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D</a></td> <td class="text"> <span></span> </td> <td class="nump">197,940<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">197,940<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(264,776)<span></span> </td> <td class="num">(264,776)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Nov. 30, 2021</a></td> <td class="nump">$ 131,449<span></span> </td> <td class="nump">125,541,505<span></span> </td> <td class="num">(125,667,604)<span></span> </td> <td class="nump">5,350<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Nov. 30, 2021</a></td> <td class="nump">131,448,444<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Feb. 28, 2022</a></td> <td class="nump">$ 131,449<span></span> </td> <td class="nump">125,708,240<span></span> </td> <td class="num">(125,838,483)<span></span> </td> <td class="nump">1,206<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Feb. 28, 2022</a></td> <td class="nump">131,448,444<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed', window );">Cash contributed by S.R. Burzynski, M.D., Ph.D.</a></td> <td class="text"> <span></span> </td> <td class="nump">40,517<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">40,517<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D</a></td> <td class="text"> <span></span> </td> <td class="nump">151,334<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">151,334<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(231,737)<span></span> </td> <td class="num">(231,737)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at May. 31, 2022</a></td> <td class="nump">$ 131,449<span></span> </td> <td class="nump">125,900,091<span></span> </td> <td class="num">(126,070,220)<span></span> </td> <td class="num">(38,680)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at May. 31, 2022</a></td> <td class="nump">131,448,444<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Feb. 28, 2022</a></td> <td class="nump">$ 131,449<span></span> </td> <td class="nump">125,708,240<span></span> </td> <td class="num">(125,838,483)<span></span> </td> <td class="nump">1,206<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Feb. 28, 2022</a></td> <td class="nump">131,448,444<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(700,294)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Nov. 30, 2022</a></td> <td class="nump">$ 131,449<span></span> </td> <td class="nump">126,380,700<span></span> </td> <td class="num">(126,538,777)<span></span> </td> <td class="num">(26,628)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Nov. 30, 2022</a></td> <td class="nump">131,448,444<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at May. 31, 2022</a></td> <td class="nump">$ 131,449<span></span> </td> <td class="nump">125,900,091<span></span> </td> <td class="num">(126,070,220)<span></span> </td> <td class="num">(38,680)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at May. 31, 2022</a></td> <td class="nump">131,448,444<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed', window );">Cash contributed by S.R. Burzynski, M.D., Ph.D.</a></td> <td class="text"> <span></span> </td> <td class="nump">86,017<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">86,017<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D</a></td> <td class="text"> <span></span> </td> <td class="nump">154,943<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">154,943<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(215,918)<span></span> </td> <td class="num">(215,918)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Aug. 31, 2022</a></td> <td class="nump">$ 131,449<span></span> </td> <td class="nump">126,141,051<span></span> </td> <td class="num">(126,286,138)<span></span> </td> <td class="num">(13,638)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Aug. 31, 2022</a></td> <td class="nump">131,448,444<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed', window );">Cash contributed by S.R. Burzynski, M.D., Ph.D.</a></td> <td class="text"> <span></span> </td> <td class="nump">48,017<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">48,017<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther', window );">FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D</a></td> <td class="text"> <span></span> </td> <td class="nump">191,632<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">191,632<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(252,639)<span></span> </td> <td class="num">(252,639)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Nov. 30, 2022</a></td> <td class="nump">$ 131,449<span></span> </td> <td class="nump">$ 126,380,700<span></span> </td> <td class="num">$ (126,538,777)<span></span> </td> <td class="num">$ (26,628)<span></span> </td> </tr> <tr class="rc"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Nov. 30, 2022</a></td> <td class="nump">131,448,444<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the cash contributed by the individual that is reported as additional paid-in capital, which is used to fund general operating expenses during the reporting year.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalOther"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other increase (decrease) in additional paid in capital (APIC).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalOther</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharesOutstanding</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>16 <FILENAME>R6.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668975365040"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br></strong></div></th> <th class="th" colspan="4">3 Months Ended</th> <th class="th" colspan="2">9 Months Ended</th> </tr> <tr> <th class="th"><div>Nov. 30, 2022</div></th> <th class="th"><div>May 31, 2022</div></th> <th class="th"><div>Nov. 30, 2021</div></th> <th class="th"><div>May 31, 2021</div></th> <th class="th"><div>Nov. 30, 2022</div></th> <th class="th"><div>Nov. 30, 2021</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss</a></td> <td class="num">$ (252,639)<span></span> </td> <td class="num">$ (231,737)<span></span> </td> <td class="num">$ (264,776)<span></span> </td> <td class="num">$ (316,283)<span></span> </td> <td class="num">$ (700,294)<span></span> </td> <td class="num">$ (805,777)<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used by operating activities:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_ClinicalTrialExpensesPaid', window );">FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D.</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">497,909<span></span> </td> <td class="nump">584,270<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Prepaids</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">1,179<span></span> </td> <td class="num">(80)<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">16,650<span></span> </td> <td class="num">(31,123)<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">8,315<span></span> </td> <td class="num">(14,287)<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">NET CASH USED BY OPERATING ACTIVITIES</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(176,241)<span></span> </td> <td class="num">(266,997)<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromContributedCapital', window );">Contribution of capital</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">174,551<span></span> </td> <td class="nump">272,701<span></span> </td> </tr> <tr class="rou"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">NET CASH PROVIDED BY FINANCING ACTIVITIES</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">174,551<span></span> </td> <td class="nump">272,701<span></span> </td> </tr> <tr class="reu"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect', window );">NET INCREASE (DECREASE) IN CASH</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="num">(1,690)<span></span> </td> <td class="nump">5,704<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AT BEGINNING OF PERIOD</a></td> <td class="text"> <span></span> </td> <td class="nump">$ 3,382<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 62<span></span> </td> <td class="nump">3,382<span></span> </td> <td class="nump">62<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">CASH AT END OF PERIOD</a></td> <td class="nump">$ 1,692<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 5,766<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 1,692<span></span> </td> <td class="nump">$ 5,766<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_ClinicalTrialExpensesPaid"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the clinical trial expenses that are incurred by the entity which are used in the treatment of cancer during the reporting period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_ClinicalTrialExpensesPaid</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromContributedCapital"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received by a corporation from a shareholder during the period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ProceedsFromContributedCapital</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>17 <FILENAME>R7.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668974388192"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION<br></strong></div></th> <th class="th" colspan="1">9 Months Ended</th> </tr> <tr><th class="th"><div>Nov. 30, 2022</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">BASIS OF PRESENTATION</a></td> <td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE A.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">BASIS OF PRESENTATION</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The financial statements of Burzynski Research Institute, <span style="white-space:pre-wrap;">Inc. (the “Company”), a Delaware corporation, include expenses incurred related to clinical trials, which were sanctioned by the U.S. Food and Drug Administration (FDA) in 1993, for Antineoplaston drugs used in the treatment of cancer. These expenses are incurred directly by S.R. Burzynski, M.D., Ph.D. (Dr. </span><span style="white-space:pre-wrap;">Burzynski or “SRB”) on behalf of the Company and have been reported as research and development costs and as additional paid-in capital. Other funds received from Dr. </span><span style="white-space:pre-wrap;">Burzynski have also been reported as additional paid-in capital. Expenses related to Dr. </span><span style="white-space:pre-wrap;">Burzynski’s medical practice (unrelated to the clinical trials) have not been included in these financial statements. Dr. Burzynski is the President, Chairman of the Board and owner of approximately </span>81.0% of the outstanding common stock of the Company, and also is the inventor and original patent holder of certain drug products known as “Antineoplastons.” </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company and Dr. <span style="white-space:pre-wrap;">Burzynski have entered into various agreements as further described in Note B. The License Agreement between the Company and Dr. Burzynski provided the Company the exclusive right in the United States, Canada and Mexico to use, manufacture, develop, sell, distribute, sublicense and otherwise exploit all the rights, titles and interest in Antineoplaston drugs used in the treatment of cancer, once the drug is approved for sale by the FDA. On July 2, 2019, the License Agreement terminated upon the expiration of the last patent licensed to the Company under such agreement. As such, the Company does not currently have licenses to any patents with respect to Antineoplastons. The Company does own </span>one US patent which was recently issued on May 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company is primarily engaged as a research and development facility for Antineoplaston drugs being tested for the use in the treatment of cancer. The Company’s investigational new drug application (“IND”) 43742 is currently under full clinical hold and the Company cannot enroll new patients into any clinical trials until the full clinical hold is removed by the FDA. At this time, however, none of the Antineoplaston drugs have received FDA approval; further, there can be no assurance that FDA approval will be granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Certain disclosures and information normally included in financial statements have been condensed or omitted. In the opinion of management of the Company, these financial statements contain all adjustments necessary for a fair presentation of financial position as of November 30, 2022 and February 28, 2022, results of operations for the three and nine months ended November 30, 2022 and 2021, and cash flows for the nine months ended November 30, 2022 and 2021. All adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results to be expected for a full year. These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022.</span></p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&trid=2197479<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>18 <FILENAME>R8.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668974515600"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ECONOMIC DEPENDENCY<br></strong></div></th> <th class="th" colspan="1">9 Months Ended</th> </tr> <tr><th class="th"><div>Nov. 30, 2022</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>ECONOMIC DEPENDENCY</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">ECONOMIC DEPENDENCY</a></td> <td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE B.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">ECONOMIC DEPENDENCY</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The Company has not generated significant revenues since its inception and has suffered losses from operations, has a working capital deficit and has an accumulated deficit. Dr. Burzynski has funded the capital and operational needs of the Company through his medical practice since inception, and has entered into various agreements to continue such funding.</span> Because the Company is entirely dependent upon the contributions for research provided by Dr. Burzynski under a research funding agreement, the Company would not be able to continue conducting its clinical trials if Dr. Burzynski ceased funding the Company’s research. In such event, the Company would be required to find immediate funding which may not be available on acceptable terms or at all. If this were to occur and the Company were not able to find adequate sources of funding, the Company would be required to cease operations. Even with Dr. Burzynski’s continued contributions under a research funding agreement, the Company may be required to seek additional capital through equity or debt financing or the sale of assets until the Company’s operating revenues are sufficient to cover operating costs and provide positive cash flow; however, there can be no assurance that the Company will be able to raise such additional capital on acceptable terms to the Company. In addition, there can be no assurance that the Company will ever achieve positive operating cash flow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The Company is economically dependent on its funding through Dr. Burzynski’s medical practice. In the past, a portion of Dr. Burzynski’s patients have been admitted and treated as part of the clinical trial programs. The Company’s IND 43742 is currently under full clinical hold and the Company cannot enroll new patients into any clinical trials until the full clinical hold is removed by the FDA. The FDA imposes numerous regulations and requirements regarding these patients, and the Company is subject to inspection at any time by the FDA. These regulations are complex and subject to interpretation and though it is management’s intention to comply fully with all such regulations, there is the risk that the Company is not in compliance and is thus subject to sanctions imposed by the FDA. In addition, as with any medical practice, Dr. Burzynski is subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice. The risks associated with Dr. Burzynski’s medical practice directly affect his ability to fund the operations of the Company.</span></p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&trid=2208762<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>19 <FILENAME>R9.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668975015280"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS AND WARRANTS<br></strong></div></th> <th class="th" colspan="1">9 Months Ended</th> </tr> <tr><th class="th"><div>Nov. 30, 2022</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK OPTIONS AND WARRANTS</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK OPTIONS AND WARRANTS</a></td> <td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE C.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">STOCK OPTIONS AND WARRANTS</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">At November 30, 2022, the Company had one stock-based employee compensation plan, which is described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">On September 14, 1996, the Company granted 600,000 stock options, with an exercise price of $0.35<span style="white-space:pre-wrap;"> per share, to an officer who is no longer with the Company. </span>The options vested as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vesting Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">400,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">September 14, 1996</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">June 1, 1997</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">June 1, 1998</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The options are valid in perpetuity. </span>None of the options have been exercised as of November 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company accounts for share-based payments to non-employees in accordance with the guidance provided by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718, <i style="font-style:italic;">Compensation – Stock Compensation</i> to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity’s own operations and supersedes the guidance in ASC 505-50.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;">Effective July 5, 2012, the Company entered into a Marketing and Consulting Agreement (the “Marketing Agreement”) with Worldwide Medical Consultants, Inc. (“WMC”) and CARIGEN, LTD (“SRB”), an entity wholly-owned and controlled by Dr. Burzynski, pursuant to which WMC will (i) provide SRB with various marketing and consulting services to assist SRB in locating and developing cancer or health related centers in certain foreign markets and (ii) make payments to the Company equal to </span><span style="font-size:10pt;">10%</span><span style="font-size:10pt;"> of each consulting fee received by WMC for the aforementioned services provided to SRB, net of certain expenses incurred by WMC (“WMC Payment”). In consideration of the WMC Payment, the Company agreed to grant to WMC warrants to acquire an aggregate of </span><span style="font-size:10pt;">2,000,000</span><span style="font-size:10pt;"> shares of the Company’s Common Stock, exercisable at </span><span style="font-size:10pt;">$0.10</span><span style="font-size:10pt;"> per share with a </span><span style="font-size:10pt;">ten year</span><span style="font-size:10pt;"> exercise period, with </span><span style="font-size:10pt;">1,000,000</span><span style="font-size:10pt;"> shares vesting upon execution of the agreement (the "Initial Warrants") and the remaining </span><span style="font-size:10pt;">1,000,000</span><span style="font-size:10pt;"> shares to vest upon the first closing of a transaction by SRB as a result of the services provided by WMC under the Marketing Agreement. The Marketing Agreement was terminated effective as of July 5, 2019 pursuant to its terms. The Initial Warrants expired on July 5, 2022 and were never exercised.</span></p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>20 <FILENAME>R10.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668975015280"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE<br></strong></div></th> <th class="th" colspan="1">9 Months Ended</th> </tr> <tr><th class="th"><div>Nov. 30, 2022</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>LOSS PER COMMON SHARE</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">LOSS PER COMMON SHARE</a></td> <td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE D.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">LOSS PER COMMON SHARE</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company accounts for loss per share in accordance with FASB ASC 260, <i style="font-style:italic;">Earnings per Share</i>. Basic loss per share amounts are calculated by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the periods, including the dilutive effect of all common stock equivalents. Dilutive options and warrants that are issued during a period or that expire or are canceled during a period are reflected in the computations for the time they were outstanding during the periods being reported. During the three and nine months ended November 30, 2022 and 2021, 600,000 stock options and 1,600,000 warrants and stock options, respectively, were excluded from the calculation of diluted loss per share because their effect would be anti-dilutive.</p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>21 <FILENAME>R11.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668978039440"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES<br></strong></div></th> <th class="th" colspan="1">9 Months Ended</th> </tr> <tr><th class="th"><div>Nov. 30, 2022</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">INCOME TAXES</a></td> <td class="text"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE E.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">INCOME TAXES</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company follows the provisions of FASB ASC 740, <i style="font-style:italic;">Income Taxes</i><span style="white-space:pre-wrap;">. The Company is not aware of any material unrecognized tax uncertainties as a result of tax positions previously taken.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company recognizes interest and penalties as interest expense when they are accrued or assessed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;white-space:pre-wrap;">The federal income tax returns of the Company for 2021, 2020, and 2019 are subject to examination by the IRS, generally for </span><span style="font-size:10pt;">three years</span><span style="font-size:10pt;"> after they are filed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The actual provision for income tax for the three and nine months ended November 30, 2022 and 2021 differ from the amounts computed by applying the U.S. federal income tax rate of 21% to the pretax loss as a result of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended November 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (53,054)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (55,603)</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxed directly to Dr. Burzynski </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,603</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible expenses and other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,968)</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,728)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,968</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.29%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended November 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (147,062)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (169,213)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxed directly to Dr. Burzynski </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147,062</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169,213</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible expenses and other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,751)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,845)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,751</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">At November 30, 2022, the Company had a net deferred tax asset of $0, which includes a valuation allowance of $164,547<span style="white-space:pre-wrap;">. The Company’s ability to utilize net operating loss ("NOL") carryforwards and alternative minimum tax credit carryforwards will depend on its ability to generate adequate future taxable income. The Company has </span>no<span style="white-space:pre-wrap;"> historical earnings on which to base an expectation of future taxable income. Accordingly, a full valuation allowance for deferred tax assets has been provided.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">As a result of the Tax Cuts and Jobs Act of 2017 (the "Act"), NOL carryforwards generated in years beginning after December 31, 2017, would carryforward indefinitely, and would apply to 80% of future taxable income. Under the Act, carrybacks of NOLs were disallowed. In March 2020, the Coronavirus Aid, Relief, and Economic Security ("CARES") Act was enacted providing a five-year carryback for losses incurred in 2018, 2019, or 2020, which allows companies to modify tax returns up to five years prior to offset taxable income from those tax years. The CARES Act also temporarily suspended the NOL limit of 80%<span style="white-space:pre-wrap;"> of taxable income through December 31, 2020, but the NOLs generated in 2018 and forward would still carryforward indefinitely. Effective January 1, 2021, NOL carryforwards generated will only apply to </span>80% of future taxable income according to the Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">As of November 30, 2022, the Company has net operating loss carryforwards in the amount of $473,902 that will expire between 2026 and 2038, and $106,782 that will carryforward indefinitely, of which $78,948 applies to 100% of future taxable income and $27,834 applies to 80% of future taxable income.</p><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>22 <FILENAME>R12.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668976244272"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS AND WARRANTS (Tables)<br></strong></div></th> <th class="th" colspan="1">9 Months Ended</th> </tr> <tr><th class="th"><div>Nov. 30, 2022</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>STOCK OPTIONS AND WARRANTS</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock', window );">Schedule of options vested</a></td> <td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vesting Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">400,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">September 14, 1996</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">June 1, 1997</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">June 1, 1998</p></td></tr></table><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>23 <FILENAME>R13.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668974815600"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Tables)<br></strong></div></th> <th class="th" colspan="1">9 Months Ended</th> </tr> <tr><th class="th"><div>Nov. 30, 2022</div></th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>INCOME TAXES</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of actual provision for income tax that differs from the amounts computed by applying the U.S. federal income tax rate to the pretax loss</a></td> <td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended November 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (53,054)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (55,603)</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxed directly to Dr. Burzynski </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,603</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible expenses and other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,968)</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,728)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,968</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.29%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended November 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (147,062)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (169,213)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxed directly to Dr. Burzynski </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147,062</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169,213</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible expenses and other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,751)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,845)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,751</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table></div><span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:textBlockItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>24 <FILENAME>R14.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668976610064"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PRESENTATION (Details)<br></strong></div></th> <th class="th" colspan="1">9 Months Ended</th> </tr> <tr><th class="th"> <div>Nov. 30, 2022 </div> <div>item </div> <div>patent</div> </th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>BASIS OF PRESENTATION</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard', window );">Percentage of outstanding stock owned by the President and Chairman of the Board</a></td> <td class="nump">81.00%<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_NumberOfPatentsOwned', window );">Number of patents owned | patent</a></td> <td class="nump">1<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval', window );">Number of antineoplaston drugs that have received FDA approval | item</a></td> <td class="nump">0<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of antineoplaston drugs that have received FDA approval.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:integerItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_NumberOfPatentsOwned"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of patents owned.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_NumberOfPatentsOwned</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:integerItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage interest of ownership held by the President of the Company, whom is also the Chairman of the Board.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>25 <FILENAME>R15.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668969505088"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STOCK OPTIONS AND WARRANTS (Details)<br></strong></div></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1"></th> <th class="th" colspan="1">9 Months Ended</th> </tr> <tr> <th class="th"> <div>Jul. 05, 2012 </div> <div>$ / shares </div> <div>shares</div> </th> <th class="th"> <div>Jun. 01, 1998 </div> <div>shares</div> </th> <th class="th"> <div>Jun. 01, 1997 </div> <div>shares</div> </th> <th class="th"> <div>Sep. 14, 1996 </div> <div>$ / shares </div> <div>shares</div> </th> <th class="th"> <div>Nov. 30, 2022 </div> <div>item </div> <div>shares</div> </th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCK OPTIONS AND WARRANTS</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans', window );">Number of stock-based employee compensation plan | item</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">1<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=bzyr_WorldwideMedicalConsultantsIncMember', window );">Worldwide Medical Consultants, Inc. ("WMC") | CARIGEN, LTD ("SRB")</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_MarketingAgreementAbstract', window );"><strong>Marketing Agreement</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement', window );">Consulting fee (as a percent)</a></td> <td class="nump">10.00%<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to be granted to acquire shares of common stock (in shares)</a></td> <td class="nump">2,000,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercisable price (in dollars per share) | $ / shares</a></td> <td class="nump">$ 0.10<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_ClassOfWarrantOrRightsExercisePeriod', window );">Warrants exercise period</a></td> <td class="text">10 years<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_SharesVestingUponExecutionOfAgreement', window );">Shares vesting upon execution of the agreement</a></td> <td class="nump">1,000,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_RemainingSharesToVestUponFirstClosingOfAgreement', window );">Remaining shares to vest upon the first closing of a transaction by SRB under the marketing agreement</a></td> <td class="nump">1,000,000<span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>STOCK OPTIONS AND WARRANTS</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">600,000<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Exercise price (in dollars per share) | $ / shares</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0.35<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Vested (in shares)</a></td> <td class="text"> <span></span> </td> <td class="nump">100,000<span></span> </td> <td class="nump">100,000<span></span> </td> <td class="nump">400,000<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_ClassOfWarrantOrRightsExercisePeriod"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the exercise period for warrants exercisable.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_ClassOfWarrantOrRightsExercisePeriod</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_MarketingAgreementAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_MarketingAgreementAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of consulting fee to be received by the Company per the marketing agreement.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_RemainingSharesToVestUponFirstClosingOfAgreement"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the remaining shares to vest upon the first closing of a transaction by SRB as a result of the services provided by WMC under the marketing agreement.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_RemainingSharesToVestUponFirstClosingOfAgreement</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share-based compensation plans approved by the entity's shareholders.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:integerItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_SharesVestingUponExecutionOfAgreement"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the shares vesting upon execution of the agreement.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_SharesVestingUponExecutionOfAgreement</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:perShareItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=bzyr_WorldwideMedicalConsultantsIncMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">dei_LegalEntityAxis=bzyr_WorldwideMedicalConsultantsIncMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bzyr_CarigenLtdMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=bzyr_CarigenLtdMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>26 <FILENAME>R16.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668970304944"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>LOSS PER COMMON SHARE (Details) - shares<br></strong></div></th> <th class="th" colspan="2">3 Months Ended</th> <th class="th" colspan="2">9 Months Ended</th> </tr> <tr> <th class="th"><div>Nov. 30, 2022</div></th> <th class="th"><div>Nov. 30, 2021</div></th> <th class="th"><div>Nov. 30, 2022</div></th> <th class="th"><div>Nov. 30, 2021</div></th> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from calculation of diluted loss per share (in shares)</a></td> <td class="nump">600,000<span></span> </td> <td class="nump">600,000<span></span> </td> <td class="nump">600,000<span></span> </td> <td class="nump">600,000<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bzyr_WarrantsAndStockOptionsMember', window );">Warrants and stock options</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded from calculation of diluted loss per share (in shares)</a></td> <td class="nump">1,600,000<span></span> </td> <td class="nump">1,600,000<span></span> </td> <td class="nump">1,600,000<span></span> </td> <td class="nump">1,600,000<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:sharesItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bzyr_WarrantsAndStockOptionsMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=bzyr_WarrantsAndStockOptionsMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>27 <FILENAME>R17.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668975363328"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES (Details) - USD ($)<br></strong></div></th> <th class="th" colspan="2">3 Months Ended</th> <th class="th" colspan="2">9 Months Ended</th> </tr> <tr> <th class="th"><div>Nov. 30, 2022</div></th> <th class="th"><div>Nov. 30, 2021</div></th> <th class="th"><div>Nov. 30, 2022</div></th> <th class="th"><div>Nov. 30, 2021</div></th> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Taxes</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. federal income tax rate (as a percent)</a></td> <td class="nump">21.00%<span></span> </td> <td class="nump">21.00%<span></span> </td> <td class="nump">21.00%<span></span> </td> <td class="nump">21.00%<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Actual income tax benefit</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Expected expense (benefit)</a></td> <td class="num">$ (53,054)<span></span> </td> <td class="num">$ (55,603)<span></span> </td> <td class="num">$ (147,062)<span></span> </td> <td class="num">$ (169,213)<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationDeductions', window );">Taxed directly to Dr. Burzynski</a></td> <td class="nump">53,054<span></span> </td> <td class="nump">55,603<span></span> </td> <td class="nump">147,062<span></span> </td> <td class="nump">169,213<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense', window );">Nondeductible expenses and other adjustments</a></td> <td class="nump">2,728<span></span> </td> <td class="num">(6,968)<span></span> </td> <td class="nump">5,845<span></span> </td> <td class="num">(10,751)<span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td> <td class="num">(2,728)<span></span> </td> <td class="nump">$ 6,968<span></span> </td> <td class="num">(5,845)<span></span> </td> <td class="nump">$ 10,751<span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">0<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td> <td class="nump">$ 164,547<span></span> </td> <td class="text"> <span></span> </td> <td class="nump">164,547<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Historical earnings</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="nump">$ 0<span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">IRS</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Taxes</strong></a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination', window );">Period after filing income tax returns subject to examination</a></td> <td class="text"> <span></span> </td> <td class="text"> <span></span> </td> <td class="text">3 years<span></span> </td> <td class="text"> <span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the period after filing income tax returns subject to examination by the taxing authority.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:durationItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationDeductions"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationDeductions</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpense"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpense</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227<br></p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_Revenues</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>credit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>28 <FILENAME>R18.htm <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <html> <head> <title></title> <link rel="stylesheet" type="text/css" href="include/report.css"> <script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript"> function toggleNextSibling (e) { if (e.nextSibling.style.display=='none') { e.nextSibling.style.display='block'; } else { e.nextSibling.style.display='none'; } }</script> </head> <body> <span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140668976617472"> <tr> <th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>INCOME TAXES - Operating Loss Carryforwards (Details)<br></strong></div></th> <th class="th" colspan="1">9 Months Ended</th> </tr> <tr><th class="th"> <div>Nov. 30, 2022 </div> <div>USD ($)</div> </th></tr> <tr class="re"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carryforwards</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards', window );">Future taxable income (in Percent)</a></td> <td class="nump">80.00%<span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct', window );">Percentage of NOL limit on taxable income under the CARES act</a></td> <td class="nump">80.00%<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_NetOperatingLossCarryForwardIndefinitely', window );">Net operating loss carryforward indefinite period</a></td> <td class="nump">$ 106,782<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=bzyr_HundredPercentFutureTaxableIncomeMember', window );">100% of future taxable income</a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carryforwards</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards', window );">Future taxable income (in Percent)</a></td> <td class="nump">100.00%<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_NetOperatingLossCarryForwardIndefinitely', window );">Net operating loss carryforward indefinite period</a></td> <td class="nump">$ 78,948<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementScenarioAxis=bzyr_EightyPercentFutureTaxableIncomeMember', window );">80% of future taxable income</a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carryforwards</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards', window );">Future taxable income (in Percent)</a></td> <td class="nump">80.00%<span></span> </td> </tr> <tr class="ro"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_NetOperatingLossCarryForwardIndefinitely', window );">Net operating loss carryforward indefinite period</a></td> <td class="nump">$ 27,834<span></span> </td> </tr> <tr class="rh"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember', window );">2026 to 2038</a></td> <td class="text"> <span></span> </td> </tr> <tr class="ro"> <td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLineItems', window );"><strong>Net operating loss carryforwards</strong></a></td> <td class="text"> <span></span> </td> </tr> <tr class="re"> <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards', window );">Net operating loss carryforward in accordance with the Act</a></td> <td class="nump">$ 473,902<span></span> </td> </tr> </table> <div style="display: none;"> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_NetOperatingLossCarryForwardIndefinitely"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>It represents net operating loss carryforward indefinite period.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_NetOperatingLossCarryForwardIndefinitely</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of future taxable income for which net operating loss carryforward indefinitely.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of NOL limit on taxable income under the CARES act.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>dtr-types:percentItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net operating loss carryforwards that will carryforward in accordance with Tax Cuts and Jobs Act of 2017.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>bzyr_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:monetaryItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>debit</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>instant</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLineItems"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLineItems</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td>us-gaap_</td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>xbrli:stringItemType</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Period Type:</strong></td> <td>duration</td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bzyr_HundredPercentFutureTaxableIncomeMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">srt_StatementScenarioAxis=bzyr_HundredPercentFutureTaxableIncomeMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=bzyr_EightyPercentFutureTaxableIncomeMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">srt_StatementScenarioAxis=bzyr_EightyPercentFutureTaxableIncomeMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember"> <tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr> <tr><td><div class="body" style="padding: 2px;"> <a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0"> <tr> <td><strong> Name:</strong></td> <td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=us-gaap_LatestTaxYearMember</td> </tr> <tr> <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td> <td></td> </tr> <tr> <td><strong> Data Type:</strong></td> <td>na</td> </tr> <tr> <td><strong> Balance Type:</strong></td> <td></td> </tr> <tr> <td><strong> Period Type:</strong></td> <td></td> </tr> </table></div> </div></td></tr> </table> </div> </body> </html> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>29 <FILENAME>bzyr-20221130x10q_htm.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <XML> <?xml version="1.0" encoding="utf-8"?> <xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:bzyr="http://www.burzynskiresearch.com/20221130" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:srt="http://fasb.org/srt/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"> <link:schemaRef xlink:href="bzyr-20221130.xsd" xlink:type="simple"/> <context id="Duration_3_1_2022_To_11_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_67nM8Z7lXEy5aoImbV3iJg"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-03-01</startDate> <endDate>2022-11-30</endDate> </period> </context> <context id="As_Of_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_C988H_c5lEirXg2bOfyMYw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-11-30</instant> </period> </context> <context id="As_Of_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lKswUaIHiEyn9JevGZ0Gvg"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-11-30</instant> </period> </context> <context id="As_Of_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yFw4lSokjkO_tlKaEbVbfg"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="As_Of_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hhGupecJrkOV3pUvJetcyA"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="As_Of_8_31_2022_aZAr42E-wEG4LLyxptSbCQ"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eXcu2NBnCkKP8GkoLn9imw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-05-31</instant> </period> </context> <context id="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__NiklRz9s0eL5ss5vnewgw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-05-31</instant> </period> </context> <context id="As_Of_5_31_2022_aH1WuS8v1UW8yzeokt0qeA"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <instant>2022-05-31</instant> </period> </context> <context id="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NTT6rcWjSkS1DUuU566q9g"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-02-28</instant> </period> </context> <context id="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JvhCi6_6NEyaCy4wUrsXFg"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-02-28</instant> </period> </context> <context id="As_Of_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3HnDsSVLSEaSsHcQ_eD5WQ"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-11-30</instant> </period> </context> <context id="As_Of_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gtjfx8jA70qc4SM14Yj3jw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-11-30</instant> </period> </context> <context id="As_Of_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_t40J9Yyvp0eMzCsyd170Lw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-08-31</instant> </period> </context> <context id="As_Of_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QfVTYoRMfUOqPfb1PY4Qtw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-08-31</instant> </period> </context> <context id="As_Of_8_31_2021_LiQ_dJGijkqI7kTCGFYSOg"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <instant>2021-08-31</instant> </period> </context> <context id="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lNN1yxnejk2tW8zeN_uI2A"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-05-31</instant> </period> </context> <context id="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OnyyqaGUF0iy63pvlajMzw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-05-31</instant> </period> </context> <context id="As_Of_5_31_2021_qG8hjPs1ckabOxyw-IisaA"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <instant>2021-05-31</instant> </period> </context> <context id="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0DY2kRmuRkykwMzYCLMEag"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-02-28</instant> </period> </context> <context id="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_txIuVwJscEWQsoDWljOsLg"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-02-28</instant> </period> </context> <context id="As_Of_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TBAhEDDdsEmkmzUW0oQzAw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-11-30</instant> </period> </context> <context id="As_Of_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ay5nAffd0UKk97xXOpf_iw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-08-31</instant> </period> </context> <context id="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UPPp8HvvukaFfAR3iE04GA"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-05-31</instant> </period> </context> <context id="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6rkROjav_UGQmnIAcgnBEA"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-02-28</instant> </period> </context> <context id="As_Of_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XeOxpxRW2k2UySfWnD5UMQ"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-11-30</instant> </period> </context> <context id="As_Of_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sb_rwZ6nVU-g3e9Wdj7-7w"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-08-31</instant> </period> </context> <context id="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IUIR5alQTkqIkz4yW1duxw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-05-31</instant> </period> </context> <context id="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QcYgvQm1sU2dNqhqk7HHhQ"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2021-02-28</instant> </period> </context> <context id="Duration_6_1_1998_To_6_1_1998_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DbEucoULE0aMqQ_3EsFxqA"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>1998-06-01</startDate> <endDate>1998-06-01</endDate> </period> </context> <context id="Duration_6_1_1997_To_6_1_1997_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_lrGBPtct1kCgRQmYPd7n8Q"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>1997-06-01</startDate> <endDate>1997-06-01</endDate> </period> </context> <context id="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9J2vQo42mEG22C8KOHHe-A"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>1996-09-14</startDate> <endDate>1996-09-14</endDate> </period> </context> <context id="Duration_9_1_2022_To_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nMckWf8ou06gtaq15KVt5A"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2022-11-30</endDate> </period> </context> <context id="Duration_6_1_2022_To_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bYsh9WfHTkq54L3M1Md8eQ"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-06-01</startDate> <endDate>2022-08-31</endDate> </period> </context> <context id="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8qgAaLYRNECoMmeZnKz0Vw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-03-01</startDate> <endDate>2022-05-31</endDate> </period> </context> <context id="Duration_9_1_2021_To_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_k3hpjFE5JU65xKnnzgO2vQ"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2021-11-30</endDate> </period> </context> <context id="Duration_6_1_2021_To_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4_eOqZpcUk-67OjGO1pofg"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-06-01</startDate> <endDate>2021-08-31</endDate> </period> </context> <context id="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TeJKkXhGtEWygQhcQKp9qw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-03-01</startDate> <endDate>2021-05-31</endDate> </period> </context> <context id="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_k0yzPQpwzUKU2JiaPznW_w"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bzyr:CarigenLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bzyr:WorldwideMedicalConsultantsIncMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2012-07-05</instant> </period> </context> <context id="As_Of_11_30_2021_2QExRwQy1EushHKZUUQPGg"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <instant>2021-11-30</instant> </period> </context> <context id="As_Of_2_28_2021_tz3utn4GW0icSAfEmME0tQ"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <instant>2021-02-28</instant> </period> </context> <context id="Duration_9_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Q6hxXm5dK0q5su70AGA9ow"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2022-11-30</endDate> </period> </context> <context id="Duration_9_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_mGRKAPT_d0i6xvYOzqjuhw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bzyr:WarrantsAndStockOptionsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2022-11-30</endDate> </period> </context> <context id="Duration_3_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_q5rwaskLYUu_ZDbHfAs6pw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-03-01</startDate> <endDate>2022-11-30</endDate> </period> </context> <context id="Duration_3_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_dopENHjSVkec1zCh35q5Hg"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bzyr:WarrantsAndStockOptionsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-03-01</startDate> <endDate>2022-11-30</endDate> </period> </context> <context id="Duration_9_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_kxHbs4IXUEaF_-ZHCfDT7w"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2021-11-30</endDate> </period> </context> <context id="Duration_9_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_u75x1ek-KkeJ32monPyZiQ"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bzyr:WarrantsAndStockOptionsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2021-11-30</endDate> </period> </context> <context id="Duration_3_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_CFxwHANUYkWnJB9fZNUxkg"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-03-01</startDate> <endDate>2021-11-30</endDate> </period> </context> <context id="Duration_3_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_wVzlOVFTnUa4yodykmvUJw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">bzyr:WarrantsAndStockOptionsMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-03-01</startDate> <endDate>2021-11-30</endDate> </period> </context> <context id="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <instant>2022-02-28</instant> </period> </context> <context id="As_Of_1_1_2023_NWkE9flst0aP1TfbgyOO3A"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <instant>2023-01-01</instant> </period> </context> <context id="As_Of_11_30_2022_us-gaap_TaxPeriodAxis_us-gaap_LatestTaxYearMember_PYUkT8vb4kidxIHJrwE-Mg"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">us-gaap:LatestTaxYearMember</xbrldi:explicitMember> </segment> </entity> <period> <instant>2022-11-30</instant> </period> </context> <context id="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <instant>2022-11-30</instant> </period> </context> <context id="Duration_3_1_2022_To_11_30_2022_srt_StatementScenarioAxis_bzyr_HundredPercentFutureTaxableIncomeMember_-mkCDpGPAUaxUXrXRSUTtA"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bzyr:HundredPercentFutureTaxableIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-03-01</startDate> <endDate>2022-11-30</endDate> </period> </context> <context id="Duration_3_1_2022_To_11_30_2022_srt_StatementScenarioAxis_bzyr_EightyPercentFutureTaxableIncomeMember_QhqQJfwexky0p43BckGK3w"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">bzyr:EightyPercentFutureTaxableIncomeMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-03-01</startDate> <endDate>2022-11-30</endDate> </period> </context> <context id="Duration_3_1_2022_To_11_30_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_gY1j0FUXpUGEySuC7dEpCA"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-03-01</startDate> <endDate>2022-11-30</endDate> </period> </context> <context id="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <startDate>2022-03-01</startDate> <endDate>2022-11-30</endDate> </period> </context> <context id="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <startDate>2021-03-01</startDate> <endDate>2021-11-30</endDate> </period> </context> <context id="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_ailYsCoPekC30-IUv4AkDw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">bzyr:CarigenLtdMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="dei:LegalEntityAxis">bzyr:WorldwideMedicalConsultantsIncMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2012-07-05</startDate> <endDate>2012-07-05</endDate> </period> </context> <context id="Duration_9_1_2022_To_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iwKsVl7Vak-URPtHD_l-rw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2022-11-30</endDate> </period> </context> <context id="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <startDate>2022-09-01</startDate> <endDate>2022-11-30</endDate> </period> </context> <context id="Duration_6_1_2022_To_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iTMc4yrn50u2G1IpUUj4rA"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-06-01</startDate> <endDate>2022-08-31</endDate> </period> </context> <context id="Duration_6_1_2022_To_8_31_2022_fMfAETlwykeXblePySWjcQ"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <startDate>2022-06-01</startDate> <endDate>2022-08-31</endDate> </period> </context> <context id="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zp73wx7c8EyZlhK6JxJqcQ"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2022-03-01</startDate> <endDate>2022-05-31</endDate> </period> </context> <context id="Duration_3_1_2022_To_5_31_2022_s5S1WhHB9UqmTCCb06YxWQ"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <startDate>2022-03-01</startDate> <endDate>2022-05-31</endDate> </period> </context> <context id="Duration_9_1_2021_To_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_I_jFFJLfpEun5ot6_dLYjA"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2021-11-30</endDate> </period> </context> <context id="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <startDate>2021-09-01</startDate> <endDate>2021-11-30</endDate> </period> </context> <context id="Duration_6_1_2021_To_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dq8AzYWypkmsekLWBSXMwQ"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-06-01</startDate> <endDate>2021-08-31</endDate> </period> </context> <context id="Duration_6_1_2021_To_8_31_2021_eTo4YOsOQkSH1oSW4mRAFA"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <startDate>2021-06-01</startDate> <endDate>2021-08-31</endDate> </period> </context> <context id="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-cT_vEjUDUW-S5rQVrW9Gg"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> <segment> <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember> </segment> </entity> <period> <startDate>2021-03-01</startDate> <endDate>2021-05-31</endDate> </period> </context> <context id="Duration_3_1_2021_To_5_31_2021_UX5UtaTbT0eersU02GWvMg"> <entity> <identifier scheme="http://www.sec.gov/CIK">0000724445</identifier> </entity> <period> <startDate>2021-03-01</startDate> <endDate>2021-05-31</endDate> </period> </context> <unit id="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A"> <measure>iso4217:USD</measure> </unit> <unit id="Unit_Standard_item_REEsf0XHJUOQ1iZoyc7Pvg"> <measure>bzyr:item</measure> </unit> <unit id="Unit_Standard_patent_dlojMfgdTECMpi5PU4YRsw"> <measure>bzyr:patent</measure> </unit> <unit id="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ"> <measure>pure</measure> </unit> <unit id="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA"> <measure>shares</measure> </unit> <unit id="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ"> <divide> <unitNumerator> <measure>iso4217:USD</measure> </unitNumerator> <unitDenominator> <measure>shares</measure> </unitDenominator> </divide> </unit> <us-gaap:CommitmentsAndContingencies contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" id="Hidden_28uFptHmGkKkuKxIDL4X0w" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" xsi:nil="true"/> <us-gaap:CommitmentsAndContingencies contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" id="Hidden_X99cv_5SxUOzg5PiZXO-8A" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A" xsi:nil="true"/> <dei:EntityRegistrantName contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Hidden_mh0lxxWAAUq8ikHJKgRx-g">BURZYNSKI RESEARCH INSTITUTE INC</dei:EntityRegistrantName> <dei:EntityCentralIndexKey contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tc_BGNkIF9jyE-grhLdlAYfeA_2_1">0000724445</dei:EntityCentralIndexKey> <dei:CurrentFiscalYearEndDate contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tc_AU4u1C4bikex6mbe7Kbkjg_3_1">--02-28</dei:CurrentFiscalYearEndDate> <dei:DocumentFiscalYearFocus contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tc_JzGP5EFzDkW-27p6XvKwXg_4_1">2023</dei:DocumentFiscalYearFocus> <dei:DocumentFiscalPeriodFocus contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tc_0XkvixJs8U2O8l5rQ_CQkQ_5_1">Q3</dei:DocumentFiscalPeriodFocus> <dei:AmendmentFlag contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tc_5wio724CykapT-JhmFSNdw_6_1">false</dei:AmendmentFlag> <us-gaap:EarningsPerShareBasic contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="2" id="Hidden_yrggzAn32E6tEvWYLtsblQ" unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ">0.00</us-gaap:EarningsPerShareBasic> <us-gaap:EarningsPerShareBasic contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="2" id="Hidden_MmQqWxGyVU-GwPUhGUCbqg" unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ">0.00</us-gaap:EarningsPerShareBasic> <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Hidden_4KIxsZbLvk-ZlAzTWBAjqg" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic> <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Hidden_MxP-HoYi0UqleVprulvt6A" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic> <dei:SecurityExchangeName contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Hidden_wMAzKWvegEq7ynJU2CLzHg">NONE</dei:SecurityExchangeName> <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="INF" id="Hidden_evElUb8klE-E4VGQk2oa0w" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:CommonStockSharesOutstanding> <us-gaap:CommonStockSharesOutstanding contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="INF" id="Hidden_xglGHUNNJEOQ4svyOQ4x-Q" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:CommonStockSharesOutstanding> <us-gaap:EarningsPerShareBasic contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="2" id="Hidden_xXzODA1LyUWnMoeXt_EYwg" unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ">-0.01</us-gaap:EarningsPerShareBasic> <us-gaap:EarningsPerShareBasic contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="2" id="Hidden_Cki4nmnCHESwy3FyGnIj0Q" unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ">-0.01</us-gaap:EarningsPerShareBasic> <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Hidden_t_yG-6s0rkeg8ROu6SiZ3A" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic> <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Hidden_6cLko7dpk06ZhrvfUJ9WUA" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic> <dei:DocumentType contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_AbXyBKBktkmIHP_29qc6SQ">10-Q</dei:DocumentType> <dei:DocumentQuarterlyReport contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tc_10MTbsOyV0C6xqcZ_M59jQ_1_0">true</dei:DocumentQuarterlyReport> <dei:DocumentPeriodEndDate contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_w4YNRDs_SEmO_42SD_zp5w">2022-11-30</dei:DocumentPeriodEndDate> <dei:DocumentTransitionReport contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tc_g1g-vKRAzk69WgkXjUdghw_1_0">false</dei:DocumentTransitionReport> <dei:EntityFileNumber contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_CaEDoqPzq0CIz-oPHBklaw">000-23425</dei:EntityFileNumber> <dei:EntityIncorporationStateCountryCode contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tc_heEbLMJyV0OwM5C4oRQUCA_1_0">DE</dei:EntityIncorporationStateCountryCode> <dei:EntityTaxIdentificationNumber contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tc_83iREvvVOEehy286tVGOgQ_1_2">76-0136810</dei:EntityTaxIdentificationNumber> <dei:EntityAddressAddressLine1 contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_yaY6weBi2kKzTrBsEInsGg">9432 Katy Freeway</dei:EntityAddressAddressLine1> <dei:EntityAddressAddressLine2 contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_s0PE0MinWUiWG6qOQj4SmQ">Suite 200</dei:EntityAddressAddressLine2> <dei:EntityAddressCityOrTown contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_T1E8xfa-XUSvbsD5BwIcdA">Houston</dei:EntityAddressCityOrTown> <dei:EntityAddressStateOrProvince contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_QCUi4ArSnEi5aVZKDVOSrQ">TX</dei:EntityAddressStateOrProvince> <dei:EntityAddressPostalZipCode contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_fJt6wEkYekenin-4Tg3YuA">77055</dei:EntityAddressPostalZipCode> <dei:CityAreaCode contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_ZngzuRcunE2uL6bHFhHqCA">713</dei:CityAreaCode> <dei:LocalPhoneNumber contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_-BJrco17AkSC7OqfdVIFZg">335-5697</dei:LocalPhoneNumber> <dei:Security12bTitle contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tc_eMnqv1y6qUqc8rbZ9yE4eg_2_0">None</dei:Security12bTitle> <dei:TradingSymbol contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tc_B7WU088fQ0upEs49tadljQ_2_2">BZYR</dei:TradingSymbol> <dei:EntityCurrentReportingStatus contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_mjp1UTlMBk-N0iRyvpDHIg">Yes</dei:EntityCurrentReportingStatus> <dei:EntityInteractiveDataCurrent contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_Nfe0RSrRckqYkDPtN4mjsw">Yes</dei:EntityInteractiveDataCurrent> <dei:EntityFilerCategory contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_l9Dr62_ZjEatGDzVzZJO9Q">Non-accelerated Filer</dei:EntityFilerCategory> <dei:EntitySmallBusiness contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_syVQooPF1EymhNjVa4uwaA">true</dei:EntitySmallBusiness> <dei:EntityEmergingGrowthCompany contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_1BhF5QlU_UikNwXtqB0t3A">false</dei:EntityEmergingGrowthCompany> <dei:EntityShellCompany contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Narr_ROmTDOuexESjq9nlwZ_80g">false</dei:EntityShellCompany> <dei:EntityCommonStockSharesOutstanding contextRef="As_Of_1_1_2023_NWkE9flst0aP1TfbgyOO3A" decimals="INF" id="Narr_S3oLAVpFCUWnYLnRENwouA" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</dei:EntityCommonStockSharesOutstanding> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Tc_CYwVw_ls4EGuR2pPVfdIKg_6_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">1692</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" id="Tc_GyHjnB7yNkaba9a_-40koA_6_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">3382</us-gaap:CashAndCashEquivalentsAtCarryingValue> <us-gaap:PrepaidExpenseCurrent contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Tc_dzYem4rH8kSRDkbwJf54qQ_7_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">100</us-gaap:PrepaidExpenseCurrent> <us-gaap:PrepaidExpenseCurrent contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" id="Tc_5L72wro49EOWNmVD4X558g_7_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">1279</us-gaap:PrepaidExpenseCurrent> <us-gaap:AssetsCurrent contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Tc_IvsQffQC1kqY3YNS7mO_Ag_9_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">1792</us-gaap:AssetsCurrent> <us-gaap:AssetsCurrent contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" id="Tc_oU9lnF6-QkeGfL8cuQUT3g_9_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">4661</us-gaap:AssetsCurrent> <us-gaap:Assets contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Tc_9_Csp3CylEOTpLi7wc8Lcw_11_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">1792</us-gaap:Assets> <us-gaap:Assets contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" id="Tc_qmmWyMk3WUG9KthyDAjxOg_11_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">4661</us-gaap:Assets> <us-gaap:AccountsPayableCurrent contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Tc_f71vJRpQmEWfQAoxitOyjA_16_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">16650</us-gaap:AccountsPayableCurrent> <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Tc_ezGOrEpB2kOHgSz7fqrjQA_17_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">11770</us-gaap:AccruedLiabilitiesCurrent> <us-gaap:AccruedLiabilitiesCurrent contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" id="Tc_xqDd3nZMfUayJ8-LMevdMQ_17_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">3455</us-gaap:AccruedLiabilitiesCurrent> <us-gaap:Liabilities contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Tc_h1nNDV4amU2IE7XeXI62Jg_19_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">28420</us-gaap:Liabilities> <us-gaap:Liabilities contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" id="Tc_LGPX6L2hqEa38sFbrkxzaA_19_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">3455</us-gaap:Liabilities> <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="INF" id="Narr_U_2k3Cb2Bk2YAUvvCMvXKg" unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare> <us-gaap:CommonStockParOrStatedValuePerShare contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="INF" id="Narr_DiauOSlOwEquWS33tskU0A" unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ">0.001</us-gaap:CommonStockParOrStatedValuePerShare> <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="INF" id="Narr_2jx6zpT5okeZAFz2rmVIaQ" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">200000000</us-gaap:CommonStockSharesAuthorized> <us-gaap:CommonStockSharesAuthorized contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="INF" id="Narr_vWmArepvfU-9GYrIfPOeag" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">200000000</us-gaap:CommonStockSharesAuthorized> <us-gaap:CommonStockSharesIssued contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="INF" id="Narr_dEZsd3YEbk2YElUSrSfY0Q" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:CommonStockSharesIssued> <us-gaap:CommonStockSharesIssued contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="INF" id="Narr_K14tv9tXZkuSblpxRhCMMA" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:CommonStockSharesIssued> <us-gaap:CommonStockValue contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Tc_QAze2GgC0kmyW7M6ok-eYg_24_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">131449</us-gaap:CommonStockValue> <us-gaap:CommonStockValue contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" id="Tc_9d11FdMlkEuWk4vzqsXSlA_24_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">131449</us-gaap:CommonStockValue> <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Tc_jXDgLPhoSUOKkIRP18ZNeQ_25_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">126380700</us-gaap:AdditionalPaidInCapitalCommonStock> <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" id="Tc_oup459wPZEOd3PfpNehvVA_25_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">125708240</us-gaap:AdditionalPaidInCapitalCommonStock> <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Tc_8O_FVk2ZHEu_0NpGXqqy-Q_26_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-126538777</us-gaap:RetainedEarningsAccumulatedDeficit> <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" id="Tc_1xgWUBZXKkSedsax56jEjg_26_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-125838483</us-gaap:RetainedEarningsAccumulatedDeficit> <us-gaap:StockholdersEquity contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Tc_pXJAoPZKNkuNV0c2zTmgBQ_28_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-26628</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" id="Tc_SfNYOlTlqkWXOLzdXBBa9w_28_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">1206</us-gaap:StockholdersEquity> <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Tc_w1U6FBDS0Uizk1zbu5m5pQ_30_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">1792</us-gaap:LiabilitiesAndStockholdersEquity> <us-gaap:LiabilitiesAndStockholdersEquity contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" id="Tc_AdkzGMtW9EGFM_tfM-0tZA_30_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">4661</us-gaap:LiabilitiesAndStockholdersEquity> <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Tc_QXX5BTxhIUmltNcE9umI2g_4_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">207651</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Tc_ihJAurdfkEiPXapJUc2iZg_4_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">214112</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Tc_tVoYAlsxQ0aCZ1LSkCX-Uw_5_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">44988</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Tc_j9xDxxlgKU-bqIJYAjw8Qg_5_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">50664</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:OperatingExpenses contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Tc_0XKwEvbJgEmo4SBLw76_kw_7_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">252639</us-gaap:OperatingExpenses> <us-gaap:OperatingExpenses contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Tc_QSqOlrA28UmxhqwfVTXtjw_7_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">264776</us-gaap:OperatingExpenses> <us-gaap:OperatingIncomeLoss contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Tc_OkByTsJsiE-E8QVVpVpuWg_9_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-252639</us-gaap:OperatingIncomeLoss> <us-gaap:OperatingIncomeLoss contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Tc_liclrK753kGpMCWsuM8Glw_9_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-264776</us-gaap:OperatingIncomeLoss> <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Tc_DTMArmC7gUC27zXJ_SpxTw_11_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-252639</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest> <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Tc_DOL16PdbN0mBW-HlsrFSjw_11_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-264776</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Tc_uUywbCC690q8D3V75MQoYA_13_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-252639</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Tc_kb_oCyTLgEi8iUYlbOY5Cg_13_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-264776</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:EarningsPerShareDiluted contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="2" id="Tc_cr5NH0ZYgEil-sFRvUbDHQ_17_3" unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ">0.00</us-gaap:EarningsPerShareDiluted> <us-gaap:EarningsPerShareDiluted contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="2" id="Tc_o6n0LGnJv0qi9w15NJ_Rvg_17_6" unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ">0.00</us-gaap:EarningsPerShareDiluted> <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Tc_EnSHpq7leE-h-OrWASsW5w_19_3" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding> <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Tc_x2wNrdOw40qHJUo4VEzE-A_19_6" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding> <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_Ke4uPE3ADk-l3YSn-ZMxxw_4_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">545960</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:ResearchAndDevelopmentExpense contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_hCzn1WGzFkGX4C6jIcPj8Q_4_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">632475</us-gaap:ResearchAndDevelopmentExpense> <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_VcBgKSBqU0-SrlYT0TjlVQ_5_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">154334</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:GeneralAndAdministrativeExpense contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_Hp3p-jY82UewCGS5n0U4_w_5_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">173302</us-gaap:GeneralAndAdministrativeExpense> <us-gaap:OperatingExpenses contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_L5SAQSzSpEWbsVf2I9Rmfw_7_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">700294</us-gaap:OperatingExpenses> <us-gaap:OperatingExpenses contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_3n6W5PoLWU-qC0mWt6bzLQ_7_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">805777</us-gaap:OperatingExpenses> <us-gaap:OperatingIncomeLoss contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_ityKcVpNG0-hzjGhey5A6g_9_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-700294</us-gaap:OperatingIncomeLoss> <us-gaap:OperatingIncomeLoss contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_yursHaOxF0eay7W50pwDmg_9_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-805777</us-gaap:OperatingIncomeLoss> <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_AgC8KlpV2EWwEwDSGKQ_Uw_13_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-700294</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest> <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_N07H1LkKUkSzHtotDvl2cA_13_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-805777</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_xpdgQSIfREurQiiveNd4-w_16_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-700294</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_vNoDsaId4UGKi7Glwch9-A_16_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-805777</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:EarningsPerShareDiluted contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="2" id="Tc_JpCHi69GrUKIKs-RpEZZgw_20_3" unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ">-0.01</us-gaap:EarningsPerShareDiluted> <us-gaap:EarningsPerShareDiluted contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="2" id="Tc_sohTWbrKbEGCpqc2XxhoOg_20_6" unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ">-0.01</us-gaap:EarningsPerShareDiluted> <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_OA_I799F6EWKfqwLmmKlFQ_22_3" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding> <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_vX2JH6oC80SpeAs6ksndPg_22_6" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding> <us-gaap:SharesOutstanding contextRef="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6rkROjav_UGQmnIAcgnBEA" decimals="INF" id="Tc_cFgaapqOG0i6-N2h5HPqUQ_4_2" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_6rkROjav_UGQmnIAcgnBEA" decimals="0" id="Tc_j_aoxcQRiEuLU-WLltkoqA_4_5" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">131449</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_JvhCi6_6NEyaCy4wUrsXFg" decimals="0" id="Tc_rF10uk78vk6A_cuhH4Pz7g_4_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">125708240</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_2_28_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_NTT6rcWjSkS1DUuU566q9g" decimals="0" id="Tc_qMpzdorBwEuNtHeAlhzBGg_4_11" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-125838483</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" id="Tc_kjcRnmyoX0un4oLeYDTx3g_4_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">1206</us-gaap:StockholdersEquity> <bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zp73wx7c8EyZlhK6JxJqcQ" decimals="0" id="Tc_u1glexgBZkexTCby4vAdlQ_6_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">40517</bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed> <bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_3_1_2022_To_5_31_2022_s5S1WhHB9UqmTCCb06YxWQ" decimals="0" id="Tc_eaPqVFCrqEyMjerDObqtSw_6_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">40517</bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed> <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_zp73wx7c8EyZlhK6JxJqcQ" decimals="0" id="Tc_6u3lxp-xtkSuzhTU3GtbtQ_8_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">151334</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther> <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_3_1_2022_To_5_31_2022_s5S1WhHB9UqmTCCb06YxWQ" decimals="0" id="Tc_pr9xgwEkeUqeL9ETHVPQMw_8_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">151334</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2022_To_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_8qgAaLYRNECoMmeZnKz0Vw" decimals="0" id="Tc_Wo8QawXeY0qzlFTIPHTNng_10_11" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-231737</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2022_To_5_31_2022_s5S1WhHB9UqmTCCb06YxWQ" decimals="0" id="Tc_4tie8V90QUyPVFU-Tsfdbw_10_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-231737</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:SharesOutstanding contextRef="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UPPp8HvvukaFfAR3iE04GA" decimals="INF" id="Tc_3ww0D2C_UkC1U7_gpjgnRg_12_2" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_UPPp8HvvukaFfAR3iE04GA" decimals="0" id="Tc_yoGQvjR1ZUS6iC9PraZymg_12_5" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">131449</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember__NiklRz9s0eL5ss5vnewgw" decimals="0" id="Tc_U-o-PcpwIUKPXu2t0qZl9g_12_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">125900091</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_5_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_eXcu2NBnCkKP8GkoLn9imw" decimals="0" id="Tc_LUMdXKn0VkGwTrKCeFErUA_12_11" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-126070220</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_5_31_2022_aH1WuS8v1UW8yzeokt0qeA" decimals="0" id="Tc_Mjog1Hwqnkq5UPPSXxBheQ_12_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-38680</us-gaap:StockholdersEquity> <bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_6_1_2022_To_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iTMc4yrn50u2G1IpUUj4rA" decimals="0" id="Tc_6wtOOei1PkCjVTQkCM4Czw_14_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">86017</bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed> <bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_6_1_2022_To_8_31_2022_fMfAETlwykeXblePySWjcQ" decimals="0" id="Tc_REwyeXOMokW5pYuN30uiRQ_14_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">86017</bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed> <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_6_1_2022_To_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iTMc4yrn50u2G1IpUUj4rA" decimals="0" id="Tc_ZLDkDZtFo02jmpA8jD60kw_16_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">154943</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther> <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_6_1_2022_To_8_31_2022_fMfAETlwykeXblePySWjcQ" decimals="0" id="Tc_LpzhSCJv0E2TCubpZsxrEg_16_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">154943</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_6_1_2022_To_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_bYsh9WfHTkq54L3M1Md8eQ" decimals="0" id="Tc_Gu_bH7a5fUWUHhJ45TLqjg_18_11" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-215918</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_6_1_2022_To_8_31_2022_fMfAETlwykeXblePySWjcQ" decimals="0" id="Tc_7_olKEAEbkaX5eBd1sQErg_18_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-215918</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:SharesOutstanding contextRef="As_Of_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ay5nAffd0UKk97xXOpf_iw" decimals="INF" id="Tc__77k5-8A40OMvtydbU9jRA_20_2" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="As_Of_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_Ay5nAffd0UKk97xXOpf_iw" decimals="0" id="Tc_bCniGGwc9UWH0Xck_NcyOg_20_5" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">131449</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_hhGupecJrkOV3pUvJetcyA" decimals="0" id="Tc_ILW_77Z0U0KorkTeukt7Sg_20_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">126141051</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_8_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_yFw4lSokjkO_tlKaEbVbfg" decimals="0" id="Tc_PLN7e5Dgykqq0YHQ7dGm6w_20_11" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-126286138</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_8_31_2022_aZAr42E-wEG4LLyxptSbCQ" decimals="0" id="Tc_6HS1UoA470Kd6SXRcf45aA_20_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-13638</us-gaap:StockholdersEquity> <bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_9_1_2022_To_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iwKsVl7Vak-URPtHD_l-rw" decimals="0" id="Tc_9BWen__u606zTj3BB-Ztbg_22_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">48017</bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed> <bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Tc_w26tfTWnpk6RUI4uXyVu3w_22_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">48017</bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed> <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_9_1_2022_To_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_iwKsVl7Vak-URPtHD_l-rw" decimals="0" id="Tc_lI2QKCWypU-JfkdGK5Va0g_24_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">191632</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther> <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Tc_xygo01tuIEykSWxYLL3sjQ_24_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">191632</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_9_1_2022_To_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_nMckWf8ou06gtaq15KVt5A" decimals="0" id="Tc_4r_xbZxlpEGFCTKfyUC9MQ_26_11" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-252639</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Tc_LL6uMa4JmUGN-w1t8xZBcQ_26_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-252639</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:SharesOutstanding contextRef="As_Of_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TBAhEDDdsEmkmzUW0oQzAw" decimals="INF" id="Tc_FyfoijdQUUm_UBDPKsYxgw_28_2" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="As_Of_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TBAhEDDdsEmkmzUW0oQzAw" decimals="0" id="Tc_RPS1lBKcDEeW1z4cdzM-cg_28_5" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">131449</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_lKswUaIHiEyn9JevGZ0Gvg" decimals="0" id="Tc_1IXYAIFtK0u533aPy0SKiQ_28_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">126380700</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_11_30_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_C988H_c5lEirXg2bOfyMYw" decimals="0" id="Tc_iC8caDxxX0K1Munxaduimw_28_11" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-126538777</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Tc_wv6V0T1XTUas73odvYBgmA_28_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-26628</us-gaap:StockholdersEquity> <us-gaap:SharesOutstanding contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QcYgvQm1sU2dNqhqk7HHhQ" decimals="INF" id="Tc_VGaGgp6i2Ey0ZgIDREoikg_4_2" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QcYgvQm1sU2dNqhqk7HHhQ" decimals="0" id="Tc__icU0a3Yu0mNMonZ55U6sA_4_5" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">131449</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_txIuVwJscEWQsoDWljOsLg" decimals="0" id="Tc_junwrPKJIEmkVHIaNLNv3Q_4_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">124684535</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_0DY2kRmuRkykwMzYCLMEag" decimals="0" id="Tc_DJg880nLckeBdwIG5ZLuOw_4_11" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-124861827</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_2_28_2021_tz3utn4GW0icSAfEmME0tQ" decimals="0" id="Tc_HIwVQV1kzkeHQ6S5eAHmlQ_4_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-45843</us-gaap:StockholdersEquity> <bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-cT_vEjUDUW-S5rQVrW9Gg" decimals="0" id="Tc_jhgJAXpOlU6YJn4APebaug_6_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">84967</bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed> <bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_3_1_2021_To_5_31_2021_UX5UtaTbT0eersU02GWvMg" decimals="0" id="Tc_6Hs2hpbqPEuYXNQf9cmdbg_6_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">84967</bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed> <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-cT_vEjUDUW-S5rQVrW9Gg" decimals="0" id="Tc_OOVnJD1P5kKQjK63guAtyQ_8_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">215926</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther> <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_3_1_2021_To_5_31_2021_UX5UtaTbT0eersU02GWvMg" decimals="0" id="Tc_tDGrLJuX4E-TWCd3fxCHrA_8_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">215926</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_TeJKkXhGtEWygQhcQKp9qw" decimals="0" id="Tc_8PzGLXh8AEq34v8mnsUTQw_10_11" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-316283</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2021_To_5_31_2021_UX5UtaTbT0eersU02GWvMg" decimals="0" id="Tc_9BuKPUFn1EOinNJB7WAEcQ_10_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-316283</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:SharesOutstanding contextRef="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IUIR5alQTkqIkz4yW1duxw" decimals="INF" id="Tc_FGVFJWs--EKbwTnxBN2dQA_12_2" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_IUIR5alQTkqIkz4yW1duxw" decimals="0" id="Tc_GnFUYCDKx0e0VpTdPzctuw_12_5" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">131449</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_OnyyqaGUF0iy63pvlajMzw" decimals="0" id="Tc_mh3mPRXLqkCiweS8oVXSaA_12_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">124985428</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_lNN1yxnejk2tW8zeN_uI2A" decimals="0" id="Tc_6_1GuNJcwE6JnEUsHmbHmQ_12_11" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-125178110</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_5_31_2021_qG8hjPs1ckabOxyw-IisaA" decimals="0" id="Tc_dCGs3Xe3L06Yc0Mzet2Ttw_12_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-61233</us-gaap:StockholdersEquity> <bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_6_1_2021_To_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dq8AzYWypkmsekLWBSXMwQ" decimals="0" id="Tc_qm98gL0EeEW_C6SuBTL4lA_14_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">87717</bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed> <bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_6_1_2021_To_8_31_2021_eTo4YOsOQkSH1oSW4mRAFA" decimals="0" id="Tc_1MkehFilGUeFLGZPsFV8lQ_14_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">87717</bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed> <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_6_1_2021_To_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_dq8AzYWypkmsekLWBSXMwQ" decimals="0" id="Tc_TQv0IjUjzU2iV3z2yyrWjQ_16_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">170403</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther> <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_6_1_2021_To_8_31_2021_eTo4YOsOQkSH1oSW4mRAFA" decimals="0" id="Tc_4Q3AFkl5OEin9M7yQc8GwQ_16_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">170403</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_6_1_2021_To_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_4_eOqZpcUk-67OjGO1pofg" decimals="0" id="Tc_JmxpKH5EVUOCNjpr5d86Vg_18_11" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-224718</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_6_1_2021_To_8_31_2021_eTo4YOsOQkSH1oSW4mRAFA" decimals="0" id="Tc_NudSdsCcLE2BVSlfdpL2Tw_18_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-224718</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:SharesOutstanding contextRef="As_Of_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sb_rwZ6nVU-g3e9Wdj7-7w" decimals="INF" id="Tc_98c_qj2J2EeFw5xEM6T2Dw_20_2" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="As_Of_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_sb_rwZ6nVU-g3e9Wdj7-7w" decimals="0" id="Tc_wYSEO93yEkalLQoAxb1vCQ_20_5" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">131449</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_QfVTYoRMfUOqPfb1PY4Qtw" decimals="0" id="Tc_Yr2p8z3sMEWDBTxr3bCMww_20_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">125243548</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_8_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_t40J9Yyvp0eMzCsyd170Lw" decimals="0" id="Tc_LvE8GRdUlkWj229iPJ9-jQ_20_11" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-125402828</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_8_31_2021_LiQ_dJGijkqI7kTCGFYSOg" decimals="0" id="Tc_JcIpectafECXb6lcEnOI6g_20_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-27831</us-gaap:StockholdersEquity> <bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_9_1_2021_To_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_I_jFFJLfpEun5ot6_dLYjA" decimals="0" id="Tc_T19POTbaxkK8lBqL4GowSw_22_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">100017</bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed> <bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Tc_CbBbHHiO00iaHObBe7IQ5g_22_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">100017</bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed> <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_9_1_2021_To_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_I_jFFJLfpEun5ot6_dLYjA" decimals="0" id="Tc_FrxTzcguUEujhnbz0THsZQ_24_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">197940</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther> <us-gaap:AdjustmentsToAdditionalPaidInCapitalOther contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Tc_arhDhopNZ0uq1UY7obbsIg_24_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">197940</us-gaap:AdjustmentsToAdditionalPaidInCapitalOther> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_9_1_2021_To_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_k3hpjFE5JU65xKnnzgO2vQ" decimals="0" id="Tc_Jjkga7TqAU2peGjP1Xmg2Q_26_11" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-264776</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Tc_M67eP-h8z0uL6rOG6bLazw_26_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-264776</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:SharesOutstanding contextRef="As_Of_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XeOxpxRW2k2UySfWnD5UMQ" decimals="INF" id="Tc_QEnrr3utdUmBultVb0Ub2A_28_2" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">131448444</us-gaap:SharesOutstanding> <us-gaap:StockholdersEquity contextRef="As_Of_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_XeOxpxRW2k2UySfWnD5UMQ" decimals="0" id="Tc_1ibGcZiDW0qLmxPFnr-QQQ_28_5" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">131449</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_gtjfx8jA70qc4SM14Yj3jw" decimals="0" id="Tc_6oELFffTfEmQVyn2wxbB1w_28_8" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">125541505</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_11_30_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3HnDsSVLSEaSsHcQ_eD5WQ" decimals="0" id="Tc_RQ-TgjGp10CQNSs-Gx5THg_28_11" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-125667604</us-gaap:StockholdersEquity> <us-gaap:StockholdersEquity contextRef="As_Of_11_30_2021_2QExRwQy1EushHKZUUQPGg" decimals="0" id="Tc_GJrbqP6uY0KAioe1GX_OfA_28_14" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">5350</us-gaap:StockholdersEquity> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_NWD-nVhv30WyYdw32gTcNw_4_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-700294</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_h0zW0KpgOEyMH3zToRt61g_4_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-805777</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic> <bzyr:ClinicalTrialExpensesPaid contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_fxYj8iD2SkSqMTCLJ0W7mQ_6_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">497909</bzyr:ClinicalTrialExpensesPaid> <bzyr:ClinicalTrialExpensesPaid contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_yq8XR2H9-UyneWJm3RL1Sw_6_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">584270</bzyr:ClinicalTrialExpensesPaid> <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_7yyqT8cIsEudxzWrHCN_Dg_9_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-1179</us-gaap:IncreaseDecreaseInPrepaidExpense> <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_WMHYFIs8EUafJIJyJNAvrQ_9_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">80</us-gaap:IncreaseDecreaseInPrepaidExpense> <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_OZ5ETSdC806mcRVlRF_naw_10_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">16650</us-gaap:IncreaseDecreaseInAccountsPayable> <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_N3EUjtExNUyFd4vxIx24dA_10_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-31123</us-gaap:IncreaseDecreaseInAccountsPayable> <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_u-9SkkDKhEuTIfJXmcFFiQ_11_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">8315</us-gaap:IncreaseDecreaseInAccruedLiabilities> <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_Yje6F6_U9EuGb2UEqGr1xg_11_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-14287</us-gaap:IncreaseDecreaseInAccruedLiabilities> <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_IxeuQKTKZ0Kisso5_g_MPA_13_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-176241</us-gaap:NetCashProvidedByUsedInOperatingActivities> <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_CYj2datPsUOkvqteCALVZw_13_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-266997</us-gaap:NetCashProvidedByUsedInOperatingActivities> <us-gaap:ProceedsFromContributedCapital contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_RG1TiH94wkObxcjvZD0_Tg_16_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">174551</us-gaap:ProceedsFromContributedCapital> <us-gaap:ProceedsFromContributedCapital contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_NFY8OV0ddE22iZPBs_wsaw_16_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">272701</us-gaap:ProceedsFromContributedCapital> <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_EMRjifAZ2EeQPfkSvSJlyQ_18_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">174551</us-gaap:NetCashProvidedByUsedInFinancingActivities> <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_YcP5mgjKBk-Ga84OLh0Gyw_18_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">272701</us-gaap:NetCashProvidedByUsedInFinancingActivities> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_XPOW-3wzlEynjbhxglBR4Q_20_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-1690</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_Y2qVE9DKP0eecAVvIPzxJQ_20_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">5704</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_2_28_2022_vsFH-XGSMEuvjKK5rAMVdw" decimals="0" id="Tc_jxj7zqmzcUK2xsYIZ79pMA_22_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">3382</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_2_28_2021_tz3utn4GW0icSAfEmME0tQ" decimals="0" id="Tc_a2ygXW1MpkeEdAZk_Tx1Pg_22_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">62</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Tc_n2htFpO--kaLI2jxu4cRqg_24_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">1692</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents> <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="As_Of_11_30_2021_2QExRwQy1EushHKZUUQPGg" decimals="0" id="Tc__Tu3-Vs-OE6rU2vdScVtGQ_24_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">5766</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents> <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tb_gRpGNCq08ECxBwUuJqY_PQ"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE A.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">BASIS OF PRESENTATION</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The financial statements of Burzynski Research Institute, <span style="white-space:pre-wrap;">Inc. (the “Company”), a Delaware corporation, include expenses incurred related to clinical trials, which were sanctioned by the U.S. Food and Drug Administration (FDA) in 1993, for Antineoplaston drugs used in the treatment of cancer. These expenses are incurred directly by S.R. Burzynski, M.D., Ph.D. (Dr. </span><span style="white-space:pre-wrap;">Burzynski or “SRB”) on behalf of the Company and have been reported as research and development costs and as additional paid-in capital. Other funds received from Dr. </span><span style="white-space:pre-wrap;">Burzynski have also been reported as additional paid-in capital. Expenses related to Dr. </span><span style="white-space:pre-wrap;">Burzynski’s medical practice (unrelated to the clinical trials) have not been included in these financial statements. Dr. Burzynski is the President, Chairman of the Board and owner of approximately </span>81.0% of the outstanding common stock of the Company, and also is the inventor and original patent holder of certain drug products known as “Antineoplastons.” </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company and Dr. <span style="white-space:pre-wrap;">Burzynski have entered into various agreements as further described in Note B. The License Agreement between the Company and Dr. Burzynski provided the Company the exclusive right in the United States, Canada and Mexico to use, manufacture, develop, sell, distribute, sublicense and otherwise exploit all the rights, titles and interest in Antineoplaston drugs used in the treatment of cancer, once the drug is approved for sale by the FDA. On July 2, 2019, the License Agreement terminated upon the expiration of the last patent licensed to the Company under such agreement. As such, the Company does not currently have licenses to any patents with respect to Antineoplastons. The Company does own </span>one US patent which was recently issued on May 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company is primarily engaged as a research and development facility for Antineoplaston drugs being tested for the use in the treatment of cancer. The Company’s investigational new drug application (“IND”) 43742 is currently under full clinical hold and the Company cannot enroll new patients into any clinical trials until the full clinical hold is removed by the FDA. At this time, however, none of the Antineoplaston drugs have received FDA approval; further, there can be no assurance that FDA approval will be granted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The accompanying unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information. Certain disclosures and information normally included in financial statements have been condensed or omitted. In the opinion of management of the Company, these financial statements contain all adjustments necessary for a fair presentation of financial position as of November 30, 2022 and February 28, 2022, results of operations for the three and nine months ended November 30, 2022 and 2021, and cash flows for the nine months ended November 30, 2022 and 2021. All adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results to be expected for a full year. These statements should be read in conjunction with the financial statements and footnotes thereto included in the Company’s Annual Report on Form 10-K for the year ended February 28, 2022.</span></p></us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock> <bzyr:OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="3" id="Narr__nNxLZizvUSYOsrGV1Vy-w" unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ">0.810</bzyr:OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard> <bzyr:NumberOfPatentsOwned contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="INF" id="Narr_y9iDBZF7NkSREWtt825jEg" unitRef="Unit_Standard_patent_dlojMfgdTECMpi5PU4YRsw">1</bzyr:NumberOfPatentsOwned> <bzyr:NumberOfAntineoplastonDrugsThatReceivedFDAApproval contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="INF" id="Narr_STI7GYlH_0WvWSb4bIeFQg" unitRef="Unit_Standard_item_REEsf0XHJUOQ1iZoyc7Pvg">0</bzyr:NumberOfAntineoplastonDrugsThatReceivedFDAApproval> <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tb_5A6EestbFEeLpu8wK9a8jg"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE B.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">ECONOMIC DEPENDENCY</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The Company has not generated significant revenues since its inception and has suffered losses from operations, has a working capital deficit and has an accumulated deficit. Dr. Burzynski has funded the capital and operational needs of the Company through his medical practice since inception, and has entered into various agreements to continue such funding.</span> Because the Company is entirely dependent upon the contributions for research provided by Dr. Burzynski under a research funding agreement, the Company would not be able to continue conducting its clinical trials if Dr. Burzynski ceased funding the Company’s research. In such event, the Company would be required to find immediate funding which may not be available on acceptable terms or at all. If this were to occur and the Company were not able to find adequate sources of funding, the Company would be required to cease operations. Even with Dr. Burzynski’s continued contributions under a research funding agreement, the Company may be required to seek additional capital through equity or debt financing or the sale of assets until the Company’s operating revenues are sufficient to cover operating costs and provide positive cash flow; however, there can be no assurance that the Company will be able to raise such additional capital on acceptable terms to the Company. In addition, there can be no assurance that the Company will ever achieve positive operating cash flow.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The Company is economically dependent on its funding through Dr. Burzynski’s medical practice. In the past, a portion of Dr. Burzynski’s patients have been admitted and treated as part of the clinical trial programs. The Company’s IND 43742 is currently under full clinical hold and the Company cannot enroll new patients into any clinical trials until the full clinical hold is removed by the FDA. The FDA imposes numerous regulations and requirements regarding these patients, and the Company is subject to inspection at any time by the FDA. These regulations are complex and subject to interpretation and though it is management’s intention to comply fully with all such regulations, there is the risk that the Company is not in compliance and is thus subject to sanctions imposed by the FDA. In addition, as with any medical practice, Dr. Burzynski is subject to potential claims by patients and other potential claimants commonly arising out of the operation of a medical practice. The risks associated with Dr. Burzynski’s medical practice directly affect his ability to fund the operations of the Company.</span></p></us-gaap:StockholdersEquityNoteDisclosureTextBlock> <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tb_Hc6XexBTQ0qsAa-vi0qYAQ"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE C.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">STOCK OPTIONS AND WARRANTS</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">At November 30, 2022, the Company had one stock-based employee compensation plan, which is described below.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">On September 14, 1996, the Company granted 600,000 stock options, with an exercise price of $0.35<span style="white-space:pre-wrap;"> per share, to an officer who is no longer with the Company. </span>The options vested as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vesting Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">400,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">September 14, 1996</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">June 1, 1997</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">June 1, 1998</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="white-space:pre-wrap;">The options are valid in perpetuity. </span>None of the options have been exercised as of November 30, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company accounts for share-based payments to non-employees in accordance with the guidance provided by the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 718, <i style="font-style:italic;">Compensation – Stock Compensation</i> to include share-based payments granted to non-employees in exchange for goods or services used or consumed in an entity’s own operations and supersedes the guidance in ASC 505-50.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;">Effective July 5, 2012, the Company entered into a Marketing and Consulting Agreement (the “Marketing Agreement”) with Worldwide Medical Consultants, Inc. (“WMC”) and CARIGEN, LTD (“SRB”), an entity wholly-owned and controlled by Dr. Burzynski, pursuant to which WMC will (i) provide SRB with various marketing and consulting services to assist SRB in locating and developing cancer or health related centers in certain foreign markets and (ii) make payments to the Company equal to </span><span style="font-size:10pt;">10%</span><span style="font-size:10pt;"> of each consulting fee received by WMC for the aforementioned services provided to SRB, net of certain expenses incurred by WMC (“WMC Payment”). In consideration of the WMC Payment, the Company agreed to grant to WMC warrants to acquire an aggregate of </span><span style="font-size:10pt;">2,000,000</span><span style="font-size:10pt;"> shares of the Company’s Common Stock, exercisable at </span><span style="font-size:10pt;">$0.10</span><span style="font-size:10pt;"> per share with a </span><span style="font-size:10pt;">ten year</span><span style="font-size:10pt;"> exercise period, with </span><span style="font-size:10pt;">1,000,000</span><span style="font-size:10pt;"> shares vesting upon execution of the agreement (the "Initial Warrants") and the remaining </span><span style="font-size:10pt;">1,000,000</span><span style="font-size:10pt;"> shares to vest upon the first closing of a transaction by SRB as a result of the services provided by WMC under the Marketing Agreement. The Marketing Agreement was terminated effective as of July 5, 2019 pursuant to its terms. The Initial Warrants expired on July 5, 2022 and were never exercised.</span></p></us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock> <bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="INF" id="Narr_uzLrQ6WZckSx5Fp16v_2Dw" unitRef="Unit_Standard_item_REEsf0XHJUOQ1iZoyc7Pvg">1</bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans> <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9J2vQo42mEG22C8KOHHe-A" decimals="INF" id="Narr_0X1iuf1uaUGbIpzPBMbfaw" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross> <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9J2vQo42mEG22C8KOHHe-A" decimals="2" id="Narr_4hPVTaghtEiWejSSVJzl3Q" unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ">0.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice> <us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tb_a5whp90HAkmXdQNl1NKO2Q"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Vesting Date</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">400,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">September 14, 1996</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">June 1, 1997</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:10.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">100,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:70.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">June 1, 1998</p></td></tr></table></us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Duration_9_14_1996_To_9_14_1996_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_9J2vQo42mEG22C8KOHHe-A" decimals="INF" id="Tc_9azp6HeFWUi9AxjaUtdLlg_2_0" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Duration_6_1_1997_To_6_1_1997_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_lrGBPtct1kCgRQmYPd7n8Q" decimals="INF" id="Tc_DOu75leMrkSjliSIjtcD0Q_3_0" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares> <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="Duration_6_1_1998_To_6_1_1998_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_DbEucoULE0aMqQ_3EsFxqA" decimals="INF" id="Tc_Df8H72L-pkaBZranw_TzYQ_4_0" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares> <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Duration_3_1_2022_To_11_30_2022_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_67nM8Z7lXEy5aoImbV3iJg" decimals="INF" id="Narr_9chjAb2Xb0Srt3TxDCqdlA" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised> <bzyr:PercentageOfConsultingFeeToBeReceivedAsPerAgreement contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_ailYsCoPekC30-IUv4AkDw" decimals="2" id="Narr_Vt3MQ4jbREOtdEM11hbQNw" unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ">0.10</bzyr:PercentageOfConsultingFeeToBeReceivedAsPerAgreement> <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_k0yzPQpwzUKU2JiaPznW_w" decimals="INF" id="Narr_Az5QnKpx10CWXT8YlV7R2Q" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">2000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights> <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="As_Of_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_k0yzPQpwzUKU2JiaPznW_w" decimals="2" id="Narr_qn-B4YB1DkKqXLsTNViw7g" unitRef="Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ">0.10</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1> <bzyr:ClassOfWarrantOrRightsExercisePeriod contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_ailYsCoPekC30-IUv4AkDw" id="Narr_m5aBmSx-YUedPOu8khhqrg">P10Y</bzyr:ClassOfWarrantOrRightsExercisePeriod> <bzyr:SharesVestingUponExecutionOfAgreement contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_ailYsCoPekC30-IUv4AkDw" decimals="INF" id="Narr_HR8Iv4ry70mhiiJagrrlbw" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">1000000</bzyr:SharesVestingUponExecutionOfAgreement> <bzyr:RemainingSharesToVestUponFirstClosingOfAgreement contextRef="Duration_7_5_2012_To_7_5_2012_dei_LegalEntityAxis_bzyr_WorldwideMedicalConsultantsIncMember_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_bzyr_CarigenLtdMember_ailYsCoPekC30-IUv4AkDw" decimals="INF" id="Narr_wiw8wRLqI0aKMRAvsKF6vw" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">1000000</bzyr:RemainingSharesToVestUponFirstClosingOfAgreement> <us-gaap:EarningsPerShareTextBlock contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tb_qmuC7AxMq0Oi3twODYDdeA"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE D.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">LOSS PER COMMON SHARE</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company accounts for loss per share in accordance with FASB ASC 260, <i style="font-style:italic;">Earnings per Share</i>. Basic loss per share amounts are calculated by dividing net loss by the weighted average number of common shares outstanding during each period. Diluted loss per share is calculated by dividing net loss by the weighted average number of common shares outstanding for the periods, including the dilutive effect of all common stock equivalents. Dilutive options and warrants that are issued during a period or that expire or are canceled during a period are reflected in the computations for the time they were outstanding during the periods being reported. During the three and nine months ended November 30, 2022 and 2021, 600,000 stock options and 1,600,000 warrants and stock options, respectively, were excluded from the calculation of diluted loss per share because their effect would be anti-dilutive.</p></us-gaap:EarningsPerShareTextBlock> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_3_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_CFxwHANUYkWnJB9fZNUxkg" decimals="INF" id="Narr_inT3yJ4V3Eqh66fJpup0Sg" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_9_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_kxHbs4IXUEaF_-ZHCfDT7w" decimals="INF" id="Narr_E4EbosmIxUikQ01pygmNyw" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_3_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_q5rwaskLYUu_ZDbHfAs6pw" decimals="INF" id="Narr_a91NNemd3EO6wY5jb2wgHA" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_9_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Q6hxXm5dK0q5su70AGA9ow" decimals="INF" id="Narr_WFHgtaIcAE28pOEQBK8HRA" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_3_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_wVzlOVFTnUa4yodykmvUJw" decimals="INF" id="Narr_az9o4f8ah0iQQrzIRmFdNw" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">1600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_9_1_2021_To_11_30_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_u75x1ek-KkeJ32monPyZiQ" decimals="INF" id="Narr_Zq4iX6WrI0K0D_sN_PHtaQ" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">1600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_3_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_dopENHjSVkec1zCh35q5Hg" decimals="INF" id="Narr_MzFTeplZU0qjQ4PC73MVgw" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">1600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Duration_9_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_bzyr_WarrantsAndStockOptionsMember_mGRKAPT_d0i6xvYOzqjuhw" decimals="INF" id="Narr_hSwgaVHNS0OmF_Y2UsYBQA" unitRef="Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA">1600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount> <us-gaap:IncomeTaxDisclosureTextBlock contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tb_Zz-p5pLRokepfwo1wxMUag"><table style="border-collapse:collapse;border:0;"><tr><td style="vertical-align:text-top;white-space:nowrap;width:54pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">NOTE E.</span></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;"><span style="font-size:10pt;font-style:italic;font-weight:bold;">INCOME TAXES</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;padding-left:54pt;text-indent:-54pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company follows the provisions of FASB ASC 740, <i style="font-style:italic;">Income Taxes</i><span style="white-space:pre-wrap;">. The Company is not aware of any material unrecognized tax uncertainties as a result of tax positions previously taken.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The Company recognizes interest and penalties as interest expense when they are accrued or assessed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;white-space:pre-wrap;">The federal income tax returns of the Company for 2021, 2020, and 2019 are subject to examination by the IRS, generally for </span><span style="font-size:10pt;">three years</span><span style="font-size:10pt;"> after they are filed.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">The actual provision for income tax for the three and nine months ended November 30, 2022 and 2021 differ from the amounts computed by applying the U.S. federal income tax rate of 21% to the pretax loss as a result of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended November 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (53,054)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (55,603)</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxed directly to Dr. Burzynski </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,603</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible expenses and other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,968)</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,728)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,968</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.29%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended November 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (147,062)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (169,213)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxed directly to Dr. Burzynski </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147,062</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169,213</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible expenses and other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,751)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,845)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,751</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">At November 30, 2022, the Company had a net deferred tax asset of $0, which includes a valuation allowance of $164,547<span style="white-space:pre-wrap;">. The Company’s ability to utilize net operating loss ("NOL") carryforwards and alternative minimum tax credit carryforwards will depend on its ability to generate adequate future taxable income. The Company has </span>no<span style="white-space:pre-wrap;"> historical earnings on which to base an expectation of future taxable income. Accordingly, a full valuation allowance for deferred tax assets has been provided.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">As a result of the Tax Cuts and Jobs Act of 2017 (the "Act"), NOL carryforwards generated in years beginning after December 31, 2017, would carryforward indefinitely, and would apply to 80% of future taxable income. Under the Act, carrybacks of NOLs were disallowed. In March 2020, the Coronavirus Aid, Relief, and Economic Security ("CARES") Act was enacted providing a five-year carryback for losses incurred in 2018, 2019, or 2020, which allows companies to modify tax returns up to five years prior to offset taxable income from those tax years. The CARES Act also temporarily suspended the NOL limit of 80%<span style="white-space:pre-wrap;"> of taxable income through December 31, 2020, but the NOLs generated in 2018 and forward would still carryforward indefinitely. Effective January 1, 2021, NOL carryforwards generated will only apply to </span>80% of future taxable income according to the Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;">As of November 30, 2022, the Company has net operating loss carryforwards in the amount of $473,902 that will expire between 2026 and 2038, and $106,782 that will carryforward indefinitely, of which $78,948 applies to 100% of future taxable income and $27,834 applies to 80% of future taxable income.</p></us-gaap:IncomeTaxDisclosureTextBlock> <bzyr:IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination contextRef="Duration_3_1_2022_To_11_30_2022_us-gaap_IncomeTaxAuthorityAxis_us-gaap_InternalRevenueServiceIRSMember_gY1j0FUXpUGEySuC7dEpCA" id="Narr_--4VoN1LOECPcYyP_-LggQ">P3Y</bzyr:IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination> <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="2" id="Narr_A7Ckl44IskqDxisVVhx_YQ" unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate> <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="2" id="Narr_1sJSO1J5c0yb4kAsD6mlPQ" unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate> <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="2" id="Narr_WRT1dwr0bEug-Nqs5tyRoQ" unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate> <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="2" id="Narr_HuVKQsEOcUqs9n0MlrLrcw" unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate> <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" id="Tb_eRxdekB7cU2sQnDjAHqo2Q"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:10pt;margin-left:0pt;visibility:hidden;">​</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.34%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Three Months Ended November 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (53,054)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (55,603)</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxed directly to Dr. Burzynski </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 53,054</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 55,603</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible expenses and other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,728</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6,968)</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,728)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,968</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.43%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p><div style="padding-left:36pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:93.29%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:23.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Nine Months Ended November 30,</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected expense (benefit)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (147,062)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (169,213)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Taxed directly to Dr. Burzynski </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 147,062</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 169,213</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Nondeductible expenses and other adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (10,751)</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (5,845)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,751</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:73.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Provision for income tax</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.23%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt;"><span style="font-size:10pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr></table></div></us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock> <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Tc_mfbv36wIkkW1xVXiCxxUrw_3_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-53054</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate> <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Tc_ff_jzN7Gw0O0wYdRrqWeiA_3_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-55603</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate> <us-gaap:IncomeTaxReconciliationDeductions contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Tc_MRT6-jHENkmEqUqkcHqZ3g_4_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">53054</us-gaap:IncomeTaxReconciliationDeductions> <us-gaap:IncomeTaxReconciliationDeductions contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Tc_80J0mInHqkG8MoraZkvqrA_4_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">55603</us-gaap:IncomeTaxReconciliationDeductions> <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Tc_TUYPMvzfbE6UCamKXMcdRw_5_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">2728</us-gaap:IncomeTaxReconciliationNondeductibleExpense> <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Tc_HpdvQm6wHEuMN-HT5jnpFA_5_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-6968</us-gaap:IncomeTaxReconciliationNondeductibleExpense> <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ" decimals="0" id="Tc_6e2Fwo8LiECwaOKiYJsRdg_6_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-2728</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance> <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_9_1_2021_To_11_30_2021_f16ZdvzaU0289qyS6zJbEw" decimals="0" id="Tc_x7AZuq3RMEuVz7xtxm0U6w_6_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">6968</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance> <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_xXvLf4rmhk2FimikZiChzg_3_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-147062</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate> <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_Kg89E9QgVUqSTUt4N6HUeQ_3_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-169213</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate> <us-gaap:IncomeTaxReconciliationDeductions contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_XFhOPdaEBUK16ln0RV4UJg_4_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">147062</us-gaap:IncomeTaxReconciliationDeductions> <us-gaap:IncomeTaxReconciliationDeductions contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_JVUHCb41qUiJZLNOt622vw_4_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">169213</us-gaap:IncomeTaxReconciliationDeductions> <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_qlVskqwvNkegEKTWTloX5A_5_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">5845</us-gaap:IncomeTaxReconciliationNondeductibleExpense> <us-gaap:IncomeTaxReconciliationNondeductibleExpense contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_Vz-0Gg_hmUOibxPQJOptjA_5_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-10751</us-gaap:IncomeTaxReconciliationNondeductibleExpense> <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Tc_rKeMYrv-_0SdTfYN7puC1w_6_3" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">-5845</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance> <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Duration_3_1_2021_To_11_30_2021_fpbWS8N8v0iIast45tKkeg" decimals="0" id="Tc_3BVe5aJALUSQ7gGejnvnHA_6_6" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">10751</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance> <us-gaap:DeferredTaxAssetsNet contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Narr_Q4_b6GsTeUKIw-HAoV9OJg" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">0</us-gaap:DeferredTaxAssetsNet> <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g" decimals="0" id="Narr_qGJuVTUc9EenyeccQgZFuw" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">164547</us-gaap:DeferredTaxAssetsValuationAllowance> <us-gaap:Revenues contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Narr_OskAeRNHEEui9moWr9E4vQ" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">0</us-gaap:Revenues> <bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="2" id="Narr_ZCHKFmC2aU2VijGRRlpJcg" unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ">0.80</bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards> <bzyr:PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="2" id="Narr_vr0RiisQ9kOb_B80Z9-fHw" unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ">0.80</bzyr:PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct> <bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="2" id="Narr_NoWIdTxCKEOpeS2bi6nP0g" unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ">0.80</bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards> <bzyr:TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards contextRef="As_Of_11_30_2022_us-gaap_TaxPeriodAxis_us-gaap_LatestTaxYearMember_PYUkT8vb4kidxIHJrwE-Mg" decimals="0" id="Narr_i5R4raHR9Um4dgaoDjq5tw" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">473902</bzyr:TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards> <bzyr:NetOperatingLossCarryForwardIndefinitely contextRef="Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA" decimals="0" id="Narr_wVNlC9dS_0mbrRyA0rGvyA" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">106782</bzyr:NetOperatingLossCarryForwardIndefinitely> <bzyr:NetOperatingLossCarryForwardIndefinitely contextRef="Duration_3_1_2022_To_11_30_2022_srt_StatementScenarioAxis_bzyr_HundredPercentFutureTaxableIncomeMember_-mkCDpGPAUaxUXrXRSUTtA" decimals="0" id="Narr_8zuIJR3O1EGvpA-Op9F7ZA" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">78948</bzyr:NetOperatingLossCarryForwardIndefinitely> <bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards contextRef="Duration_3_1_2022_To_11_30_2022_srt_StatementScenarioAxis_bzyr_HundredPercentFutureTaxableIncomeMember_-mkCDpGPAUaxUXrXRSUTtA" decimals="2" id="Narr_Lvd5iki5H02fKqYq4VRQ4Q" unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ">1</bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards> <bzyr:NetOperatingLossCarryForwardIndefinitely contextRef="Duration_3_1_2022_To_11_30_2022_srt_StatementScenarioAxis_bzyr_EightyPercentFutureTaxableIncomeMember_QhqQJfwexky0p43BckGK3w" decimals="0" id="Narr_thtQRJ-d00yuFX0ln24How" unitRef="Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A">27834</bzyr:NetOperatingLossCarryForwardIndefinitely> <bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards contextRef="Duration_3_1_2022_To_11_30_2022_srt_StatementScenarioAxis_bzyr_EightyPercentFutureTaxableIncomeMember_QhqQJfwexky0p43BckGK3w" decimals="2" id="Narr_Kic-n82i-kmSeq-VYb-efQ" unitRef="Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ">0.80</bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards> </xbrl> </XML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>EXCEL <SEQUENCE>30 <FILENAME>Financial_Report.xlsx <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> begin 644 Financial_Report.xlsx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end </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>31 <FILENAME>Show.js <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>32 <FILENAME>report.css <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>XML <SEQUENCE>33 <FILENAME>FilingSummary.xml <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> <XML> <?xml version='1.0' encoding='utf-8'?> <FilingSummary> <Version>3.22.4</Version> <ProcessingTime/> <ReportFormat>html</ReportFormat> <ContextCount>71</ContextCount> <ElementCount>104</ElementCount> <EntityCount>1</EntityCount> <FootnotesReported>false</FootnotesReported> <SegmentCount>12</SegmentCount> <ScenarioCount>0</ScenarioCount> <TuplesReported>false</TuplesReported> <UnitCount>6</UnitCount> <MyReports> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R1.htm</HtmlFileName> <LongName>00090 - Document - Document and Entity Information</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation</Role> <ShortName>Document and Entity Information</ShortName> <MenuCategory>Cover</MenuCategory> <Position>1</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R2.htm</HtmlFileName> <LongName>00100 - Statement - BALANCE SHEETS</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/StatementBalanceSheets</Role> <ShortName>BALANCE SHEETS</ShortName> <MenuCategory>Statements</MenuCategory> <Position>2</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R3.htm</HtmlFileName> <LongName>00105 - Statement - BALANCE SHEETS (Parenthetical)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical</Role> <ShortName>BALANCE SHEETS (Parenthetical)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>3</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R4.htm</HtmlFileName> <LongName>00200 - Statement - STATEMENTS OF OPERATIONS</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/StatementStatementsOfOperations</Role> <ShortName>STATEMENTS OF OPERATIONS</ShortName> <MenuCategory>Statements</MenuCategory> <Position>4</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R5.htm</HtmlFileName> <LongName>00300 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit</Role> <ShortName>STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)</ShortName> <MenuCategory>Statements</MenuCategory> <Position>5</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R6.htm</HtmlFileName> <LongName>00400 - Statement - STATEMENTS OF CASH FLOWS</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows</Role> <ShortName>STATEMENTS OF CASH FLOWS</ShortName> <MenuCategory>Statements</MenuCategory> <Position>6</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R7.htm</HtmlFileName> <LongName>10101 - Disclosure - BASIS OF PRESENTATION</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentation</Role> <ShortName>BASIS OF PRESENTATION</ShortName> <MenuCategory>Notes</MenuCategory> <Position>7</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R8.htm</HtmlFileName> <LongName>10201 - Disclosure - ECONOMIC DEPENDENCY</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/DisclosureEconomicDependency</Role> <ShortName>ECONOMIC DEPENDENCY</ShortName> <MenuCategory>Notes</MenuCategory> <Position>8</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R9.htm</HtmlFileName> <LongName>10301 - Disclosure - STOCK OPTIONS AND WARRANTS</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrants</Role> <ShortName>STOCK OPTIONS AND WARRANTS</ShortName> <MenuCategory>Notes</MenuCategory> <Position>9</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R10.htm</HtmlFileName> <LongName>10401 - Disclosure - LOSS PER COMMON SHARE</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShare</Role> <ShortName>LOSS PER COMMON SHARE</ShortName> <MenuCategory>Notes</MenuCategory> <Position>10</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R11.htm</HtmlFileName> <LongName>10501 - Disclosure - INCOME TAXES</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/DisclosureIncomeTaxes</Role> <ShortName>INCOME TAXES</ShortName> <MenuCategory>Notes</MenuCategory> <Position>11</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R12.htm</HtmlFileName> <LongName>30303 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsTables</Role> <ShortName>STOCK OPTIONS AND WARRANTS (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrants</ParentRole> <Position>12</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R13.htm</HtmlFileName> <LongName>30503 - Disclosure - INCOME TAXES (Tables)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesTables</Role> <ShortName>INCOME TAXES (Tables)</ShortName> <MenuCategory>Tables</MenuCategory> <ParentRole>http://www.burzynskiresearch.com/role/DisclosureIncomeTaxes</ParentRole> <Position>13</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R14.htm</HtmlFileName> <LongName>40101 - Disclosure - BASIS OF PRESENTATION (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentationDetails</Role> <ShortName>BASIS OF PRESENTATION (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentation</ParentRole> <Position>14</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R15.htm</HtmlFileName> <LongName>40301 - Disclosure - STOCK OPTIONS AND WARRANTS (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails</Role> <ShortName>STOCK OPTIONS AND WARRANTS (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsTables</ParentRole> <Position>15</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R16.htm</HtmlFileName> <LongName>40401 - Disclosure - LOSS PER COMMON SHARE (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails</Role> <ShortName>LOSS PER COMMON SHARE (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShare</ParentRole> <Position>16</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R17.htm</HtmlFileName> <LongName>40501 - Disclosure - INCOME TAXES (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails</Role> <ShortName>INCOME TAXES (Details)</ShortName> <MenuCategory>Details</MenuCategory> <ParentRole>http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesTables</ParentRole> <Position>17</Position> </Report> <Report instance="bzyr-20221130x10q.htm"> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <HtmlFileName>R18.htm</HtmlFileName> <LongName>40502 - Disclosure - INCOME TAXES - Operating Loss Carryforwards (Details)</LongName> <ReportType>Sheet</ReportType> <Role>http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails</Role> <ShortName>INCOME TAXES - Operating Loss Carryforwards (Details)</ShortName> <MenuCategory>Details</MenuCategory> <Position>18</Position> </Report> <Report> <IsDefault>false</IsDefault> <HasEmbeddedReports>false</HasEmbeddedReports> <LongName>All Reports</LongName> <ReportType>Book</ReportType> <ShortName>All Reports</ShortName> </Report> </MyReports> <Logs> <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 12 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, dei:SecurityExchangeName, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareBasic, us-gaap:WeightedAverageNumberOfSharesOutstandingBasic - bzyr-20221130x10q.htm 9</Log> <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 2 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:CommitmentsAndContingencies - bzyr-20221130x10q.htm 9</Log> </Logs> <InputFiles> <File doctype="10-Q" original="bzyr-20221130x10q.htm">bzyr-20221130x10q.htm</File> <File>bzyr-20221130.xsd</File> <File>bzyr-20221130_cal.xml</File> <File>bzyr-20221130_def.xml</File> <File>bzyr-20221130_lab.xml</File> <File>bzyr-20221130_pre.xml</File> <File>bzyr-20221130xex31d1.htm</File> <File>bzyr-20221130xex31d2.htm</File> <File>bzyr-20221130xex32d1.htm</File> <File>bzyr-20221130xex32d2.htm</File> </InputFiles> <SupplementalFiles/> <BaseTaxonomies> <BaseTaxonomy items="203">http://fasb.org/us-gaap/2022</BaseTaxonomy> <BaseTaxonomy items="30">http://xbrl.sec.gov/dei/2022</BaseTaxonomy> </BaseTaxonomies> <HasPresentationLinkbase>true</HasPresentationLinkbase> <HasCalculationLinkbase>true</HasCalculationLinkbase> </FilingSummary> </XML> </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>JSON <SEQUENCE>36 <FILENAME>MetaLinks.json <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> { "instance": { "bzyr-20221130x10q.htm": { "axisCustom": 0, "axisStandard": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2022": 203, "http://xbrl.sec.gov/dei/2022": 30 }, "contextCount": 71, "dts": { "calculationLink": { "local": [ "bzyr-20221130_cal.xml" ] }, "definitionLink": { "local": [ "bzyr-20221130_def.xml" ] }, "inline": { "local": [ "bzyr-20221130x10q.htm" ] }, "labelLink": { "local": [ "bzyr-20221130_lab.xml" ] }, "presentationLink": { "local": [ "bzyr-20221130_pre.xml" ] }, "schema": { "local": [ "bzyr-20221130.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 164, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2022": 12, "http://xbrl.sec.gov/dei/2022": 7, "total": 19 }, "keyCustom": 15, "keyStandard": 89, "memberCustom": 5, "memberStandard": 6, "nsprefix": "bzyr", "nsuri": "http://www.burzynskiresearch.com/20221130", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "00090 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10401 - Disclosure - LOSS PER COMMON SHARE", "menuCat": "Notes", "order": "10", "role": "http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShare", "shortName": "LOSS PER COMMON SHARE", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:EarningsPerShareTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10501 - Disclosure - INCOME TAXES", "menuCat": "Notes", "order": "11", "role": "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxes", "shortName": "INCOME TAXES", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30303 - Disclosure - STOCK OPTIONS AND WARRANTS (Tables)", "menuCat": "Tables", "order": "12", "role": "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsTables", "shortName": "STOCK OPTIONS AND WARRANTS (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "30503 - Disclosure - INCOME TAXES (Tables)", "menuCat": "Tables", "order": "13", "role": "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesTables", "shortName": "INCOME TAXES (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g", "decimals": "3", "first": true, "lang": null, "name": "bzyr:OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40101 - Disclosure - BASIS OF PRESENTATION (Details)", "menuCat": "Details", "order": "14", "role": "http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentationDetails", "shortName": "BASIS OF PRESENTATION (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g", "decimals": "3", "first": true, "lang": null, "name": "bzyr:OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ", "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": "INF", "first": true, "lang": null, "name": "bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_REEsf0XHJUOQ1iZoyc7Pvg", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40301 - Disclosure - STOCK OPTIONS AND WARRANTS (Details)", "menuCat": "Details", "order": "15", "role": "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails", "shortName": "STOCK OPTIONS AND WARRANTS (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": "INF", "first": true, "lang": null, "name": "bzyr:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_item_REEsf0XHJUOQ1iZoyc7Pvg", "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_9_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Q6hxXm5dK0q5su70AGA9ow", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40401 - Disclosure - LOSS PER COMMON SHARE (Details)", "menuCat": "Details", "order": "16", "role": "http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails", "shortName": "LOSS PER COMMON SHARE (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "p", "us-gaap:EarningsPerShareTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_9_1_2022_To_11_30_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_Q6hxXm5dK0q5su70AGA9ow", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_shares_9R_uc86Qu0m1IXwYNlwlCA", "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40501 - Disclosure - INCOME TAXES (Details)", "menuCat": "Details", "order": "17", "role": "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails", "shortName": "INCOME TAXES (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ", "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": "2", "first": true, "lang": null, "name": "bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "40502 - Disclosure - INCOME TAXES - Operating Loss Carryforwards (Details)", "menuCat": "Details", "order": "18", "role": "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails", "shortName": "INCOME TAXES - Operating Loss Carryforwards (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": "2", "first": true, "lang": null, "name": "bzyr:PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_pure_I07eJMzsfkOtz2qYKnoxQQ", "xsiNil": "false" } }, "R2": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00100 - Statement - BALANCE SHEETS", "menuCat": "Statements", "order": "2", "role": "http://www.burzynskiresearch.com/role/StatementBalanceSheets", "shortName": "BALANCE SHEETS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A", "xsiNil": "false" } }, "R3": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00105 - Statement - BALANCE SHEETS (Parenthetical)", "menuCat": "Statements", "order": "3", "role": "http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical", "shortName": "BALANCE SHEETS (Parenthetical)", "subGroupType": "parenthetical", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "As_Of_11_30_2022_VfMqUdywfEa4pUucoWup5g", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:CommonStockParOrStatedValuePerShare", "reportCount": 1, "unique": true, "unitRef": "Unit_Divide_USD_shares_Vn2ykGJRjUuCP3ac_fJvvQ", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00200 - Statement - STATEMENTS OF OPERATIONS", "menuCat": "Statements", "order": "4", "role": "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations", "shortName": "STATEMENTS OF OPERATIONS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:ResearchAndDevelopmentExpense", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "As_Of_2_28_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_QcYgvQm1sU2dNqhqk7HHhQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:StockholdersEquity", "reportCount": 1, "unitRef": "Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00300 - Statement - STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)", "menuCat": "Statements", "order": "5", "role": "http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit", "shortName": "STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2021_To_5_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_-cT_vEjUDUW-S5rQVrW9Gg", "decimals": "0", "lang": null, "name": "bzyr:AdjustmentsToAdditionalPaidInCapitalCashContributed", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_9_1_2022_To_11_30_2022_01YJLF8z3UqRVyYR-erwvQ", "decimals": "0", "first": true, "lang": null, "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic", "reportCount": 1, "unitRef": "Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "00400 - Statement - STATEMENTS OF CASH FLOWS", "menuCat": "Statements", "order": "6", "role": "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows", "shortName": "STATEMENTS OF CASH FLOWS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "table", "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": "0", "lang": null, "name": "bzyr:ClinicalTrialExpensesPaid", "reportCount": 1, "unique": true, "unitRef": "Unit_Standard_USD_yAbm7cvIdkSWY2fqx0dw9A", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10101 - Disclosure - BASIS OF PRESENTATION", "menuCat": "Notes", "order": "7", "role": "http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentation", "shortName": "BASIS OF PRESENTATION", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10201 - Disclosure - ECONOMIC DEPENDENCY", "menuCat": "Notes", "order": "8", "role": "http://www.burzynskiresearch.com/role/DisclosureEconomicDependency", "shortName": "ECONOMIC DEPENDENCY", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "10301 - Disclosure - STOCK OPTIONS AND WARRANTS", "menuCat": "Notes", "order": "9", "role": "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrants", "shortName": "STOCK OPTIONS AND WARRANTS", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "div", "body", "html" ], "baseRef": "bzyr-20221130x10q.htm", "contextRef": "Duration_3_1_2022_To_11_30_2022_QOpqaMYd_UK6voXE4md1ZA", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 12, "tag": { "bzyr_AdjustmentsToAdditionalPaidInCapitalCashContributed": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the cash contributed by the individual that is reported as additional paid-in capital, which is used to fund general operating expenses during the reporting year.", "label": "Adjustments to Additional Paid in Capital, Cash Contributed", "terseLabel": "Cash contributed by S.R. Burzynski, M.D., Ph.D." } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalCashContributed", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "bzyr_CarigenLtdMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Carigen Ltd., an entity wholly owned and controlled by Dr. Burzynski.", "label": "CARIGEN, LTD (\"SRB\")" } } }, "localname": "CarigenLtdMember", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "bzyr_ClassOfWarrantOrRightsExercisePeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the exercise period for warrants exercisable.", "label": "Class of Warrant or Rights Exercise Period", "terseLabel": "Warrants exercise period" } } }, "localname": "ClassOfWarrantOrRightsExercisePeriod", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "durationItemType" }, "bzyr_ClinicalTrialExpensesPaid": { "auth_ref": [], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents the clinical trial expenses that are incurred by the entity which are used in the treatment of cancer during the reporting period.", "label": "Clinical Trial Expenses Paid", "terseLabel": "FDA clinical trial expenses paid directly by S.R. Burzynski M.D., Ph.D." } } }, "localname": "ClinicalTrialExpensesPaid", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "bzyr_EightyPercentFutureTaxableIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to 80% future taxable income.", "label": "80% of future taxable income" } } }, "localname": "EightyPercentFutureTaxableIncomeMember", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "bzyr_HundredPercentFutureTaxableIncomeMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information relating to 100% future taxable income.", "label": "100% of future taxable income" } } }, "localname": "HundredPercentFutureTaxableIncomeMember", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "bzyr_IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the period after filing income tax returns subject to examination by the taxing authority.", "label": "Income Tax Examination, Period after Filing Income Tax Returns Subject to Examination", "terseLabel": "Period after filing income tax returns subject to examination" } } }, "localname": "IncomeTaxExaminationPeriodAfterFilingIncomeTaxReturnsSubjectToExamination", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "durationItemType" }, "bzyr_MarketingAgreementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Marketing Agreement [Abstract]", "terseLabel": "Marketing Agreement" } } }, "localname": "MarketingAgreementAbstract", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "bzyr_NetOperatingLossCarryForwardIndefinitely": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "It represents net operating loss carryforward indefinite period.", "label": "Net Operating Loss Carry Forward Indefinitely", "terseLabel": "Net operating loss carryforward indefinite period" } } }, "localname": "NetOperatingLossCarryForwardIndefinitely", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "bzyr_NumberOfAntineoplastonDrugsThatReceivedFDAApproval": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the number of antineoplaston drugs that have received FDA approval.", "label": "Number of Antineoplaston Drugs that Received FDA Approval", "terseLabel": "Number of antineoplaston drugs that have received FDA approval" } } }, "localname": "NumberOfAntineoplastonDrugsThatReceivedFDAApproval", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentationDetails" ], "xbrltype": "integerItemType" }, "bzyr_NumberOfPatentsOwned": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of patents owned.", "label": "Number of Patents Owned", "terseLabel": "Number of patents owned" } } }, "localname": "NumberOfPatentsOwned", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentationDetails" ], "xbrltype": "integerItemType" }, "bzyr_OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage interest of ownership held by the President of the Company, whom is also the Chairman of the Board.", "label": "Ownership Interest Percentage Held by Company President and Chairman of Board", "terseLabel": "Percentage of outstanding stock owned by the President and Chairman of the Board" } } }, "localname": "OwnershipInterestPercentageHeldByCompanyPresidentAndChairmanOfBoard", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentationDetails" ], "xbrltype": "percentItemType" }, "bzyr_PercentageOfConsultingFeeToBeReceivedAsPerAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of consulting fee to be received by the Company per the marketing agreement.", "label": "Percentage of Consulting Fee to be Received as Per Agreement", "terseLabel": "Consulting fee (as a percent)" } } }, "localname": "PercentageOfConsultingFeeToBeReceivedAsPerAgreement", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "percentItemType" }, "bzyr_PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The percentage of future taxable income for which net operating loss carryforward indefinitely.", "label": "Percentage of Future Taxable Income, Net Operating Loss Carryforwards", "terseLabel": "Future taxable income (in Percent)" } } }, "localname": "PercentageOfFutureTaxableIncomeNetOperatingLossCarryforwards", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "percentItemType" }, "bzyr_PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the percentage of NOL limit on taxable income under the CARES act.", "label": "Percentage on Net Operating loss Carryforwards Limit of Taxable Income Under Coronavirus Aid, Relief, and Economic Security Act", "terseLabel": "Percentage of NOL limit on taxable income under the CARES act" } } }, "localname": "PercentageOnNetOperatingLossCarryforwardsLimitOfTaxableIncomeUnderCoronavirusAidReliefAndEconomicSecurityAct", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "percentItemType" }, "bzyr_RemainingSharesToVestUponFirstClosingOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the remaining shares to vest upon the first closing of a transaction by SRB as a result of the services provided by WMC under the marketing agreement.", "label": "Remaining Shares to Vest upon First Closing of Agreement", "terseLabel": "Remaining shares to vest upon the first closing of a transaction by SRB under the marketing agreement" } } }, "localname": "RemainingSharesToVestUponFirstClosingOfAgreement", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "bzyr_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of share-based compensation plans approved by the entity's shareholders.", "label": "Share Based Compensation Arrangement, by Share Based Payment Award, Number of Plans", "terseLabel": "Number of stock-based employee compensation plan" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfPlans", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "integerItemType" }, "bzyr_SharesVestingUponExecutionOfAgreement": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the shares vesting upon execution of the agreement.", "label": "Shares Vesting upon Execution of Agreement", "terseLabel": "Shares vesting upon execution of the agreement" } } }, "localname": "SharesVestingUponExecutionOfAgreement", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "bzyr_TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of net operating loss carryforwards that will carryforward in accordance with Tax Cuts and Jobs Act of 2017.", "label": "Tax Cuts and Jobs Act of 2017, Net Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforward in accordance with the Act" } } }, "localname": "TaxCutsAndJobsActOf2017NetOperatingLossCarryforwards", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "monetaryItemType" }, "bzyr_WarrantsAndStockOptionsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to warrants and stock options.", "label": "Warrants and stock options" } } }, "localname": "WarrantsAndStockOptionsMember", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "bzyr_WorldwideMedicalConsultantsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Worldwide Medical Consultants Inc.", "label": "Worldwide Medical Consultants, Inc. (\"WMC\")" } } }, "localname": "WorldwideMedicalConsultantsIncMember", "nsuri": "http://www.burzynskiresearch.com/20221130", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Document and Entity Information" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "gYearItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r235" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r236" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding", "terseLabel": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r237" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r233" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r232" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r234" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "srt_ScenarioUnspecifiedDomain": { "auth_ref": [ "r74", "r132", "r238", "r244" ], "lang": { "en-us": { "role": { "label": "Scenario, Unspecified [Domain]" } } }, "localname": "ScenarioUnspecifiedDomain", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "srt_StatementScenarioAxis": { "auth_ref": [ "r74", "r132", "r238", "r239", "r244" ], "lang": { "en-us": { "role": { "label": "Scenario [Axis]" } } }, "localname": "StatementScenarioAxis", "nsuri": "http://fasb.org/srt/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r8", "r231" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts Payable, Current", "terseLabel": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r10" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accrued Liabilities, Current", "terseLabel": "Accrued liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r3" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional Paid in Capital, Common Stock", "terseLabel": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r165", "r166", "r167", "r241", "r242", "r243", "r251" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used by operating activities:" } } }, "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalOther": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of other increase (decrease) in additional paid in capital (APIC).", "label": "Adjustments to Additional Paid in Capital, Clinical Trial Expenses", "verboseLabel": "FDA clinical trial expenses paid directly by S.R. Burzynski, M.D., Ph.D" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalOther", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r83" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Shares excluded from calculation of diluted loss per share (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Information by type of antidilutive security.", "label": "Antidilutive Securities [Axis]" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails" ], "xbrltype": "stringItemType" }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "auth_ref": [ "r22" ], "lang": { "en-us": { "role": { "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.", "label": "Antidilutive Securities, Name [Domain]" } } }, "localname": "AntidilutiveSecuritiesNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Assets": { "auth_ref": [ "r36", "r40", "r49", "r59", "r92", "r95", "r99", "r104", "r108", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r185", "r187", "r193", "r231", "r246", "r247", "r254" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "ASSETS" } } }, "localname": "AssetsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r47", "r51", "r59", "r104", "r108", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r185", "r187", "r193", "r231", "r246", "r247", "r254" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "Assets, Current", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r20", "r48", "r225" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r16", "r20", "r21" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents", "periodEndLabel": "CASH AT END OF PERIOD", "periodStartLabel": "CASH AT BEGINNING OF PERIOD" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": { "auth_ref": [ "r16", "r34" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "totalLabel": "NET INCREASE (DECREASE) IN CASH" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercisable price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "auth_ref": [ "r129" ], "lang": { "en-us": { "role": { "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.", "label": "Class of Warrant or Right Number of Securities to be Called by Warrants or Rights WMC Payment Consideration", "terseLabel": "Warrants to be granted to acquire shares of common stock (in shares)" } } }, "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r11", "r38", "r43" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and Contingencies", "terseLabel": "Commitments and contingencies" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r241", "r242", "r251" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r2", "r24" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheetsParenthetical" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r2", "r231" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock, $.001 par value; 200,000,000 shares authorized; 131,448,444 shares issued and outstanding as of November 30, 2022 and February 28, 2022" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNet": { "auth_ref": [ "r250" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.", "label": "Deferred Tax Assets, Net of Valuation Allowance", "terseLabel": "Net deferred tax asset" } } }, "localname": "DeferredTaxAssetsNet", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DeferredTaxAssetsNetAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net [Abstract]", "terseLabel": "Deferred tax assets:" } } }, "localname": "DeferredTaxAssetsNetAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r173" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.", "label": "Deferred Tax Assets, Valuation Allowance", "terseLabel": "Valuation allowance" } } }, "localname": "DeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "auth_ref": [ "r135", "r162", "r163", "r164", "r168", "r230" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for share-based payment arrangement.", "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]", "terseLabel": "STOCK OPTIONS AND WARRANTS" } } }, "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrants" ], "xbrltype": "textBlockItemType" }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STOCK OPTIONS AND WARRANTS" } } }, "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "LOSS PER COMMON SHARE", "terseLabel": "Earnings per share information:" } } }, "localname": "EarningsPerShareAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r56", "r66", "r67", "r68", "r69", "r70", "r75", "r78", "r80", "r81", "r82", "r86", "r191", "r192", "r216", "r218", "r227" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Earnings Per Share, Basic", "terseLabel": "Loss per common share Basic" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareDiluted": { "auth_ref": [ "r56", "r66", "r67", "r68", "r69", "r70", "r78", "r80", "r81", "r82", "r86", "r191", "r192", "r216", "r218", "r227" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.", "label": "Earnings Per Share, Diluted", "terseLabel": "Loss per common share Diluted" } } }, "localname": "EarningsPerShareDiluted", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerShareTextBlock": { "auth_ref": [ "r83", "r84", "r85", "r87" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for earnings per share.", "label": "Earnings Per Share [Text Block]", "terseLabel": "LOSS PER COMMON SHARE" } } }, "localname": "EarningsPerShareTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShare" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r60", "r170", "r179" ], "lang": { "en-us": { "role": { "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).", "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate", "terseLabel": "U.S. federal income tax rate (as a percent)" } } }, "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "percentItemType" }, "us-gaap_EmployeeStockOptionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.", "label": "Stock options" } } }, "localname": "EmployeeStockOptionMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails", "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r24", "r46", "r52", "r53", "r54", "r62", "r63", "r64", "r65", "r71", "r73", "r88", "r105", "r130", "r165", "r166", "r167", "r175", "r176", "r190", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r220", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r14" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and Administrative Expense", "terseLabel": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "auth_ref": [ "r13", "r35", "r39", "r44", "r92", "r94", "r98", "r100", "r217", "r229" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.", "label": "Income (Loss) from Continuing Operations before Income Taxes, Extraordinary Items, Noncontrolling Interest", "totalLabel": "Loss before provision for income tax" } } }, "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF OPERATIONS" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityAxis": { "auth_ref": [ "r29" ], "lang": { "en-us": { "role": { "documentation": "Information by tax jurisdiction.", "label": "Income Tax Authority [Axis]" } } }, "localname": "IncomeTaxAuthorityAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxAuthorityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.", "label": "Income Tax Authority [Domain]" } } }, "localname": "IncomeTaxAuthorityDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r60", "r171", "r172", "r174", "r177", "r180", "r182", "r183", "r184" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]", "terseLabel": "INCOME TAXES" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExaminationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Income Tax Examination [Line Items]", "terseLabel": "Income Taxes" } } }, "localname": "IncomeTaxExaminationLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExaminationTable": { "auth_ref": [ "r30" ], "lang": { "en-us": { "role": { "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.", "label": "Income Tax Examination [Table]" } } }, "localname": "IncomeTaxExaminationTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r61", "r72", "r73", "r91", "r169", "r178", "r181", "r219" ], "calculation": { "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "Income Tax Expense (Benefit)", "totalLabel": "Provision for income tax" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]", "terseLabel": "Actual income tax benefit" } } }, "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "auth_ref": [ "r248" ], "calculation": { "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails": { "order": 4.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.", "label": "Income Tax Reconciliation, Change in Deferred Tax Assets Valuation Allowance", "terseLabel": "Change in valuation allowance" } } }, "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationDeductions": { "auth_ref": [ "r248" ], "calculation": { "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails": { "order": 2.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations attributable to deduction. Includes, but is not limited to, dividend deduction, deduction for dividend paid to employee stock ownership plan (ESOP), Medicare prescription drug benefit subsidy deduction, and other deductions.", "label": "Income Tax Reconciliation, Deductions", "terseLabel": "Taxed directly to Dr. Burzynski" } } }, "localname": "IncomeTaxReconciliationDeductions", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": { "auth_ref": [ "r170" ], "calculation": { "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails": { "order": 1.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.", "label": "Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate", "verboseLabel": "Expected expense (benefit)" } } }, "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncomeTaxReconciliationNondeductibleExpense": { "auth_ref": [ "r248" ], "calculation": { "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails": { "order": 3.0, "parentTag": "us-gaap_IncomeTaxExpenseBenefit", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.", "label": "Income Tax Reconciliation, Nondeductible Expense", "terseLabel": "Nondeductible expenses and other adjustments" } } }, "localname": "IncomeTaxReconciliationNondeductibleExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r18" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r18" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r18" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "Increase (Decrease) in Prepaid Expense", "negatedLabel": "Prepaids" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Increase (Decrease) in Stockholders' Equity" } } }, "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_InternalRevenueServiceIRSMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Designated tax department of the United States of America government entitled to levy and collect income taxes from the entity.", "label": "IRS" } } }, "localname": "InternalRevenueServiceIRSMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "domainItemType" }, "us-gaap_LatestTaxYearMember": { "auth_ref": [ "r249" ], "lang": { "en-us": { "role": { "documentation": "Latest identified tax year.", "label": "2026 to 2038" } } }, "localname": "LatestTaxYearMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r9", "r59", "r104", "r108", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r186", "r187", "r188", "r193", "r228", "r246", "r254", "r255" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "Liabilities", "totalLabel": "CURRENT AND TOTAL LIABILITIES" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r7", "r37", "r42", "r231", "r240", "r245", "r252" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity (deficit)" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "terseLabel": "LIABILITIES AND STOCKHOLDERS' DEFICIT" } } }, "localname": "LiabilitiesAndStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r57" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "NET CASH PROVIDED BY FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]", "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r16", "r17", "r19" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "NET CASH USED BY OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]", "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": { "auth_ref": [ "r66", "r67", "r68", "r69", "r75", "r76", "r79", "r82", "r92", "r94", "r98", "r100", "r229" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.", "label": "Net Income (Loss) Available to Common Stockholders, Basic", "terseLabel": "Net loss", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLossAvailableToCommonStockholdersBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit", "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows", "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "Operating Expenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r92", "r94", "r98", "r100", "r229" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "Operating Income (Loss)", "totalLabel": "Operating loss" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLossCarryforwardsLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Net operating loss carryforwards" } } }, "localname": "OperatingLossCarryforwardsLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingLossCarryforwardsTable": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.", "label": "Operating Loss Carryforwards [Table]" } } }, "localname": "OperatingLossCarryforwardsTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "auth_ref": [ "r0", "r33" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "BASIS OF PRESENTATION" } } }, "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureBasisOfPresentation" ], "xbrltype": "textBlockItemType" }, "us-gaap_PrepaidExpenseCurrent": { "auth_ref": [ "r50", "r106", "r107", "r226" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Expense, Current", "terseLabel": "Prepaids" } } }, "localname": "PrepaidExpenseCurrent", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromContributedCapital": { "auth_ref": [ "r15" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow associated with the amount received by a corporation from a shareholder during the period.", "label": "Proceeds from Contributed Capital", "verboseLabel": "Contribution of capital" } } }, "localname": "ProceedsFromContributedCapital", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfCashFlows" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r131", "r201", "r202" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r131", "r201", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r253" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r28", "r45", "r256" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and Development Expense", "terseLabel": "Research and development" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r4", "r25", "r41", "r223", "r224", "r231" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Earnings (Accumulated Deficit)", "terseLabel": "Retained deficit" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r46", "r62", "r63", "r64", "r65", "r71", "r73", "r105", "r165", "r166", "r167", "r175", "r176", "r190", "r220", "r222" ], "lang": { "en-us": { "role": { "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.", "label": "Retained Deficit" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r55", "r59", "r89", "r90", "r93", "r96", "r97", "r101", "r102", "r103", "r104", "r108", "r109", "r110", "r111", "r112", "r113", "r114", "r115", "r116", "r193", "r217", "r246" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues", "terseLabel": "Historical earnings" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesDetails" ], "xbrltype": "monetaryItemType" }, "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.", "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]", "terseLabel": "Schedule of actual provision for income tax that differs from the amounts computed by applying the U.S. federal income tax rate to the pretax loss" } } }, "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of number, weighted-average exercise price or conversion ratio, aggregate intrinsic value, and weighted-average remaining contractual term for outstanding options that are fully vested and expected to vest. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.", "label": "Schedule of Share Based Compensation Arrangement by Share Based Payment Award Options Vested [Table Text Block]", "terseLabel": "Schedule of options vested" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsTables" ], "xbrltype": "textBlockItemType" }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "auth_ref": [ "r133", "r134", "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of information about share-based payment arrangement.", "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]" } } }, "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]", "verboseLabel": "STOCK OPTIONS AND WARRANTS" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Gross number of share options (or share units) granted during the period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r136", "r137", "r138", "r139", "r140", "r141", "r142", "r143", "r144", "r145", "r146", "r147", "r148", "r149", "r150", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "auth_ref": [ "r143" ], "lang": { "en-us": { "role": { "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.", "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Exercise price (in dollars per share)" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "perShareItemType" }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of options vested.", "label": "Share Based Compensation Arrangement by Share Based Payment Award, Options, Vested in Period", "terseLabel": "Vested (in shares)" } } }, "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "Shares, Outstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" ], "xbrltype": "sharesItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r12", "r24", "r46", "r52", "r53", "r54", "r62", "r63", "r64", "r65", "r71", "r73", "r88", "r105", "r130", "r165", "r166", "r167", "r175", "r176", "r190", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r220", "r221", "r222" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]", "terseLabel": "Statement" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails", "http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENTS OF CASH FLOWS" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "BALANCE SHEETS" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "STATEMENT OF STOCKHOLDERS' EQUITY (DEFICIT)" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r62", "r63", "r64", "r88", "r203" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureLossPerCommonShareDetails", "http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "auth_ref": [ "r1", "r2", "r24", "r25", "r144" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period.", "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period", "terseLabel": "Exercised (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureStockOptionsAndWarrantsDetails" ], "xbrltype": "sharesItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r2", "r5", "r6", "r23", "r231", "r240", "r245", "r252" ], "calculation": { "http://www.burzynskiresearch.com/role/StatementBalanceSheets": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.", "label": "Stockholders' Equity Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity (deficit)" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets", "http://www.burzynskiresearch.com/role/StatementStatementOfStockholdersEquityDeficit" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' Equity Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity (deficit)" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementBalanceSheets" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "ECONOMIC DEPENDENCY" } } }, "localname": "StockholdersEquityNoteAbstract", "nsuri": "http://fasb.org/us-gaap/2022", "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r26", "r58", "r117", "r118", "r119", "r120", "r121", "r122", "r123", "r124", "r125", "r126", "r127", "r128", "r130", "r189" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.", "label": "Stockholders' Equity Note Disclosure [Text Block]", "terseLabel": "ECONOMIC DEPENDENCY" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureEconomicDependency" ], "xbrltype": "textBlockItemType" }, "us-gaap_TaxPeriodAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information about the period subject to enacted tax laws.", "label": "Tax Period [Axis]" } } }, "localname": "TaxPeriodAxis", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "stringItemType" }, "us-gaap_TaxPeriodDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Identified tax period.", "label": "Tax Period [Domain]" } } }, "localname": "TaxPeriodDomain", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/DisclosureIncomeTaxesOperatingLossCarryforwardsDetails" ], "xbrltype": "domainItemType" }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "auth_ref": [ "r77", "r82" ], "lang": { "en-us": { "role": { "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Weighted average number of common shares outstanding Diluted" } } }, "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "sharesItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r75", "r82" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Weighted average number of common shares outstanding Basic" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2022", "presentation": [ "http://www.burzynskiresearch.com/role/StatementStatementsOfOperations" ], "xbrltype": "sharesItemType" } }, "unitCount": 6 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "205", "URI": "https://asc.fasb.org/topic&trid=2122149", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "05", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=126905020&loc=d3e5879-108316", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "340", "URI": "https://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496171-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496180-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21475-112644", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(10))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(f)(3)", "Topic": "715", "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(l)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "718", "URI": "https://asc.fasb.org/topic&trid=2228938", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 6.I.Fact.4)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org/topic&trid=2144680", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=SL126733271-114008", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61929-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62059-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62395-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e62479-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=SL6807758-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org/extlink&oid=126939881&loc=d3e61872-109447", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r232": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r233": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r234": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r235": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r236": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r237": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "450", "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662", "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r26": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org/topic&trid=2208762", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r33": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "810", "URI": "https://asc.fasb.org/topic&trid=2197479", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "20", "Topic": "940", "URI": "https://asc.fasb.org/extlink&oid=126941158&loc=d3e41242-110953", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(15))", "Topic": "942", "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03.(a),19)", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(8))", "Topic": "944", "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(7))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r57": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r59": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.M.Q2)", "Topic": "250", "URI": "https://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1377-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "260", "URI": "https://asc.fasb.org/topic&trid=2144383", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } </TEXT> </DOCUMENT> <DOCUMENT> <TYPE>ZIP <SEQUENCE>37 <FILENAME>0001558370-23-000269-xbrl.zip <DESCRIPTION>IDEA: XBRL DOCUMENT <TEXT> begin 644 0001558370-23-000269-xbrl.zip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end </TEXT> </DOCUMENT> </SEC-DOCUMENT>